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General Introduction 9 
A comprehensive review on the metabolic and molecular bases of oxidative phosphorylation 
(OXPHOS) diseases has been written recently by Shoffner and Wallace (1995), which is used as a 
reference throughout this chapter 
1. Mitochondrial encephalomyopathies 
The development of mitochondrial medicine started in 1962 when Luft and colleagues 
described a patient with nonthyroidal hypermetabolism, whose muscle mitochondria showed 
structural abnormalities like crystalline inclusions OXPHOS function in her mitochondria was 
abnormal because ATP production was only "loosely coupled" to respiration (review by Luft, 1994) 
Over the following two decades, investigations of mitochondrial diseases were initially 
dominated by morphological and clinical descriptions, mostly concerning patients with mitochondrial 
myopathies Typically, ragged red fibers (RRF), representing large accumulations of mitochondria, 
were frequently identified in patient muscle sections with the modified Gomori-tnchrome staining 
Later, specific biochemical defects were described in increasing number, including pyruvate 
dehydrogenase complex (PDHC) deficiency, carnitine palmitoyltransferase (CPT) deficiency, 
carnitine deficiencies, and various abnormalities of OXPHOS enzyme activities (reviews Sengers et 
al, 1984, Schölte, 1988, Shanske and DiMauro, 1994) Tissues with a high ATP demand, like 
skeletal muscle and brain, are most often affected, hence the name encephalomyopathy, but also 
liver, heart, kidneys, pancreas, small intestine, or optic nerves can be affected 
In 1988, a breakthrough in mitochondrial pathophysiology occurred with the first reports of 
pathogenetic mtDNA mutations in neuromuscular disorders with mitochondrial involvement 
(Wallace et al, 1988, Holt et al, 1988) 
Clinically there is a remarkable heterogeneity between patients In young children major 
symptoms are hypotonia, failure to thrive, psychomotor delay and/or seizures (Sengers et al, 1984) 
Several well defined syndromes, usually in patients with later onset, can be identified (ι) Kearns-
Sayre syndrome, (и) myoclonus epilepsy and ragged red fibers syndrome (MERRF), (in) Leber 
hereditary optic neuropathy (LHON), (ìv) mitochondrial myopathy, encephalopathy, lactic acidosis, 
and stroke-like episodes (MELAS), (ν) Leigh disease or subacute necrotizing encephalopathy, and 
(vi) chronic progressive external ophthalmoplegia (CPEO) However, clinical expressions vary 
considerable and overlap between syndromes is common and may make diagnosis difficult, as shown 
recently in a study of 51 patients where the use of routinely available clinical investigations was 
evaluated (Jackson et al, 1995) The universal consequence of a failure of mitochondria to produce 
ATP is excessive lactic acid production (Figure 1, Robinson, 1993) 
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Figure 1: Schematic representation of the A'! 1' production by the OXPHOS system m relationship \4th the 
conversion of glucose to pyruvate and lactate Any major defect in the OXPHOS system will result in a change 
of both cytosolic and mitochondrial NADYNADH rcdo\ states, which communicate through the 
malatc/aspartatc and glyccrol-3-phosphate shuttle systems (not shown) Depending on the NADVNADH redox 
couple in the cytosol pyruvate is converted to lactate by lactate dehydrogenase (LDH) Acetyl-CoA is also 
generated by the ß-o\idation of fatty acids (not shown) Adapted from Robinson (1993) 
2. Mitochondrial respiratory chain and oxidative phosphorylation 
The mitochondrial energy-generating system, oxidative phosphorylation, is composed of five 
enzyme complexes assembled from genes of both the mtDNA and nDNA (Figure 2) 
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Figure 2: Diagram o/OXPHOS The four respiratory complexes and complex V are shown in the mitochondrial 
inner membrane Above is the lntermcmbranc space and below is the mitochondrial matrix The subunit 
composition of each complex is presented in a table below Modified from Wallace (1992) 
Complexes I to IV make up the respiratory chain, which transfers electrons from NADH and 
FADH2, generated from various reactions inside and outside (through the malate-aspartate and 
glycerol-3-phosphate shuttles) the mitochondrion (Figure 1), to oxygen, the terminal electron 
acceptor Concomitantly protons are translocated out of the mitochondrial matrix across the inner 
membrane by complexes I, III and IV This creates an proton gradient which is used by complex V 
(ATP synthase) to synthesize ATP from ADP + P, The resulting ATP is then exchanged across the 
inner membrane for cytosolic ADP by the adenine nucleotide translocase (ANT) 
Complex I (NADH ubiquinone oxidoreductase, EC 16 5 3) transfers electrons from NADH 
through redox groups as flavin mononucleotide (FMN) and multiple iron-sulfur centers finally to 
ubiquinone (coenzyme Q10) Complex I purified from bovine heart consists of approximately 41 
subunits (Walker, 1992) with a calculated molecular mass of more than 900 kDa The functions of 
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the 41 subunits are not well defined Seven hydrophobic subunits (ND1, ND2, ND3, ND4, ND4L, 
ND5, and ND6) are encoded by the mtDNA (figure 3) Rotenone, a selective inhibitor of complex I, 
binds to ND1 The remaining 34 or more subunits are encoded by the nuclear DNA and have all been 
characterized by sequence analysis for the bovine enzyme (Walker, 1992) The 51 kDa subunit 
probably contains both the FMN and the NADH binding sites Unexpectedly, subunit SDAP (~8 
kDa) has a covalently bound pantothenic acid moiety and appears to be an acyl carrier protein 
possibly involved in phospholipid biosynthesis The existence of isoenzymes has been suggested by 
the observation of tissue specific defects within the same patient (eg Whatmough et al, 1989) 
Furthermore, the subunit composition of complex I from rat liver, kidney and lung differs from that 
present in heart, brain and skeletal muscle (Clay and Ragan, 1988) Chromosomal assignment has 
been made for human complex I subunits 75 kDa (2q33-q34), 51 kDa (1 lql3), 24 kDa (18pl 1, De 
Coo et al, 1995) 
Complex II (succinate ubiquinone oxidoreductase, EC 13 5 1) performs a key step in the 
citric acid cycle, in which succinate is dehydrogenated to fumarate and electrons are donated to 
ubiquinone It is composed of four nuclear encoded subunits a 70 kDa flavoprotein subunit (Fp), a 
27 kDa iron-sulfur protein (Ip), and 15 5 kDa and 13 5 kDa membrane anchoring polypeptides The 
iron-sulfur proteins of complex II from human liver and fibroblasts differ in two amino acids from 
each other, suggesting that tissue-specific isoforms may exist The Fp subunit gene is duplicated in 
the human genome (3q29, 5pl5), with only the latter being expressed in human-hamster somatic cell 
hybrids (Bourgeron et al, 1995) 
Complex III (ubiquinol ferrocytochrome с oxidoreductase or cytochrome ¿t, complex, EC 
1 10 2 2), which transfers electrons from ubiquinol to cytochrome t, is composed of 11 subunits 
core proteins I and II, cytochrome b, cytochrome c,, the Rieske iron-sulfur protein and six low-
molecular weight polypeptides The primary redox groups are cytochrome b, cytochrome c, and the 
Rieske iron-sulfur protein Only cytochrome b is encoded by the mtDNA (Figure 3) Bovine complex 
III isolated from heart or liver tissue does not exhibit tissue-specific differences as analyzed by 
Western blotting, isoelectric focussing and partial amino terminal sequencing (Vazquez-Acevedo et 
al, 1993) However, the heterogeneous tissue expression of complex 111 defects in patients suggests 
the occurrence of isoforms and tissue specific regulation The chromosomal localization has been 
made for the human complex III subunits core I (3p21), core II (16pl2), cytochrome c, (8q24), the 
Rieske iron-sulfur protein (22ql3, 19ql2-ql3 1), and the ubiquinone binding protein (134 kDa, 
chromosome 8) 
Complex IV (ferrocytochrome с oxygen oxidoreductase or cytochrome с oxidase, EC 
1 9 3 1), the last complex of the respiratory chain, collects electrons from reduced cytochrome с and 
donates them to oxygen, which is then reduced to water Mammalian complex IV is composed of 13 
polypeptide subunits Subunits I, II, and III are encoded by the mtDNA and the remaining subunits 
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(IV, Va, Vb, Vla, VIb, Vie, Vila, Vllb, Vile, Vili) are encoded by the nuclear DNA Subunits I and 
II carry the copper atoms and hemes a and a, that form the redox centers for electron transfer 
Subunit II also contains the cytochrome с binding site Subunit III is proposed to play a role in 
proton translocation and/or assembly of the enzyme Subunits Via and Vila have both tissue specific 
isoforms, a liver (L) and a muscle (M) form, and are developmental^ regulated, since the M-form is 
absent in fetal muscle The following subunits have been mapped on the human genome IV (16q22-
qter), Vb (2cen-ql3), VIb (19ql3 1), VIIa-M (19), VIIa-L (4q31-qter and 14q21-qter) and Mil 
(1 Iql2-ql3) Pseudogenes have been found for subunits IV, Vb and VIb The crystal structure at 2 8 
Л resolution of both Paracoccus demtnficans and bovine heart cytochrome с oxidase has been 
recently described (Iwata et al, 1995, Tsukihara et al, 1995) Two proton transfer pathways and 
several metal sites could be identified 
Complex V (ATP synthase, EC3 6 1 34) uses the transmembrane proton gradient generated 
by complexes I, III and IV as the source of energy for synthesizing ATP from ADP + P, The 
complex consists of two moieties a catalytic portion F, and a membrane portion F0, which 
translocates protons into the mitochondrial matrix, the two portions being joined by a stalk The F, 
portion consists of five different subunits with the stoichiometry α 3β 3γδε The β subunit is 
considered to be the catalytic protein, whereas a regulatory role is ascribed to the a subunit Two 
small peptides, the Ca2*-binding protein (СВР) and IF, or Pullman-Monroy inhibitor (PMI), can bind 
to the F, portion of complex V and inhibit its ATPase activity The F0 portion is composed of at least 
nine subunits (Collinson et al., 1994a), named subunit a (ATPase 6), subunit b, subunit с (proteolipid 
subunit 9), subunit d, subunit e or oligomycin sensitivity-conferring protein (OSCP), subunit f, 
subunit g, coupling factor 6 (F6) and A6L (ATPase 8) Subunits a and A6L are encoded by the 
mtDNA The stalk contains subunits OSCP, F6, b and d (Collinson et al., 1994b) The precise 
function of most of the F0 and F, subunits is unknown 
Three expressed genes exist for ATPase subunit c, all encoding the same mature subunit, and 
differing only in the import sequences (Yan et al., 1994) Two isoforms of subunit γ, a liver and 
heart type, are generated by alternative splicing they differ by the addition of a single amino acid 
(Asp) at the С terminus of the liver type isoform (Matsuda et al, 1993) Subunit β has been mapped 
on chromosome 12pl 3-qter and one form of subunit с is located on chromosome 2 
Aside from the genes that encode OXPHOS subunits, there is a vast array of nuclear genes 
that are necessary for the formation of a functional OXPHOS system The analysis of respiratory-
deficient mutant yeast strains, also called pet mutants, has yielded a large number of genes involved 
in mtDNA transcription, translation and assembly of OXPHOS complexes (reviews TzagolofTand 
Dieckmann, 1990, Grivell, 1995) Only one human gene, oxal, involved in cytochrome с oxidase 
assembly, has yet been identified (Bonnefoy et ai, 1994) Because the mitochondrial genome 
encodes only 13 proteins, most mitochondrial proteins are synthesized in the cytosol and imported 
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into the mitochondria by a complex import machinery including receptors located in the outer 
membrane (review Lithgow et al, 1995), and several chaperones acting as unfoldases, pulling 
devises, and foldases (review Martinus et al, 1995) 
3. Mitochondrial DNA 
The human mtDNA has been sequenced (Anderson et al, 1981), and shown to be a 16,569-
bp, double-stranded, circular molecule that codes for the rRNAs and tRNAs of mitochondrial protein 
synthesis as well as 13 polypeptides of the OXPHOS apparatus (Figure 3) The guanine-nch strand is 
called the heavy (H) strand and the cytosine-nch strand is called the light (L) strand Twelve 
OXPHOS subunit genes, the 12S and 16S rRNA genes, and 14 tRNA genes are transcribed from the 
Η-strand One OXPHOS subunit gene (ND6 of complex I) and eight tRNA genes are transcribed 
from the L-strand The displacement (D) loop contains genetic information necessary for replication 
and transcription Since each cell can contain tens to hundreds of mitochondria with multiple copies 
of mtDNA per mitochondrion, there are hundreds to thousands of mtDNA per cell 
The genetic code of the mtDNA differs from the "universal" mammalian nuclear genetic code 
As a consequence, mitochondrial genes and mRNAs cannot function in the nuclear-cytosol 
compartment, which is of practical importance when considering potential approaches to gene 
therapy of mtDNA defects 
Mitochondrial genetics has five unique characteristics 
1. mtDNA in humans is maternally inherited 
2. Mammalian mtDNA has a 10- to 20-fold higher rate of mutation than single-copy nuclear genes 
and is therefore more susceptible to deleterious gene mutations than its nuclear counterpart 
3. OXPHOS diseases are frequently caused by heteroplasmic mtDNA mutations resulting from the 
presence of both mutant and normal mtDNAs within the cell During cell division and mitochondrial 
proliferation, the proportion of mutant mitochondrial genomes may shift in daughter cells, a process 
called random replicative segregation, and the phenotype may change accordingly 
4. The phenotypic expression of a pathogenetic mtDNA mutation depends on the energetic 
requirements of a certain tissue and the severity of the OXPHOS defect Each tissue requires a 
different minimum level (threshold) of mitochondrial ATP production to sustain normal cellular 
functions Organs with the highest ATP demand are brain, heart, skeletal muscle, and pancreas 
5. OXPHOS capacities decline with age, in parallel with accumulation of somatic cell mtDNA 
mutations, possibly as a result of accumulated oxidative damage 
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Figure 3: 77;e organization of the human mtDNA Genes encoded by the Η-strand and the L-slrand are labeled 
outside of, or within, Ihc circle, respectively 0 H , 0 L , origin of Η-strand, L-slrand synthesis, P,, , P L , H-strand, 
L-strand promoter The 22 tRNA genes are designated by the single letter code for amino acids (from Ballingcr 
et al, 1994) 
4. mtDNA mutations 
Proof that mtDNA mutations cause disease first came from papers published in 1988 Wallace 
and colleagues found a G-Α transition at mtDNA position 11778, in codon 340 of the ND4 gene of 
complex I, in LHON pedigrees displaying maternal inheritance Holt and colleagues reported an 
association of different sporadic human encephalomyopathies with large deletions of mtDNA 
MtDNA rearrangements (deletions and duplications) are now known to be a major cause of 
Pearson's pancreas and marrow syndrome and of ocular myopathies, as Kearns-Sayre syndrome and 
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chronic progressive external ophthalmoplegia (CPEO) A mtDNA depletion, resulting from an error 
in mtDNA copy number control, has been observed in a few patients, mostly with complex IV 
deficiency MtDNA point mutations have been associated with LHON, myoclonus epilepsy and 
ragged red fibers syndrome (MERRF), mitochondrial myopathy, encephalopathy, lactic acidosis, and 
stroke-like episodes (MELAS), neurogenic muscle weakness, ataxia, and retinitis pigmentosa 
(NARP), together with Leigh disease or subacute necrotizing encephalopathy, adult onset 
mitochondrial myopathy and cardiomyopathy, and mitochondrial myopathy (Table 1) 
Nucleotide 
1555 
3243 
3:50 
3251 
3252 
3256 
3260 
3271 
3302 
3303 
3394 
3460 
4160 
4216 
4269 
4917 
5244 
5703 
7444 
8344 
8456 
8993 
8993 
11084 
11778 
14484 
13708 
15257 
15812 
15923 
15990 
Mutation* 
A - G 
A - G 
T - C 
A - G 
A - G 
С - Τ 
A - G 
Τ - С 
А - G 
С - Т 
т - с 
G - А 
Τ - С 
Т - С 
А - G 
A - G 
G - А 
G - А 
G - А 
G - А 
Τ - С 
Τ - G 
Τ - С 
A - G 
G -A 
Τ - С 
G - A 
G - A 
G - A 
A - G 
С -Τ 
Gene location 
12SrRNA 
tRNA-Lcu(UUR) 
tRNA-Leu 
tRNA-Leu 
IRNA-Leu 
IRNA-Leu 
(UUR) 
(ULR) 
(LUR) 
(UUR) 
iRNA-Leu(UUR) 
tRNA-Leu 
iRNA-Lcu 
IRNA-Leu 
NDI 
NDI 
NDI 
NDI 
tRNA Ile 
\'D2 
ND2 
tRNA-Asn 
СОХ I 
iRNA-Lys 
tRNA-Lys 
ATPase 6 
ATPase 6 
ND4 
ND4 
ND6 
ND5 
Cjtb 
C u b 
tRNA-Thr 
iRNA-Pro 
(UUR) 
(UUR) 
(ULR) 
Phenotype 
AID 
MELAS PCO diabetes hearing loss 
Myopathy 
MELAS 
MELAS 
Multisystem PEO 
Cardiomyopathy myopathy 
MELAS 
Myopathy 
Cardiomyopathy 
LHON 
LHON 
LHON 
LHON 
Mulns) siem'cardiomyopathy 
LHON 
LHON 
Myopathy (PEO) 
LHON 
MERRF 
MERRF 
NARP MILS 
NARP MILS 
MELAS 
LHON 
LHON 
LHON 
LHON 
LHON 
Infantile respiratory deficiency 
M\opathy 
Reference* 
Prezanl el al, 1993 
Goto el al, 1990 
Goto el al. 1992b 
Sweeney el al 1993 
Morten eroi, 1993 
Moracser al. 1993b 
Zeuanier a/, 1991 
Goto el al, 1991 
Bindoli er al. 1993 
Silvestri el al. 1993b 
Brown el al, 1992b 
Huoponen ei al. 1991 
Howell el al. 1991 
Mackey and Howell, 1992 
Tannkcríj / 1992 
Johns and Berrnan, 1991 
Brown et al, 1992c 
Moraesfla/ , 1993b 
Brown ci al, 1992b 
Shoffner el al, 1990 
Sibestnefo/ 1992 
Holt el al 1990 
deVnescr и/. 1993 
Lerlnlera/, 1992 
Wallace el al, 1988 
Johns el al, 1992 
Johns and Berman, 1991 
Johns and Neufeld, 1991 
Johns and Neufeld, 1991 
Yoonela/ 1991 
Moraes el al, 1993a 
" L-slrand sequence 
first published article 
Table 1 : Phenotypes associated with mtDNA point mutations Table and cited references are reproduced from 
Schon et a! (1994) AID, aminoghcoside-induced deafness, MILS, maternally inherited Leigh's syndrome 
In 1992, both rearrangements and point mutations have been shown also to be associated with 
diabetes mellitus and deafness (Ballinger et al., 1992, Van den Ouweland et al., 1992) To date, 
more than 40 point mutations associated with variable clinical phenotypes, have been described 
Point mutations which cause mitochondrial myopathies are most frequently found in tRNA 
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genes A pathogenetic tRNA mutation will inhibit mitochondrial translation and thus affect the 
expression of all mtDNA protein-coding genes Especially, the gene for tRNAUu<UUR) seems to be an 
"etiological hot spot" for mtDNA mutations, with up to nine different point mutations and one single 
nucleotide pair deletion (Shoffner et al, 1995) reported to date This may be related to the binding 
of a transcription termination factor downstream of the rRNA genes, within the tRNAU u ( U U R ) gene 
Only a few missense mutations have been reported, most of them in LHON patients Two 
point mutations, in ND4 (at bp 11084), and, recently, in COMI (at bp 9957, Manfredi et al, 1995), 
have been reported in MELAS patients The former is now considered to be a nonpathogenetic 
polymorphism Keightley et al (1996) recently desenbed a patient with recurrent myoglobinuria, 
severe complex IV deficiency in skeletal muscle mitochondria and a 15-bp microdeletion in the 
СОШ gene Point mutations in the ATPase 6 gene at bp 8993 and 9176 (Thyagarajan et al, 1995) 
have been reported in patients with NARP and Leigh syndrome 
5. Nuclear DNA mutations 
Only one nuclear DNA mutation in an OXPHOS gene has been described to date by 
Bourgeron et al (1995) Two siblings with Leigh syndrome and complex II deficiency were shown 
to be homozygous for an Arg554Trp substitution in the Fp subunit of complex II Various groups 
are screening the structural genes of cytochrome с oxidase, whose cDNA sequences are all known, 
for mutations in patients with isolated COX deficiency Sofar, none have been identified (Van den 
Bogert, personal communication) 
6. Biochemical analysis of OXPHOS 
The complete oxidation of pyruvate, glutamine, or fatty acids to C 0 2 and H 2 0 with the 
concomitant synthesis of ATP is a very complex process The overall respiratory chain flux can be 
measured using Polarographie (Sherralt et al, 1988), spectrophotometric (Birch-Machin et al, 
1993) or radiochemical procedures (Tnjbels et al, 1988) Either oxygen consumption, ferncyanide 
reduction or ' ^ 0 2 production is measured All three methods use intact mitochondria, either 
isolated, or in homogenized tissue Oxygen consumption can also be measured in permeabilized cells 
(Rustin et al, 1994) By using a variety of different oxidizable substrates and inhibitors, information 
can be obtained on the fluxes through various segments of the respiratory chain The ATP formed by 
OXPHOS can be measured enzymatically after protein denaturation by HCIO., and neutralization by 
KOH Intact cell respiration can be studied, e g using lymphocytes or cultured skin fibroblasts In 
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these cells also the conversion of glucose to pyruvate and lactate can be measured (Robinson et ai, 
1990) The ratio of the latter two products gives important information about the redox state of the 
cell and thus reveals problems in respiratory function (Figure 1) 
Skeletal muscle morphology can be studied on fresh frozen sections using a wide range of 
cytochemical and immunocytochemical techniques Fibers can be classified by the characteristics of 
myofibrillar ATPase Demonstration of the extent and distribution of lipid deposition within muscle 
fibers can be a feature of many disorders A characteristic histological feature of skeletal muscle in 
patients with mtDNA deletions or tRNA point mutations is the presence of ragged red fibers Such 
fibers, which are demonstrable with the modified Gomori trichrome stain, represent large 
accumulations of morphologically abnormal mitochondria, usually with decreased or undetectable 
cytochrome с oxidase activity Similar skeletal muscle pathology is not seen in patients with point 
mutations in protein-coding genes of mtDNA The cytological and biochemical abnormalities are 
segmental, with the result that individual muscle fibers appear as a linear mosaic of normal fiber 
segments interrupted by segments with severe OXPHOS defects (review by Shoubndge, 1994) The 
distribution and expression of mutant and wild-type mtDNAs can be studied using ;// situ 
hybridization, immunohistochemistry and single-fiber PCR techniques 
Complexes II, III and IV contain oxidizable cytochromes (named b, cL, a, and a,), which have 
characteristic absorption spectra Cytochrome concentrations can be measured 
spectrophotometrically in mitochondrial fractions using either chemical or enzymatic reduction 
(Sherratt et ai, 1988) A limitation is the necessity of purifying mitochondria from large amounts of 
tissue Increased sensitivity is achieved by recording spectra at very low temperatures (-190 °C) 
A large number of enzymes are localized in mitochondria The majority of these enzymes are 
unique to this organelle, including citrate synthase and cytochrome с oxidase, which are used as 
"markers" for mitochondria OXPHOS enzyme activities can be measured spectrophotometrically in 
purified mitochondria or homogenized tissue (fresh or frozen) by various assays (Trijbels et ai, 
1988, Zheng et ai, 1990, Birch-Machin et al, 1994, Rustin et al, 1994) When the natural substrate 
is too hydrophobic (e g coenzyme Q,0), artificial electron acceptors or donors which are more 
water-soluble have to be used Special care has to be taken for the latency of several enzymes in the 
mitochondrial inner membrane, which necessitates the disruption of the membrane by sonication, 
freeze-thawing or detergents The specificity of an assay can be tested by adding a specific inhibitor 
of an OXPHOS complex, e g rotenone for complex I, malonate for complex II, antimycin for 
complex III, azide or cyanide for complex IV, and oligomycin for complex V 
Immunoblotting techniques have been used to characterize OXPHOS deficiencies in patient's 
mitochondria at the molecular level (Kennaway et al, 1984, Morgan-Hughes et al, 1988, DiMauro 
et ai, 1990) Antibodies were raised against purified OXPHOS complexes or their subunits, mostly 
isolated from bovine heart mitochondria 
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Prenatal diagnosis of several OXPHOS defects is possible by enzymic measurements in 
chorionic villi or cultured amniotic fluid cells (Ruitenbeek et al, 1992) Tissue specific defects and 
heteroplasmic mtDNA mutations might not be expressed in these cells The expression of the defect 
in chorionic villi or amniotic fluid cells is more likely when the defect is also present in fibroblasts of 
the proband Screening for DNA mutations is difficult, since hardly any nuclear DNA mutations are 
known, and because mitochondrial DNA mutations may be masked by their heteroplasmic 
occurrence and variable clinical phenotype 
7. Model systems 
A cellular model of mtDNA-lmked diseases was developed by the use of human mtDNA-less 
(p°) cells repopulated with mutant mitochondria through fusion with enucleated patient-derived cells 
(Figure 4, King and Attardi, 1989) 
Figure 4: Mitochondria transfer into p"cells by cytoplast fusion Enucleation of p' cells is performed by 
cenlnfugalion in the presence of cylochalasin B, which causes the detachment of nuclei from the anchored 
monolayer and their pelleting lo the bottom of the bottle The enucleated cells (cyloplasts) arc then fused with p" 
cells in the presence of pol>elh\lene ghcol, and ihe fusion products, selected for in the absence of uridine or 
pyrmalc (from Attardi et al, 1991) 
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This model system has provided a valuable tool for investigating the complementation and 
segregation of mtDNA mutations (Attardi el al, 1995), and for studying the phenotypic 
manifestation of the "common" mtDNA deletion (4977 base pairs) associated with CPEO (Hayashi 
et al, 1991), and of several mtDNA point mutations in the genes coding for tRNAIy' (Chomyn et al, 
1991), tRNAUu<UUR) (King et al, 1992) and ATPase 6 (Trounce et al, 1994), associated with the 
MERRF, MELAS, and NARP syndrome, respectively These studies have demonstrated that the 
mtDNA mutations mentioned above cause defects in mitochondrial protein synthesis and cell 
respiration, in particular, the biochemical defect underlying the protein synthesis impairment in the 
MERRF syndrome caused by the 8344 mutation has been elucidated (Enriquez et al, 1995) 
Furthermore, it has been shown that these mutations are functionally recessive, since wild-type 
mtDNA, even when present in relatively small proportion, can protecl a cell against the phenotypic 
effects of the mtDNA mutation (Hayashi el al, 1991, Boulet el al, 1992, Chomyn el al, 1992) 
Recently, the reverse system was applied by fusing complex IV deficient, patient-derived p° cells 
with cytoplasts from normal fibroblasts These cybnds maintained the COX (-) phenotype, showing 
the nuclear DNA origin of complex IV deficiency in the patient with Leigh syndrome (Tiranti el al, 
1995) 
Mammalian OXPHOS enzymes are very complex (Figure 2), consisting of multiple subunits, 
many of which are not sequenced yet, and of which the function is unknown Other organisms 
contain similar enzymes, much smaller in size and complexity, with sequence homology to their 
mammalian counterparts E g , in mammals, complex I contains 41 different subunits, the enzyme of 
the fungus Neurospora crassa still consists of at least 30 different subunits, but the related bacterial 
counterparts of Escherichia coli and Paracoccus demtnficans are composed of only 17 and 14 
subunits, respectively, which have been fully sequenced (review Friedrich et al, 1993) Site-directed 
mutagenesis and gene disruption are used to study the topology, assembly and function of the 
OXPHOS complex subunits Also the genetic analysis of respiratory deficient mutant strains of 
Saccharomyccs cerevisiae and their revenants contribute to the understanding of structure-function 
relationship of various subunits (Grivell, 1995) 
Animal models are not yet available for mitochondrial encephalomyopathies, for two reasons 
First, it is technically very difficult to generate an animal model for heteroplasmic mtDNA point 
mutations Conventional DNA transfeclion systems cannot be applied to target the DNA sequence 
with the mutation to the mitochondrial genome inside the mitochondria Second, as only one nuclear 
OXPHOS mutation has been described (Bourgeron et al, 1995), the choice of a certain nuclear gene 
for modifying or knocking out is difficult The fact that nuclear mutations have been rarely found to 
date might even suggest that mutations in most structural OXPHOS are lethal in the embryonal 
stage Two animals with myopathy have been described A horse had complex I deficiency associated 
with profound exercise intolerance (Valberg el al, 1994) Muscle sections showed ragged red fibers 
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and morphologically abnormal mitochondria An english sheep dog with exercise intolerance and 
lactic acidosis had ragged red fibers in its muscle, associated with complex IV deficiency and 
reduced mRNA levels of subunits COX I and COX II in muscle and fibroblasts (Vijayasarathy et al, 
1994) 
8. Scope of this thesis 
The major goal of this thesis was to improve assays and develop new techniques to 
characterize OXPHOS deficiencies in mitochondrial myopathy patients 
Chapter II describes the methodology for designing antibodies against human mitochondrial DNA 
encoded subunits and their use in an immunoprecipitation assay 
Several of these and other antibodies are used (Chapter III) to characterize complex I deficiencies 
in mitochondrial myopathy patients by immunoblotting of small amounts of their skeletal muscle 
mitochondria 
In Chapter IV a two-dimensional electrophoretic system, detecting all five assembled OXPHOS 
complexes in one gel, was used to analyze and quantitate OXPHOS enzymes in muscle tissue of 
(encephalo-)myopathy patients with enzymatic OXPHOS defects and/or mtDNA mutations 
The same method was also rescaled for blood platelets and cultured cells, like fibroblasts (Chapter 
V) 
Histology, enzymatic analysis, two-dimensional electrophoresis and metabolic labeling of muscle 
and/or fibroblasts were used to characterize a unique patient with a combined deficiency of complex 
I and IV in his muscle, but only complex I deficiency in his fibroblasts (Chapter VI) 
Chapter VII describes a patient in whom a complex III deficiency has been investigated with a 
modified method for the enzymatic measurement of complex III 
Finally, in Chapter Vili a cellular model system for mtDNA-lmked diseases was used to study the 
phenotype/genotype relationship of the 3243 mtDNA mutation associated with the MELAS 
syndrome 
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Introduction 
Antibodies directed against a short synthetic peptide sequence predicted 
from a given gene sequence were shown by Walter et al.1 to be able to 
recognize a full-length protein containing that short peptide sequence. This 
approach has been applied extensively for the identification of the proteins 
encoded in cloned genes.1 A successful application has been in the identifi­
cation of the mitochondrial translation products 2 6 corresponding to the 
reading frames7 of human mitochondrial DNA (mtDNA). Peptide-specific 
antibodies specific for individual mtDNA-encoded polypeptides have also 
been used to immunoprecipitate entire respiratory complexes containing 
t h e m , 8 1 0 as well as in the molecular analysis of defects associated with 
mitochondrial diseases.11"13 
This chapter focuses on the use of peptide-specific antibodies in immu-
1
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noprecipitation experiments involving mtDNA-encoded polypeptides. 
However, before going into the details of these experiments, we summarize 
the steps that were carried out in producing the peptide-specific antibodies. 
Selection and Synthesis of Peptides 
The peptides used for the studies mentioned above on mtDNA-encoded 
polypeptides were 7 to 18 amino acids long (Table I). The length depended 
on the presence and location of amino acids utilizable for coupling the 
peptide to a carrier protein and was limited by the presence of amino acids 
that would present difficulties for peptide synthesis, such as proline near 
the COOH terminus and cysteine. Sometimes the peptide was lengthened 
to increase the distance between proline and the COOH terminus. 
Whenever possible, the COOH-terminal peptide was chosen for synthe­
sis, because it was considered to be likely to be exposed in the complete 
polypeptide chain. In addition, the attachment of its NH 2 terminus to a 
carrier protein is easily done.2 The second choice was the NH2-terminal 
peptide, which in the intact protein might also be easily accessible to anti­
bodies. In some cases, internal peptides were tried. Among these, some 
(ND1-I1, ND1-I2, ND6-I1, and ND6-I2) were chosen from among the 
hydrophilic portions of the protein, as determined by a Kyte-Doolittle 
hydropathy plot.1" Other peptides (ND4-I1, ND4-I2, ND4-I3, ND4-I4, 
ND4-I5, ND5-I, and ND6-I3) were chosen on the basis of hydrophilicity, 
surface probability, flexibility, high probability of β turns, and low α-helix 
or /3-sheet propensity15 using the computer programs PEPPLOT or PLOTS-
TRUCTURE. 1 6 When no amino acid suitable for coupling was present in 
the selected peptide sequence, such an amino acid was added at the NH 2 
terminus of COOH-terminal peptides and at the COOH terminus of NH2-
terminal peptides, and at either or both ends of internal peptides (Table 
I). Alternatively, the activatable 5-acetylthioacetyl (SATA) group was 
attached to the NH 2 terminus.
17 
For the determination of the peptide-carrier ratio, a radioactive amino 
acid was included in the synthesized peptide,2·3 or the peptide was extended 
with L-norleucine at the NH 2 terminus.
17
 The peptides were synthesized 
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peplide-specißc antibodies 
TABLE I 
A B I L I T Y T O I M M U N O P R E C I P I T A T E P O L Y P E P T I D E " 
Peptide 
COII-N3i ,c 
COII-C' 
A8-N' 
A8-C3 
A6-C 
ND1-I12 
(3397-3420) 
ND1-I22 
(3475-3498) 
ND1-C 
ND3-C1" 
ND3-C2" 
Cytb-N2 
NDa-N' 
ND4-N5 
ND4-C' 
ND4L-N5 
ND4L-C5 
ND5-N5 
ND5-C5 
ND6-N6 
ND6-C* 
NDo-Il6 
(14,422-14,454) 
ND6-I26 
(14.593-14,622) 
ND4-I111 
(11,000-11,041) 
ND4-1211 
(11,162-11,194) 
ND4-I3" 
(11,587-11.684) 
ND4-I411 
(11,744-11,776) 
ND4-I511 
(12,017-12,064) 
ND4-C" 
ND5 -I" 
(12,397-12.441) 
ND6-I311 
(14.242-14.292) 
Sequence 
MAHAAQVGLQ(E)" 
KIFEMGPVFTL 
MPQLNTTV(Y) 
(K)SLHSLPPQS 
(K)VSLYLHDNT 
AcMQLRKGPN(Y) 
(Y)TKEPLKPA(Y) 
(K)PITISSIPPQT 
KGLDWTE 
(Y)LQKGLDWTE 
MTPMRKINP(E) 
INPLAQPV(E) 
MLKLIVP(E) 
(K)PDIITGFSS 
MPLIYNM(E) 
(K)HNLNLLQ-X 
MTMHTTM(AE) 
(K)TLLLIT 
MMYALF(E) 
(K)IVIEIARGN 
AIEEYPEAWGS 
AcGFSSKPSPIY 
•QRHLSSEPLSRKKL* 
*RWGNQPERLNA 
»LRQTDLKSL 
•LANSNYERTHS 
•THHINNMKPSFTRENT 
*PDIITGFSS 
»TTLVNPNKKNSYPHY 
•EGEGSGFIREDPIGAGA 
Attachment 
E D C ' 
GLUT 
BDB 
GLUT 
GLUT 
BDB 
BDB 
GLUT 
GLUT 
BDB 
EDC 
EDC 
EDC 
GLUT 
EDC 
GLUT 
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'The first 22 peptides were synthesized and antisera to them were produced by Dennis Trovato, 
Donna D Strong, Marcia Riley, Barbara Cottrell, and Russell F Doohttle, Department of Chemis-
try, University of California at San Diego, La Jolla, California The last eight peptides were 
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by Merrifield solid-phase procedures.18·19 In most cases, the amino acid 
composition of the synthesized peptides was checked by amino acid analysis 
after acid hydrolysis. Furthermore, the homogeneity and correct charge 
were in some cases determined by paper electrophoresis.2"6 The homogene­
ity was also checked in some cases by high-performance liquid chromatogra­
phy.3·11 Mass spectroscopy was also used to confirm the correct molecular 
weight of the peptide.11 Checks such as these were done (1) to ensure that 
the correct amino acids had been used in the synthesis and (2) to ensure 
that blocking groups, such as those used on acidic side chains, had been 
completely removed.2 
Coupling of Peptides to Carrier Proteins 
Peptides were coupled to a carrier protein [bovine serum albumin (BSA) 
or myoglobin, or ovalbumin] with one of several chemical linkers. Table I 
lists the coupling reagents that were used for the various peptides. An easy 
linker to use2 is glutaraldehyde, which links amino groups in the peptide 
to amino groups on the carrier. The method using water-soluble carbodii-
" R В Memfield.7 Am Chem Soc 85,2149(1964) 
1 9
 J M Stewart and J D Young, "Solid Phase Peptide Synthesis " Freeman, San Fran­
cisco, 1969 
synthesized by G I Tesser, Laboratory of Organic Chemistry, University of Nijmegen, 
The Netherlands 
* N. C, and I denote NH ;-terminal, COOH-terminal, and internal portions of the poly­
peptide. 
' COII, Cytochromc-r oxidase subunit II, A8, H*-ATPase subunit 8, originally known as 
A6L\ A6, H "-ATPase subunit 6, ND1, ND2, ND3, ND4, ND4L, ND5, and ND6, subumts 
of the rotenone-sensitive N ADH dehydrogenase The reading frames for the ND polypep­
tides were originally designated URF1, URF2, URF3, etc ,7 and were renamed subsequent 
to the functional identification of the respective translation products 6 8 
d
 Amino acids in parentheses were not present in the protein sequence but were included 
to facilitate attachment to the carrier molecule. Ac, Acetyl, X, a-aminobutync acid 
' BDB, Btsdiazobenzidine, BSA, bovine serum albumin; EDC, water-soluble carbodumide, 
GLUT, glutaraldehyde, MHS, 6-maleimidohexanoic acid W-hydroxysuccinimide ester, 
OA, ovalbumin, Sulfo-MBS, 6-maleimidobenzoic acid AZ-hydroxysulfosuccinimide ester 
' R F. Doolitlle, personal communication (1981, 1983). 
K The asterisk (*) indicates the extension of the peptide at its NH 2 terminus with 
5-acetyllhioacetyl and norleucine. 
* Relative ability of the antiserum raised against the peptide to immunoprecipitale the 
corresponding polypeptide. - , no immunoprecipitate formed, +, + + , + + + , relatively 
low, intermediate, and high efficiency of specific immunoprecipitation, respectively, as 
estimated by comparison of autoradiogram band intensities of the polypeptide in the 
immunoprecipitate and in the starting material, total mitochondrial lysate 
peptide-specific antibodies 33 
mide links carboxyl groups on the peptide to amino groups on the carrier 
protein.2 Bisdiazobenzidine forms bridges between phenolic rings, thus 
linking tyrosines to tyrosines.2 5-Acetylthioacetyl (SATA) generates a sulf-
hydryl group on the amino terminus of the peptide after deprotection, 
which can be used for coupling to a maleimidated carrier molecule.17 6-
Maleimidohexanoic acid /V-hydroxysuccinimide ester (MHS; Pierce, Rock-
ford, IL) and 6-maleimidobenzoic acid /V-hydroxysulfosuccinimide ester 
(Sulfo-MBS; Pierce) are used to maleimidate the carrier molecules and 
also serve as a linker between the peptide and the carrier molecules.11 
Some thought should be given to the carrier protein to be used, because 
it is likely that antibodies to the carrier protein, as well as to the peptide, 
will be produced by the rabbit.3 These carrier protein-specific antibodies 
can be dealt with in one of two ways, as discussed below in the section on 
immunization. 
Determination of Peptide-Carrier Ratio 
The average number of peptides attached to a molecule of carrier 
protein was determined in one of two ways: either a small amount of 
radioactive amino acid was incorporated in the peptide sequence, and 
then the radioactivity of the peptide-carrier conjugate after dialysis was 
determined, or the peptides were extended with L-norleucine (Nie) at the 
NH2 terminus, and then the ratio of Nie to the other amino acids was 
determined by amino acid analysis of the hydrolyzed conjugate.17 Tricine-
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)20 
was sometimes used to get a rough idea of the peptide-carrier ratio in 
the conjugates and an indication of the extent of cross-linking between 
carrier molecules. 
Immunization and Antibody Preparation 
All antisera were raised in rabbits. Two rabbits were injected with a given 
antigen at 2- to 3-week intervals. Each rabbit received the peptide-carrier 
protein conjugate mixed in a 1:1 (v/v) ratio with the Freund's adjuvant sys-
tem [complete, FCA (Difco, Laboratories, Detroit, MI), for initial injections, 
or incomplete, FIA, for booster injections]. The Ribi adjuvant system (Ribi 
ImmunoChem Research, Inc., Hamilton, MT) yielded only low levels of pep-
tide-specific antibodies.1 ' One of the protocols for the administration of adju-
vant preparations was as follows: antigen conjugate-FCA (1 mg conjugate, 
total volume 2 ml) was injected intradermally at 20 sites on the back of the 
animal; antigen conjugate-FIA (0.5-mg conjugate, total volume 1 ml) was 
20
 H Schagger and G. von Jagow, Anal Biochem. 166, 368 (1987). 
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injected intramuscularly and subcutaneously Blood samples were taken be 
fore the first injection (preimmune serum) and either 2 weeks after or imme­
diately before the booster injections The sera were prepared and then stored 
at - 20° In some cases, -y-globuhns were isolated from the serum by precipita­
tion with 33% saturated ammonium sulfate9 or by passing the serum over a 
protein-Α Sepharose column (Pharmacia/LKB Biotechnology, Piscataway, 
NJ) In earlier experiments, we routinely removed the carrier protein-specific 
antibodies from the γ-globulin fraction by passing the latter over an affinity 
column to which the earner protein alone had been covalently linked The 
flow-through thus contained peptide-specific antibodies devoid of earner-
specific antibodies This purification step has since been found to be unneces­
sary for immunoprecipitation expenments, as the same earner protein is 
never used m expenments done with the antibodies For example, the pep­
tides were coupled in most instances to BSA (Table I) In immunoprecipita­
tion protocols using the antibodies generated to those peptides, ovalbumin, 
rather than BSA, is used as the blocking agent Thus, any BSA-specific anti­
bodies that may be present m the antibody preparation do not form îmmuno-
precipitates 
Enzyme-Linked Immunosorbent Assay 
The presence of peptide-specific antibodies was detected by double 
immunodiffusion against peptide coupled to a different earner3 or by solid-
phase radioimmunoassay with antibodies after they had been passed over 
a earner protein-affinity column twice 3 Titers were determined by enzyme-
linked immunosorbent assay (ELISA),21 using the peptides coupled with 
a different linker to a different carrier protein as coating antigens, in order 
to exclude reactions of no interest 
Protocol for Labeling and Immunoprecipitation of Mitochondnal 
Translation Products 
Pulse Labeling with [35S]Methionine 
To label specifically mitochondnal translation products, an inhibitor of 
cytosohc protein synthesis, such as emetine or cycloheximide, is used Eme-
tine is supenor for suppressing extramitochondnal protein synthesis, but 
it should be noted that its action is irreversible We have usually labeled 
cells with at least 25 μ θ / m l [35S]methionme for 2 hr in methiomne-free 
medium in the presence of 100 ßg emetine/ml For this labeling protocol 
21
 H J Geerhgs W J Weijer W Bloemhof! G W Welling and S Welling Wester J 
Immunol Methods 106, 239 (1988) 
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we do not carry out a chase. The details of the labeling protocol are given 
elsewhere in this volume22 (see also note 1 below). 
To obtain cleaner immunoprecipitates, it is advisable to isolate the 
mitochondrial fraction as described.22 The mitochondria can be stored fro-
zen at -70° until needed. Alternatively, whole-cell lysates can be used in 
the immunoprecipitation protocol; however, these lysates will have lower 
specific activity than the mitochondrial fraction and may give less clean 
immunoprecipitates. The protein concentration of an SDS lysate of a sample 
and the concentration of incorporated radioactivity of the isolated mito-
chondria or of the whole-cell preparation should be determined.22 The 
specific activity of a mitochondria preparation should preferably be at least 
1000 disintegrations/min (dpm)^g, and that of a whole-cell preparation 
should be at least 500 dpm/p.g. The amount of protein used in an immuno-
precipitation reaction is 30 to 100 /¿g. 
Immunoprecipitation 
Stock Solutions 
1 M Tris-HCl, pH 8.0 (25°) 
1 M Phenylmethylsulfonyl fluoride (PMSF) in dimethyl sulfoxide 
(DMSO) or 0.25 M PMSF in ethanol (PMSF is very toxic; therefore, 
the solution of PMSF in DMSO should never be made in amounts 
greater than 1 ml and should be used with care, because, if the 
solution is spilled on the skin, the DMSO, and presumably the PMSF 
dissolved in it, will be absorbed through the skin) 
20% (w/v) Sodium dodecyl sulfate (SDS) 
10 mg/ml Ovalbumin in water (use another protein if ovalbumin was 
used as the carrier molecule for immunization) 
Freshly made 10% (w/v) Triton X-100 
10X NET: 1.5 M NaCl, 0.5 M Tris base, 50 mM EDTA, 0.2% (w/v) 
NaN3; adjust to pH 9.0 with hydrochloric acid (see note 2 below) 
Procedure. Within 24 h of use, prewash the immunoadsorbent, formalde-
hyde-fixed cells of Staphylococcus aureus, strain Cowan I (Zysorbin, Zymed 
Laboratories, San Francisco, CA), with approximately 10 volumes of l x 
NET, 0.5% Triton X-100. Incubate the well-suspended immunoadsorbent 
in this buffer at room temperature for 15 min. Centrifuge the suspension 
(at 10,000 g for 8 min in a Sorvall rotor, or in a microcentrifuge at 12,800 
g for 3 min), and suspend the pellet in the same buffer. Centrifuge the 
suspension immediately and suspend the pellet in 1 x NET. Centrifuge the 
2:
 A. Chomyn, this volume [18] 
36 Chapter II 
suspension once more and suspend the final pellet in l x NET containing 
1 mg/ml ovalbumin, 1 mM PMSF, 1 mA/ methionine, at the original suspen­
sion concentration, that is, so as to make a 10% (v/v) suspension Keep the 
suspension at 4° until needed 
Lyse the mitochondria or cell suspension in 1% SDS (w/v) at 1 4 mg 
protein/ml We carry out this step by diluting the preparation, for example, 
40 μg protein per reaction, to 2 8 mg protein/ml with water or with 0 25 
M sucrose, 10 mM Tns-HCl, pH 6 7, and then adding an equal volume, in 
this case, 14 3 μ.1, of 10 mM Tns-HCl, pH 8 0, 2% SDS, 1 mM PMSF 
Incubate the lysate at 37° for 15 to 60 min, and then add 9 volumes of a 
mixture consisting of 1 ml of lOx NET, 1 ml of 10 mg/ml ovalbumin, 7 ml 
distilled water, and 10 μΐ of 1 M PMSF at room temperature Mix and add 
120 μ.1 S aureus suspension (prewashed) Agitate at room temperature 30 
to 60 min Pellet the immunoadsorbent, and add to the supernatant 100 
μg of the -y-globulin fraction of the antiserum or 10 μ.1 of the antiserum 
Incubate the lysate-antibody mixture overnight at 4° with gentle mixing 
Bring samples to room temperature and add 120 μ.1 fixed S aureus suspen­
sion (prewashed) Incubate at room temperature with agitation for 1 hr 
Centrifuge the suspension to collect the S aureus (2 min in a microcentrifuge 
at 12,800 g) and wash the pellet three times at room temperature, twice 
with 1 ml of l x NET, 1 mg/ml ovalbumin, 0 1% SDS, 1 mM PMSF, and 
2 mM methionine, and a third time with 1 ml of 10 mM Tns-HCl, pH 8 0 
Remove the last supernatant completely (carry out an extra, brief spin to 
collect the last bit of supernatant) and add to the pellet 60 μΐ of 5 mM 
Tns-HCl, pH 8 0, 1% SDS, 1 mM PMSF Suspend the pellet well and 
incubate at 37° for 30 mm Centrifuge the suspension in the microcentrifuge 
for 4 mm (12,800 g) and transfer the supernatant (the eluate) to a fresh 
tube Store at -70°, or analyze 30-40 μΐ immediately by SDS-gel electro­
phoresis To prepare the sample for electrophoresis on a Laemmh23 gel, 
add one-fourth volume of 5x sample buffer which contains only 1% SDS 
An SDS concentration greater than 1 % in the sample will cause low molecu­
lar weight polypeptides to run as diffuse bands 2 2 The conditions for gel 
electrophoresis and fluorography are given elsewhere in this volume 2 2 
Control immunoprecipitation reactions should always be done, to distin­
guish specific immunoprecipitates from background precipitates An essen­
tial control reaction is one performed, preferably, with preimmune serum 
or, otherwise, with normal serum in the place of the peptide-specific antise­
rum Another useful control is an antibody reaction earned out in the 
presence of 5 to 20 μg of the corresponding synthetic peptide 
2 3
 U Laemmli Nature (London) 227, 680 (1970) 
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Notes 
1. Pretreatment of the cells with chloramphenicol at 40 p.g/ml in com-
plete medium for 22 hr prior to labeling will increase the amount of label 
incorporated into at least some of the mitochondrial translation products 
during a 2-hr pulse.10·22 
2. We have found that, for most of the peptide-specific antibodies di-
rected against mitochondrial translation products, more of the respective 
polypeptide is immunoprecipitated in a high pH buffer (pH 9.0 at 25°), as 
compared to a pH 7.4 buffer, and fewer nonspecific polypeptides contami-
nate the immunoprecipitate. There are three exceptions: H+-ATPase sub-
unit 6, H*-ATPase 8, and ND2 are more efficiently precipitated by the 
A6-C, A8-C, and ND2-N antibodies at pH 7.4. 
3. Purification of the peptide-specific antibodies by affinity chromatog-
raphy with a column to which the specific peptide is covalently linked does 
not lead to improved immunoprecipitation of the respective polypeptide. 
4. The immunoadsorbent protein A-Sepharose, in our hands, does not 
substitute well for formaldehyde-fixed S. aureus. 
5. Triton X-100, which is often used in conjunction with SDS in immuno-
precipitation experiments, is actually inhibitory for the immunochemical 
reactions described here.3 
Results 
The ability of all the peptide-specific antibodies tested to immunoprecip-
itate human mitochondrial translation products is listed in Table I. Also 
included are the peptide sequence used, the attachment procedure, the 
carrier molecule, and the peptide-carrier ratio. It can be seen that in general 
either the COOH- and/or NH2-terminal peptides gave good results. The 
C-terminal peptides were more often successful than their N-terminal coun-
terparts. Only in the cases of ND5 and ND6 did these antibodies not 
precipitate their respective polypeptide. On the other hand, antibodies 
against predicted internal epitopes were successful in precipitating the ND5 
and ND6 polypeptides. It must be stated, however, that the prediction of 
internal epitopes was successful in only one of five and two of three cases 
for ND4 and ND6, respectively. Only one internal peptide sequence of 
ND5 was tried, which yielded weakly reactive antibodies. Two internal 
peptides of ND1 failed to yield antibodies capable of precipitating ND1. 
There was no correlation between the peptide-carrier ratio and the effi-
ciency of the antiserum in immunoprecipitating the respective polypeptide. 
Other Uses of Peptide-Specific Antibodies 
Peptide-specific antibodies against COII-C, ND1-C, ND3-C, and 
ND4L-C (Table I) have been used in Western blots of HeLa cell mitochon-
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dna (COII-C)1 0 and bovine (ND1-C, ND3-C, and ND4L-C) heart mito­
chondria.24 Similarly, antibodies against ND4-I5, ND4-C, ND5-I, and ND6-
13 (Table I) have been used successfully in Western blots of human skeletal 
muscle mitochondria, both from control individuals and from mitochondrial 
myopathy patients with various respiratory chain enzyme deficiencies.11·25 
The specificity of the reaction can be determined by a preincubation of the 
antibodies with the free peptide. In addition, antibodies against an internal 
peptide of Neurospora crassa N D l 2 6 that has 12 of 14 amino acids identical 
with the homologous human sequence reacted in this assay.25 The enhanced 
chemiluminescence (ECL) kit (Amersham, Arlington Heights, IL) is very 
sensitive for detection of weakly bound antibodies. 
Peptide-specific antibodies to human mitochondrial translation products 
have also been used successfully for immunohistochemistry. Specifically, 
COII-C antibodies (Table I) have been used to detect the presence or 
absence of the corresponding polypeptides in skeletal muscle sections.13 
A word of caution should be given here regarding the use of peptide-
specific antibodies for immunohistochemistry. As the peptides can be quite 
short, there is a possibility that the peptide-specific antibodies could cross-
react with a noncorresponding polypeptide(s) containing a similar peptide 
sequence. In fact, such a case has been reported.3 Antibodies specific for 
a COOH-terminal peptide of the mitochondrial translation product H+-
ATPase subunit 8 cross-reacted with NDl. The peptide sequences were 
A8-C: ( K ) S L H S L P P Q S 
ND1-C: ( K ) P I T I S S I P P Q T 
Thus, four of the last eight amino acids in H+-ATPase subunit 8 were 
identical to four amino acids in the COOH-terminal octapeptide of NDl, 
and, furthermore, the two polypeptides had similar amino acids in three of 
the remaining four positions in the COOH-terminal octapeptide. Similarly, 
antibodies directed against a COOH-terminal peptide of NDl cross-reacted 
with H+-ATPase subunit 8.4 Thus, any peptide-specific antibodies that will 
be used to detect the presence of a protein by a method that does not 
reveal the size of the protein should first be characterized at the molecular 
level, by immunoprecipitation or Western blots, ideally using the same 
source of material that will be used in the immunohistochemistry, for exam­
ple, whole cells, muscle preparations, or subcellular fractions. 
2 4
 F G. Ρ Earley, S. D Patel, С. I. Ragan. and G. Attardi, FEBS Lett. 219, 108 (1987) 
" H. А. С M. Bentlage, R. de Coo, H ter Laak, R. Sengers. F. Tnjbels, W. Ruitenbeek, W. 
Schlote, К Pfeiffer, S Gencic, G. von Jagow, and H. Schagger, Eur. J. Biochem. 227, 
909 (1995). 
2 6
 R. Zauner, J. Christner, G. Jung, U. Borchart, W. Machleidt, A. Videira, and S. Werner, 
Eur J Biochem 150, 447 (1985) 
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Abstract 
Antibodies have been raised against svnthetic peptides corresponding to several computer predicted epitopes of three mtDNA encoded 
subunits ND4 ND5 and ND6 of the human respiratory chain NADH dehydrogenase (Complex I) Antibodies were ch iractenzed bv a 
sensitive immunoblottmg assay using proteins from human skeletal muscle mitochondria and by immunoprecipitation of radio labeled 
HeLa cell mitochondrial translation products Only antibodies against two of six selected peptides of the ND4 subunil ι e the С terminal 
peptide and an internal peptide close to the С terminus reacted in both assays with Ihe subunil Antibodies raised against an internal 
peptide close lo (he N terminus of the ND5 subunil and antibodies raised against an internal epitope of the ND6 subunit also reacted in 
both the imniunoblolling and immunoprecipitation assays The antibodies described above ind other Complex I subunit or holoinzyme 
specific antibodies were used to investigate the subunit deficiencies of the respiratory NADH dehydrogenase in the skeletal muscle of 
patients affected by mitochondrial myopathies associated with Complex I defects The reduction in enzyme activitv correlated in an 
immunoblot assay with a decrease of four mtDNA encoded subuniis of the enzyme as well as with a decrease of other subunits of 
Complex I encoded in the nDNA The present work provides the first evidence of a decrease in NADH dehydrogenase subunits encoded 
in the mitochondrial genome in myopathy patients 
ke\Hords NADH dehydrogenase Complex I deficiency ND subunil Piplidc specific antibody Mitochondrial mvopjlhv 
1 Introduction 
Mitochondrial (encephalo)myopathies are a heleroge 
ncous group of disorders affecting predominantly skeletal 
muscle and the central nervous system A defect in Ihe 
mitochondrial energy metabolism is thought to be the 
primary cause of disease One of the respiratory chain 
enzymes that is frequently found deficient in various Us 
sues of patients is NADH-ubiquinone oxidoreductase 
(NADH dehydrogenase or Complex I EC 1 6 99 3) [1,2] 
Abbreviations ECL, enhanced chemiluminescence FAB fasi alom 
bombardment MELAS mitochondrial myopathy encephalopathy lactic 
acidosis and ыгоке like episodes 
Corresponding author Fax + 3 1 8 0 616428 
ll spans Ihe mitochondrial inner membrane and oxidizes 
NADH generaled by substrate oxidations in the matrix 
This large multimene protein consists of at least 41 sub 
units (review [4]), including seven (called ND) subunits 
that are encoded in the mitochondrial genome [4 5] 
Antibodies against Complex I subunits are very useful 
for studying the molecular basts of mitochondrial en 
cephalomyopathies Polyclonal antibodies against purified 
beef heart Complex I have been previously shown to react 
with only approximately 15 subunits of the enzyme in 
human mitochondria The use of these antibodies with 
skeletal mitochondrial proteins from myopathy patients 
showed a generalized reduction of all cross reacting poly 
peptides, in some cases with a disproportionate and severe 
deficiency of a few subuniis [1,6] The ND subunits were 
nol detected by these antibodies 
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Tibie 1 
Amino a id sequi.ni.LN of selected pLptides as shown in Fig 1 
Peptide (Number) Amino acid sequence 
ND4 [ 
ND4 I 
ND4 I, 
ND4 [4 
ND4 I, 
MM Г 
ND5 I 
ND6 I, 
( SI 94) 
(135 145) 
(277-28S) 
(329 339) 
(42П 435) 
(451-459) 
< 21- 35) 
(12S 144) 
SATA Me Oln Arg His Leu Ser Ser Glu Pro Leu Ser Arg Lvs Lvs Leu 
SATA Nie Arg Trp Gly A.sn Gin Pru Glu Arg Leu Asn Ala 
SATA Nie Leu Arg Gin Thr Asp Leu l ys Ser Leu 
SATA Nie leu Ala Asn Ser Asn Tir Glu Arg Thr His Ser 
SATA Nie Thr His HIS Ile Ain Asn Mel Lvs Pro Ser Phe Thr A/g Glu Asn Thr 
SATA Nie Pru Asp lie Ile Thr Gly Phe Ser Ser 
SATA Nie Thr Thr Leu Val Asn Pro Asn Lys Lys Asn Ser Туг Pro His Туг 
SAT's Nie Glu Glv Glu Glv Ser Glv Phe Ile Arg Glu Asp Pro Ile Glv Ala Glv Ab 
In braci 
5 acctvl 
.eis are eisen ihe amino acid numbers corresponding lo Anderson et al [12] The peptides were entended with L norleueine (Me) and 
hioacelv] (SATA) at the amino terminus for determination of the peptide carrier ratio and coupling procedures respectively [14] 
Antibodies against synthetic peptides corresponding to 
the С or N terminal regions of the human mlDNA en 
coded subunits have been previously used to identify the 
corresponding polypeptides by immunoprecipitation assays 
[4 5 7 8] and occasionally by immunoblolting [9] Anti 
bodies against peptides of predicted antigenic sequences 
can recognize epitopes on the whole proton [10 11] Since 
the hydrophobic ND subunits are very difficult to purify 
and have a low immunogenics we have raised antibodies 
against a few chemically synthesized peptides correspond 
ing to predicted epitopes In this paper we describe the 
preparation and characterization of antibodies against scv 
eral peptides of human mitochondrial NADU dehydro 
genäse subunits ND4, ND5 and ND6 and the use of these 
antibodies as well as of antibodies specific for other 
subunits of the enzyme for the molecular analysis of 
Kyle Doolittle (9 residues) 
ND4 
ND5 
ND6 
0 
3 J 
I 
0 I, I, 
CD 
I, 200 
he 1 The hydrophohieity profiles for the human ND4 ND5 and ND6 subunils They are shown as calculated with a sequence window of У residues The 
selected peptides (Table 1) are marked by boxes below the ammo acid axis Open or closed boxes indicale coupling of the peptides to either BSA wilfl 
MHS or OA with sulfo MBS respectively I
 ( and I below NDr. indicate peptides (amino aeid numbers 74 84 and 18 27 respectively) used bv Chomvn 
et al h] 
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Complex I defects in human mitochondrial myopathies 
Multiple deficiencies of mlDNA- and nuclear encoded 
subunits ot this enzvme complex have been detected in 
myopathy patients, and shown to correlate with the sever­
ity of the enzyme defect 
2. Materials and methods 
2 I Selection and synthesis of peptides 
The reported sequence of the human mitochondrial 
genome [12] was computer analyzed using the program 
PEPPLOT [Π] Criteria for selection of linear epitopes 
were hvdrophilicitv. surface probability flexibility, high 
β turn and low α-helix or ß-sheet propensity [11] The 
amino acid sequences of the selected peptides lor ND4, 
ND5 and ND6 are shown in Table I their position in each 
subunil is shown in Fig I Several candidate epitopes of 
ND4 were selected The C-ierminal peptide previously 
used by Manottini et al [8], even though it was not a 
predicted epitope by the criteria mentioned above, was 
synthesized for purpose of comparison Only one internal 
epitope of ND5 and ND6 was chosen For ND6 this was 
the only candidate epitope not used previously by Chomyn 
et al [5] The peptides were custom synthesized by Dr 
G I Tesser (Laboratory of Organic Chemistry. University 
of Nijmegen, The Netherlands) by solid phase peptide 
chemistry The peptides were extended with L-norleucine 
(Nie) and i-acetylthioacetyl (SATA) at the N-terminus for 
determination of the peptide-carrier ratio and coupling-pro-
cedures, respectively [14] 
2 2 FPLC, FAB mass spectra and ammo acid analysis 
Peptides were analyzed by reversed-phase chromatog-
raphy using a PepRPC HR 5 / 5 column (Pharmacia/LKB) 
and a continuous gradient of acetonilnle (0-40%, v / v ) in 
0 1% (v/v) tnfluoroacctic acid created by an FPLC system 
(Pharmacia/LKB) FAB mass spectra of collected peak 
fractions were analyzed by Dr G van de Werken (Na-
tional Institute of Health, Bilthovcn, The Netherlands) The 
samples were hydrolvzed with 6 M HCl for 1 h at 150°C 
or 18 h at 120°C in vacuum hydrolysis tubes (Pierce) The 
amino acid content of the hydrolysates was determined 
with an Alpha-Plus amino acid analyzer (Pharmacia/LKB) 
2 3 Coupling of peptides to carrier proteins 
Peptides were coupled to the carrier proteins bovine 
serum albumin (BSA), myoglobin (MYO) or ovalbumin 
(OA, all from Sigma) with 6-malcimidohexanoic acid N-
hydroxysuccimmide ester (MHS, Pierce) according to 
Schielen et al [14], except that 6-maleimidobenzoic acid 
W-hydroxysulfosuccinimide ester (Sulfo MBS, Pierce) was 
used as a linker in some cases 
2 4 Immunization of rabbits 
Two rabbits were injected with each antigen at 2-1 
week intervals Each rabbit received a pcptide-camer pro-
tein conjugate mixed in a 1 1 (v /v) ratio with the Freund s 
adjuvant system (complete, FCA or incomplete, FLA 
Difco) Conjugates of ND4 I, and ND4-C were also tested 
with the Ribi adjuvant system (RAS, Sanbio) The admin 
istration of adjuvant preparations was as follows FCA (1 
mg conjugate, total volume 2 ml) intradermals at 20 sites 
on the back of the animal FIA (0 5 mg conjugate total 
volume 1 ml) intramuscularly and subcutancoush RAS 
(first dose 1 mg conjugate, thereafter 0 5 mg. each total 
volume 1 ml) at multiple places according to suggestions 
of the manufacturer Blood samples were taken before the 
first injection (preimmune serum) and either 2 weeks alter 
or immediately before the booster injections The sera 
were prepared and stored at - 20°C Before use, they were 
made free of jnnbodies against the carrier proteins b\ 
passing them twice over a column of carrier protein conju-
gated to CNBr-activated Scpharose (Pharmacia/LKB) γ 
Globulins were isolated by fractionating the sera over a 
Protein A Sepharose column (Pharmacia/LKB) 
The rabbit antibodies against the 24 kDa subunit of 
bovine Complex I were raised using the purified protein 
over expressed in Escherichia coll (Wilks, P E , Medd, 
S M and Walker, J E . unpublished data) The adenine 
nucleotide translocase (ANT ) was isolated from bovine 
heart mitochondria bv subsequent chromatography [15] 
and electrophoresis [16] The ATPase (Complex V) was 
purified from human heart mitochondria by blue native 
electrophoresis [17] Antibodies were raised in rabbits bv 
inoculation of the purified proteins into the popliteal Ivmph 
nodes according to Sigei et al [18] The antibodies against 
the ATPase react mainly with the /3-subunit in an im-
munoblot assay (results not shown) The antibodies against 
the bovine Complex I holo-enzyme and the ND1 subunit 
of Nettrospora crassa were kind gifts from Dr U Наг 
nisch (Department of Biochemistry, University of Dussel­
dorf Germany) and Dr S Werner (Department of Physio­
logical Chemistry, University of Munich, Germany), re­
spectively The former showed a reaction with approxi 
matcly 10 subunits of Complex I preparations from bovine 
and human heart tissue (results not shown) The latter were 
raised against a highly conserved peptide which has 12 of 
14 amino acids identical with the homologous human 
sequence [19] 
2 5 Enzyme-linked immunosorbent assay (ELISA) 
Antibody liters were determined by LL1SA assays es­
sentially as described by Gcerhgs et al [20] using the 
peptides coupled with a different linker to a different 
carrier protein as coating antigens, in order to exclude any 
cross reactions The titer is defined as the reciprocal of the 
serum dilution giving an ELISA-signal above background 
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(no scrum addition), equivalent to twice the sum of the 
mean background and Us standard deviation The antibod­
ies raised against the earner and the linking part were also 
assayed The specificity of each reaction was investigated 
by testing the serum sample after a preincubation with the 
corresponding peptide 
2 6 1 abelmg and immunoprecipitation of mitochondrial 
translation products 
HeLa cells were labeled for 2 h with ["S]mcthionine 
(20-50 дСі/ml 1000-1500 Ci/mmol) in the presence of 
emetine, an inhibitor of cytoplasmic protein synthesis, at 
100 Mg/ml and at a cell concentration of 2 lO^/ml [21], 
whereafter the mitochondrial fraction was isolated [7] 
Immunoprecipitation was carried out using a SDS lysate of 
this fraction as described previously [8] except that 80 /ig 
of mitochondrial suspension (15 104 cpm) was used in 
each experiment For each reaction either 8 5 μΐ of anti 
serum or 85 μg of the y globulin fraction was used 
Inhibition by peptides was tested by adding to the scrum 5 
μ] peptide solution in dimethylsulfoxide (DMSO) at 1 
mg/ml Where slated, 5 μΐ DMSO was used as a control 
The final immunoprecipnatcs were run on a 15-20% 
(w/v) exponential gradient SDS Polyacrylamide gel [22] 
and prepared for fluorography [23] The previously de 
scribed antibodies against ND4-C(451 459), ND5 N(1-7), 
ND5 C(598 601) and ND6-1,(74 84) were used for refer­
ence purposes [4 5] 
2 7 Patients and controls 
Specimens of the quadriceps muscle were removed by 
biopsy from patients suspected to have a defect in oxida­
tive phosphorylation From patients PI and P6 also au­
topsy material removed within 1 h after death was studied 
Seven patients wert selected for this studv based upon 
extensive biochemical analysis which pointed towards a 
Complex 1 deficiency A brief overview of some clinical 
features and laboratory data is presented in Table 2 Con 
trol specimens were considered those in which a mitochon­
drial defect had been excluded by normal substrate oxida 
tion rates and individual enzyme measurements as previ 
ously described [24] 
P5 and P7 are patients diagnosed in our hospital with 
the MELAS syndrome both carry an A to G transition at 
position 3243 in approximately 50% of their skeletal mus­
cle miDNA (Van Oost, В A , personal communication) 
All other patients and controls lack this as well as other 
known mtDNA mutations associated with mitochondrial 
myopathies or respiratory chain defects [25] P5 and P6 are 
previously described patients [26 27] 
2 S Enzvnu measurements 
The activities of the rotenone-sensitive NADH 
ubiquinone-1 oxidorcductase (Complex I), sucunate-cyto 
chrome-c oxidoreductase (Complex 11 III) cytochrome с 
oxidase (Complex IV) and citrate synthase were measured 
in 600 X ( supernatant or, where stated in mitochondria 
of homogenized skeletal muscle as described previously 
[24] The activities in 600 X g supernatants from fresh 
biopsy muscle were first normalized for citrate synthase 
activities All activities are expressed as a percentage of 
the mean of controls Ubiquinone-1 was a gift from Hoff 
man-La Roche, Basel Switzerland 
2 9 SDS Polyacrylamide gel electrophoresis and western 
blotting 
Mitochondrial proteins isolated bv differential centrif 
ugation of homogenized skeletal muscle specimens were 
Table 2 
ClmiLal laboratory and morphological features of patients studied 
Patiei it/st\ 
Diagnosis 
Age i t onset * 
AgL at biopsy * 
Progression a 
H)potonid 
Strokes 
Seizures 
Retinopathy 
Deafness 
Lactic acidosis 
RRF 
Family history 
Complex 1 b 
Complex II I I I h 
Complex IV ь 
l / F 
encephalomynpathy 
inf 
12 d 
t 2 7 d 
-t 
-
+ 
na 
na 
+ 
-
-
Π 
98 
88 
2 / F 
myopalhy 
mf 
14 
-
-
-
-
-
-
-
-
+ 
13 
77 
112 
1 / M 
enciphalomyopathy 
mf 
81 d 
t S l d 
+ 
+ 
-
na 
+ 
-
-
14 
49 
102 
4 / M 
entephalomyopathy 
mf 
16 d 
t 3 0 d 
+ 
-
-
-
na 
+ 
-
+ 
20 
101 
104 
5 / M 
M H A S 
22 
25 
slow 
-
+ 
+ 
-
+ 
+ 
+ 
-
27 
77 
57 
6 / F 
encLphalomyopalhy 
4 
17 
t l 7 
-
-
-
-
-
+ 
-
+ 
221 
751 
621 
7 / F 
MELAS 
mf 
20 
t 2 0 
-
+ 
+ 
na 
+ 
+ 
+ 
+ 
34 
57 
97 
' In years unless otherwise specified mf infantile d davs f autopsy na not available 
' Atlivitics in 600 x g supernatant are expressed as a percentage of the mean ol controls 
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fractionated (2 ^g protein per lane) on 1 0 ^ or 16 5% slab 
gels in a Mini-Protein II Apparatus (Bio-Rad) according to 
Schagger and Von Jagow [28] Proteins were blotted onto 
0 2 μτη nitrocellulose paper [29] Immunodetection was 
performed at ambient temperature as follows Where staled, 
the blot paper was cut in strips Unoccupied sites were 
blocked with phosphate buffered saline solution, 0 5% 
(w/v) Tween 20 (PBST) and 5% (w/v) non-fat dry milk 
powder for 1 h Thereafter the strips were incubated 
consecutively with the γ-globulins, a 1 5000 dilution of 
biotinylaled swine anti-rabbit immunoglobulins, a 1 10000 
dilution of a streptavidin/biotinylated horse radish peroxi­
dase mixture (both Dako) in PBST with 1 5% (w/v) BSA 
and 1% (v/v) normal swine serum (Dako), each for 1 h 
The γ-globulins (1 mg/ml) were diluted 100 to 2000-times 
in PBST with 0 5% (w/v) BSA, and occasionally, as 
specified below, premcubated for 1 h with 0 25 mg/ml 
peptide dissolved in DMSO. samples premcubated with 
the same amount of DMSO served as a control Between 
the various steps the strips were washed three limes with 
a 
M 
ND5-I ND6-I, ND6-I3 
pept pept P r e pepi pept pepi р г е 
ND4-L ND4-C 
pept pepi P f e pept pept р г е 
ND5-
COI-
ND4-
Cytb-cj 
ND2-
N D 1 -
СОПК 
соп-
ND6-
ND3-
» · 
ND4L-
А8-
Fig 2 [mmunoprtcipiiaiion capacity of suhunil specific antibodies In panel a, ihe immunoprecipitates using ND5 and ND6 peptide specific antibodies are 
shown in panel b those using ND4 peptide antibodies Pre pre immune serum, — pept or +• pept with addition of S μ[ DMSO or 5 μΙ peptide (1 mg/ml 
DMSO) respectively The immunoprecipitates were analyzed on a 15-20% exponential gradient SDS polyairylamidc gel sjstcm [22] followed by 
fluorography [23] The dried gels were exposed for 5 weeks (a) or 7 days (b) The asterisks m panel a show the positions of the immunoprLcipitaied NDS 
and ND6 suhunits Ілпе M contains HeLa cell mitochondrial proteins labelled with [35S]mtthionine in the presence of emelme The 13 subunits encoded 
in the mlDNA arc indicated on the left 
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PBST The ECL kit (Amershjm) was used for detection of 
bound antibodies 
Rabbit antibodies raised against ANT or the ATPase 
complex were used as an internal standard for mitochon 
drial protein recovery at a dilution of 1 2000 Quantitation 
of the blots was carried out by scanning the films with a 
LKB laser densitometer 
3 Results 
? / Anuhbib and coupling ofpeptides 
Reversed phase chromatography showed that the pep 
tides were pure to the extend of 70% or more (results not 
shown) Mass spectrometry analysis of the major peaks 
confirmed the expected mass of the peptides indicating 
complete removal of the protecting groups The crude 
peptide preparations were coupled to carrier proteins with 
out further purification since only the full-length products 
were expected to contain the SATA group necessary for 
coupling [14] Coupling ratios were determined by amino 
acid analysis of the conjugates comparing the amount of 
L-norlcucine (specific for the peptides) with that of amino 
acids found only in the carrier proteins Coupling ratios 
were 4-10 and 7-20 peptides per OA or BSA carrier 
molecule, respectively The maximum available free amino 
groups in both carrier proteins are 10 and 27, respectively 
[11] 
Table 3 
Antibody liters against peptides carrier proteins or linkers 
Antibody 
ND4 1, 
ND4 1 
ND4 1, 
ND4 l 4 
ND4 1, 
N D 4 C 
NDS I 
NDh I , 
T i t e r l x l O ' ) 
peptide 
197 
197 
142(19) 
6S6 
M i 
161 (1 6) 
6S6 
71 
against 
earner 
90 
9U 
91 (3 6) 
RIO 
27(1 
280(7 7) 
810 
8111 
linker 
8 1 
8 1 
0 3 ( < 0 03> 
0 9 ' 
25 
0 9 ( < 0 03) 
1 8 ' 
0 9 -
Sera were prepared from blood samples laken after three immunizations 
The values are averages of data for two animals between pircnthescs are 
the titers for RAS treated animals 
Indícales protocols using BSA/M1IS as earner/linker combination in 
all other cases OA/sulfo MBS was used 
3 2 Antibody production 
Antibody titers reached maximum values after three 
immunizations All rabbits responded to the conjugates 
used for immunization In the first experiments the RAS-
treated animals showed antibody tilers that were lower by 
a factor 10 to 40, than those of FCA/FIA treated animals 
(Tabic 4) The linkers (MHS or sulfo MBS) produced only 
low levels of antibodies in all animals, except for those 
immunized with ND4-I, MHS has already been shown to 
be poorly immunogenic [40] AJÍ subsequent experiments 
were done with the sera from the FCA/FIA-trcatcd ani-
mals 
kDa 
97 
66 
45 
ND4- ND4-C ND5-I ND6-
- + - + -
'з A 
+ J t • ρ 
31 -
21 5-
144-
6.5-
Fig 1 Analysis of subunil specific antibodies by Western blotting Western blots uf skeletal muscle mitochondrial proteins tested with antisera against 
iSD-1 I ND4 С ND5 I and NDft I, Mitochondrial proteins (2 ¿tg) isolated from skeletal muscle of a control individual (CI in Fig 5) were separated on 
a ItS Ч^е SDS polvacr>lamidc gel according ю Schagger and Von Jagow [28] The ND4 specific antibodies were both diluted 1000 limes the ND*i and 
ND6 specific antibodies 100 limes The ECL system was used for detection The exposure time was 15 s for the ND4 I, ND4 С and ND6 I, lanes and 
30 s for NDS 1 A and В + indicates a preincubation of the antiserum with the specific peptide preparation in DMSO (final concentration 1) 2*i mg/ml) 
- indicates a preincubation with the same volume of DMSO In lanes A and В no primary antibodies were added in lane В also (he incubation with the 
secondary (hiotinylated) antibodies was omitted On the left the migration positions of water soluble molecular weight marker proteins (Bio Rad) are 
indie ifcd 
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3 ? Immunoprecipilation capacity of sublimi specific anti­
bodies 
The results of the immunoprecipilation studies are 
shown in Fig 2 Lane M shows the pattern of HeLa cell 
mitochondrial translation products labeled with ["S]meth-
lonine in the presence of emetine Note the migration of 
ND6 as a doublet in the exponential gradient system used 
here [22] (see Discussion) It appears from Fig 2 that only 
antibodies against ND4-I< and ND4-C were capable of 
immunoprecipitating the labeled ND4 subunit, in a reac­
tion inhibited by the specific peptide This immunoprecip­
ilation was as effective as that observed with the ND4 С 
antiserum described by Chomyn et al [4] (results not 
shown) The other ND4 peptide-specific antibodies were 
negative in this assay 
Also the antibodies against ND5-I and ND6-I, precipi­
tated the ND5 and ND6 subunit. respectively, the reaction 
with each protein being inhibited by the corresponding 
peptide The ND5 subunit could be visualized only afler 
long exposure of the film This resulted in some back 
ground of non-specific bands not inhibited by the specific 
peptide (Fig 2) Antibodies against C- and N-terminal 
peptides of ND5 showed no reaction (results not shown) 
Our ND6 1, peptide antibodies precipitated ten times 
more ND6 than the ND6-I, antiserum, which has been 
used previously to identify ND6 as a NADH dehydro­
genase subunit [5] The immunoprccipitatcd ND6 migrated 
in the gel as a doublet as in (he original sample (lane M in 
Fig 2) The higher molecular weight bands in the ND6 I, 
(-pepi) lane may be a result of aggregation during the 
assay [5] Purified γ globulins gave an identical immuno­
precipilation pattern as total scrum (results not shown) 
? 4 Analysis of subunit specific antibodies by Western 
blotting 
Fig 3 shows the results of Western blotting experi 
ments carried out after SDS-polyacrylamide gel elec­
trophoresis by using mitochondrial proteins from human 
skeletal muscle as antigens and γ-globulin-fractions as 
pcptide-spccitic antibodies With the ECL detection system 
2 ^g of mitochondrial protein per lane was already suffi­
cient for a good signal Total serum gave a very high 
background signal, in part caused by the high levels of 
antibodies to the earner proteins (results not shown) 
Therefore, purified -y-globulin-fractions, from which the 
anti carrier antibodies had been removed, were used 
The antibodies against ND4-I5 and ND4-C reacted very 
strongly with a protein of apparent molecular mass of 39 
kOa (as estimated from its electrophoretic mobility, re la 
tive to that of water soluble marker proteins), the reaction 
being inhibited by (he specific peptide (Fig 3 first four 
lanes) The molecular mass of this protein is in agreement 
with that previously reported for bovine and human ND4, 
on the basis of its electrophoretic mobility in SDS-poly-
acrylamide gels [4,9,31] The difference in size estimate 
relative to that predicted from the DNA sequence is due to 
the use in the experiments cited above, of hvdrophilic 
marker proteins, which bind less SDS than the hvdropho-
bic mitochondrial translation products [8] The antiserum 
against ND4-I5, which has 12 of 16 amino acids identical 
with the homologous bovine sequence, also reacted with a 
mitochondrial protein from bovine heart of approximately 
the same molecular mass (results not shown) The other 
ND4 peptide-specific antibodies were negative even in up 
to 100-fold lower dilutions (results not shown) 
The antibodies against ND5-1 and ND6-I, also showed 
peptide specific reactions The ND5-l-spccific antibodies 
produced two bands in a reaction that could be inhibited 
by the specific peptide In particular they gave a strong 
reaction with a protein of apparent molecular mass of 51 
kDa, and a minor reaction with a protein of a somewhat 
higher electrophoretic mobility (Fig 1, fifth and sixth 
lane) The 51 kDa protein has the electrophoretic mobility 
in an SDS-polyacrylamide gel, expecled for the ND5 geni, 
product, the difference from the mass expecled for this 
product (66 kDa) being due to the bias in size estimates 
which was mentioned above The minor reaction wiih the 
protein moving faster than the '51 kDa protein could Ы 
explained as resulting from a cross reaction with another 
mitochondrial protein with a similar or ideniical ND5 I 
epitope(s), however, a computer search did not yield a 
known protein containing a sequence homologous for the 
amino acid sequence used The ND6-I,-specific antibodies 
gave a specific reaction with a protein of apparent molecu 
lar mass of - 8 kDa, as estimated relative to the marker 
proteins (Fig 3) Here too, the difference in molecular 
mass from that predicted from the DNA sequence (18 6 
kDa) is due to the bias in size estimates introduced b\ the 
use of hydrophilic proteins for the standard curve [8] ПоІІі 
the ND5-1- and ND6-I,-specific antibodies gave a weak 
reaction in the immunoblot as compared to the ND4 
antibodies Therefore 10-times less diluted antibodies and 
also longer exposure times with the ECI svstem in the 
case of ND5, had to be used This caused the rather high 
background in lanes ND5 I and ND6-1, in Fig 3 The 
background in the upper portion of the lanes is most likclv 
caused by biotin containing proteins reacting with the 
streptavidin/horseradish peroxidase biotin complex as 
shown in lanes A and B, where the primary and, in lane D, 
also the secondary antibodies, were omitted during the 
incubations The molecular weights of the slower migrai 
ing proteins (arrows) are in agreement with those ol biotin 
containing carboxylases, as reported by Robinson et al 
[32] 
? 5 Immunoblot ting of skeletal mitochondrial proteins from 
myopathy patients with subunit or holoenzyme specific an 
tibodies 
The antibodies produced here and other subunit or 
holoenzyme specific antibodies were used to analyze the 
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quantitative behaviour of the corresponding subunits in the 
respiratory NADH dehydrogenase of skeletal muscle from 
mitochondrial myopathy patients exhibiting an enzymatical 
Complex I deficiency. 
Fig. 4 shows that antibodies against the bovine Com­
plex I holoenzyme (panel a) and against the ND1 peptide 
of Neurospora crassa (panel b) both gave weaker reac­
tions with mitochondrial proteins from patients P1-P5, as 
compared to the reactions observed with material from 
control individuals; patients P6 and P7 were not investi­
gated with these antibodies. Antibodies against the bovine 
Complex I holoenzyme gave a specific reaction with ap­
proximately ten proteins when tested against a Complex I 
preparation from bovine or human heart tissue (results not 
shown). Their position is indicated by arrowheads in Fig. 
4. part a. These are probably all encoded in nDNA. The 
background in the upper portion of the lanes is, again, 
most likely caused by biotin-containing proteins reacting 
with the streptavidin/horseradish peroxidase biotin com­
plex, as shown in Fig. 3. The bands marked with asterisks 
in the lower portion of the patient lanes PI, P3 and P4, 
which have a stronger intensity or a different mobility, as 
compared to the bands from control individuals migrating 
at the same positions, are probably degradation products. 
Note that the strong reaction with a protein of apparent 
molecular mass of 24 kDa in the patient lanes of Fig. 4 is 
not the result of a reaction with antibodies against the 24 
kDa subunit of Complex I (shown in Fig. 5). 
The reaction with antibodies against the human ATPase 
β subunit also exhibited a normal intensity in the samples 
from patients P1-P5, as compared to the controls (Fig. 5, 
panel c), indicating the absence of significant differences 
in the purity of the mitochondria. 
Fig. 5 shows that antibodies against the ND4-I,, ND5-1 
and ND6-I-, peptides, as well as antibodies against the 
purified bovine 24 kDa FeS protein of Complex I, which is 
encoded in the nuclear genome, gave weaker reactions 
when tested with material from all seven patients studied, 
as compared to the reactions with samples from control 
individuals. This was not caused by differences in the 
purity of the mitochondria, because, except for patient P4, 
no large differences were seen among the various samples 
a P 2 C 5 P, C 6 P 3 C 3 C 4 P 5 C 7 C 8 P 4 
75kDa 
••¿••Англ! ~ n —\-·• · 
24kDa 
kDa 
-78 
-66 
-45 
- 3 0 
* 
*-22 
- 1 4 
ND1 
ATPase^ »-1 
Fig. 4. Western blots using antisera against whole Complex I, its ND1 subunit and the ATPase β subunit. Control and patient mitochondrial proteins (2 
/ig each) were separated on two identical 10% SDS-polyacrylamide gels [28], Panel a shows a portion of one blot incubated with antibodies against the 
bovine Complex I holoenzyme The positions of the 24 kDa, 75 kDa and other subunits. which show a reaction between the antibodies and blots of purified 
Complex I preparations, are indicated on the left. On the right, the migration positions of water-soluble molecular weight marker proteins (Pharmacia/LKB) 
are indicated The other blot was cut into horizontal strips. Panel b shows the reaction with antibodies against the ND1 peptide of Neurospora crassa. 
Panel с shows the reaction with antibodies against the /3-subunit of human ATPase. The asterisks in lanes PI, P3 and P4 indicate the positions of possible 
degradation products (see Discussion). The ECL system was used for detection in all blots. 
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P1 C^  P2 C2 P3 C3 P4 P5 P6 C4 P7 
ND5 • 
ND4 * -
ND6 • 
24 kDa • 
ANT » a 
Complex I 0 152 8 83 6 77 0 23 28 74 55 
(%) 
big 5. Western blots using annsera against the ND4. ND5. NDii and 24 kDa sublimits of Complex ! or the ANT protein Control and patient mitochondrial 
proteins (2 /ig each) were separated on a 16.5ri SDS-polyacr\lamide gel [28]- After the transfer, the nitrocellulose paper was cut into four horizontal strips 
corresponding to the expected molecular weights of the subunits of interest and the parts were incubated with antibodies against ND4-1, and ND5-I. 
N1)6-1,. 24 kDa protein or ANT The activity of Complex I in the isolated mitochondria is given below each lane. It is expressed as a percentage of the 
mean of controls (mean + S D : 168 ± 59 (л = 11) or 200 ± 8.5 nmol/min per mg protein (n = 15) for mitochondria isolated from frozen or fresh muscle 
homogenate. respectively). * Indicates the position of the band cross reacting with the ND5-I antibodies (see also Fig. 3). 
in the reaction with antibodies against the bovine ANT 
protein (Fig. 4. bottom) or human ATPase β subunit (Fig. 
4. panel с). The strong reduction of ANT in mitochondria 
from patient P4 may have been caused by an additional 
deficiency of ANT protein in this patient. Support for this 
interpretation comes from the observation that the protein 
cross-reacting with the ND5-I antibodies, which is marked 
by an asterisk in Fig. 5, appeared to be present in mito­
chondria of patient 4 in the same amount as, e.g., in the 
samples of P5 and P6. which show a good reaction with 
the ANT-specific antibodies. The possibility of an ANT 
deficiency in patient P4 is presently under further investi­
gation. 
There is a good correlation between the signal of im-
munodetected Complex I subunits, as determined by den­
sitometry, and the activities of Complex I in isolated 
mitochondria from different individuals, as shown in the 
lower part of Fig. 5. The correlation coefficients for the 
ND4. ND5. ND6 and 24 kDa subunits, normalized for the 
ANT signal, were 0.82, 0.93, 0.86 and 0.92, respectively. 
Patients PI, P2, and P3, who exhibit a complete or near-
complete absence of enzyme activity, appear to contain 
negligible amounts of the tested Complex I subunits in 
their skeletal muscle mitochondria. Patients P5, P6 and P7, 
who have moderately or substantially decreased Complex I 
activities, show a proportional reduction in reactivity of 
their mitochondrial proteins with all four Complex I sub-
unit antibodies, whereas they exhibit amounts of ANT and 
ND5-I cross-reacting protein comparable, e.g., to those of 
control C4. 
4. Discussion 
We have shown that it is possible to raise antibodies 
successfully against computer-predicted linear epitopes of 
mitochondrial membrane proteins. Furthermore, these anti­
bodies were shown to react with the corresponding pro­
teins not only in immunoprecipitation assays, but also in 
Western blots. Using the Ribi adjuvant system for immu­
nization, consistently much lower antibody titers were 
observed, as compared to the immunizations carried out 
with the Freund's adjuvant (Table 3). This phenomenon 
has previously been observed in rabbits using rat microso­
mal epoxide hydrolase as an antigen [33]. 
Only two of six predicted epitopes of ND4 yielded 
antibodies positive in both the immunoprecipitation and 
the immunoblot assays. These were the C-terminal peptide 
and an internal peptide (I,) close to it. Fcarnley and 
Walker [34] predicted that all five internal peptides are 
situated between transmembrane segments. Whether these 
predictions are incorrect, or whether these peptides do not 
form linear epitopes in the presence of SDS is not clear at 
present. 
Antibodies against internal peptides of ND5 and ND6 
reacted also in both the immunoprecipitation and the im­
munoblot assays. For ND5, these are the first antibodies 
reported with this capacity. The previously-tested ND5-N 
and ND.S-C peptide-specific antibodies [8] were not capa­
ble of precipitating ND5. In the immunoblot analysis 
carried out here, the observed reaction with two bands 
could be inhibited by preincubation of the ND5-I antibod-
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ics with us corresponding peptide The prulLin correspond-
ing lo the upper strong band is most likely Nü^ because 
it has the expected molecular mass, as estimated relative to 
h\drophilic marker proteins and because it is reduced in 
amount in mitochondria from Complex I-dchcient patients 
1 he lower, weak band may have been produced bv a 
reaction with an unknown protein containing α sequence 
homologous to the NDS-1 peptide sequence 
In the exponential gradient gel system used here, the 
ND6 subunil migrated as a doublet band, possiblv resulting 
from απ unknown posi-translational modification ot a frac­
tion of the protein molecules The immunoprecipilated 
ND6 also appeared as a doublet In clectrophoretic runs of 
proteins from in isolated HcLa cell mitochondria and of 
libroblast whole cell extracts ND6 has always been found 
io migrate as a doublet, making the possibility ol prole-
olvlic degradation as the cause ot the doublet formation 
less likelv (H Bentlage unpublished observations) Also 
in 20 cm long 16S r f acrvlamide gels using the Tricine 
bulfer svstem [28] ND6 appeared as a doublet band (re­
sults not shown) The strong immunopreopitation reaction 
ot thL ND6-1, antibodies as compared to the NDft-l, 
antibodies can be explained bv a difference in either the 
titer or afhnilv of the two tvpes of antibodies The nature 
ol the difference was not further investigated In the 
Western blotting experiments ND6 appeared as α single 
band prohabh because of a different size (S cm) of the gel 
svsiem used 
In the immunoblols it was essential to use y-globulm 
Irauions depleted of antibodies to the carrier proteins in 
order to reduce the background The remaining back­
ground could be partially explained bv the presence ot 
biolin-conlaimng proteins in skeletal muscle mitochondria 
A lower background appeared in the immunoprecipitation 
assavs since onlv Π proteins were labeled that could give 
rise to non-specihc signals 
The antibodies produced in the present work and other 
subunit- or holocn/ymc-specitic antibodies were used lei 
investigate the presence and amount ot mlDNA- and nu­
clear encoded subunits ot the respiratory NADH dehydro­
genase in the skeletal muscle of patients affected by 
mvopathies associated with a Complex I dehciency The 
results obtained indicated lower levels of the three 
mlDNA encoded subunits (ND4, ND5 and NDo) and one 
nuclear encoded subunit (24 kDa) in all seven patients 
studied Also N u l and several other nuclear encoded 
subunits were found to be less abundant in live patients 
studied when ND1 peptide specific and Complex 1 
holocnzvme-spcofic antibodies, respectively were used 
I he latter antibodies gave a reaction in the samples from 
patients, with two bands that were either not present (2Ü 
kDa) or less strongly represented (24 kDa) in the samples 
Irom control individuals The band that migrated with an 
apparent molecular weight of 24 kDa in the samples from 
patients (Fig 4) was shown not to react with 24 kDa 
subunit specific antibodies (big 5) Both bands probably 
represent degradation products This degradation phe 
nomenon has been previously observed bv Robinson [15] 
A generalized reduction of immunoreactive Complex I 
subunits has previously been found in mitochondrial m\ 
opathy patients with a Complex I deficiene\ bv immuno 
blotting experiments utilizing polyclonal antibodies against 
bovine Complex I and antibodies specific for six nuclear 
encoded iron-sulfur proteins [1.6) However, the mlDNA 
encoded subunits were not identified in these experiments 
Theretore the present work provides the first evidence of α 
decrease in the latter subunits in mitochondria of mvopa 
thv patients It was found here that the remaining amount 
ol reacting subunits correlated with the residu il Complex I 
activity in the skeletal muscle mitochondria 
In the case of the two MLLAS patients (Pi and P7) a 
reduced rale ol mitochondrial protein s\nthcsis [16.17] 
would account for the reduced amount ot mitochondrial 
translation products and ι resulting decreased lssunhlv of 
Complex I In the other ρ merits the undcrlung defect 
could again be a reduced protein svnlhetic capacilv or a 
disturbed assemblv and subsequent degradation of Com 
plex I subunits The Litter process has been shown to occur 
in α HeLa cell mutant lacking the ND4 subunit [18] 
Whether this pathogenetic mechanism operates in an\ of 
our patients remains to be determined The antibodies 
described here will be useful for idenlilving defects in 
biosvnlhesis or stabilitv ot subunits encoded in mtDNA 
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Human diseases with defects in oxidative phosphorylation 
1. Decreased amounts of assembled oxidative phosphorylation complexes 
in mitochondrial encephalomyopathies 
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The amount of oxidative phosphorvlation enzymes in mitochondrial encephalormop lthv patients has 
been studied b> two-dimensional electrophoresis (blue native PAGE/Tncine SDS PAGb) Only 20 mg 
mustie was required to identify and analyse complexes I III IV and V after Coonussic staining In most 
cases reduced amounts of the involved complcx(cs) correlated well with decreased enzyme activities The 
reliability of the method was reflected by the constant mutual ratio of the complexes lound in all controls 
Deviations I rom normal ratios were tound to he more sensiti\e indicators for a delect than the absolute 
quantities which varied considerably within (he control group both in the enzymic and in the electropho-
rctic analysis The effect of the mitochondrial iRNA' " M mutation in mitochondrial myopathy encepha 
lopalhy laclic acidosis and stroke like episodes on the amount of oxidative phosphorylation complexes 
was demonstrated for the first lime directly on the protein level In patients without known DNA 
mutations specific defects of single complexes were identified The new technique is a sensitive method 
for the identification ot oxidative phosphorylation delects complementary to enzymic measurements 
Ke\\\ords Mitochondrial encephalomyopathies respiratory chain deficiencies blue native electrophore 
sis rruDNA 
Mitochondrial myopathies are a heterogeneous group ol dis 
orders ¿Meeting predominantly skeletal muscle and the central 
nervous system A delect in the mitochondrial energy mctabo 
lism is thought to be the primary cause of disease [1 2 | Each 
mitochondrion contains its own mtDNA that codes lor Π geiiLS 
ol oxidative phosphorylation (OXPHOS) proteins plus the two 
structural rRNAs and 22 tRNAs necessary for expression [Ί] 
Recently several mutations ol mtDNA have been described in 
association with mitochondrial encephalomyopathies or other 
neurological disorders [4] Examples of these are large scale 
deletions of mlDNA in chronic progressive external ophthal 
moplegia (C P K ) ) L^ l point mutations in the mitochondrial 
[RNA1 u l l M or the tRNA' gene in mitochondrial mvopathv 
encephalopathy lactic acidosis and stroke like episodes 
(MELAS) [b\ and in myoclonic epilepsy and ragged red fibers 
(MERRF) [7] or in the gene coding for the ATPase 6 subunit 
in Leigh s s>ndrome [81 These mutations are usually tound only 
in a proportion ol the mtDNA molecules (heleroplasniy) which 
may vary between different tissues and which determines the 
phenotypic expression of the mutation in a given tissue 
Corn ψαιιώim to II Schagger Zentrum der Biologischen Chi 
mie Universiuisklinikiim Frankfurt Theodor Stem Kai 7 Haus 2*iß 
D 60S90 Frankfurt am Main Germany 
fa\ - 4 9 69 61016970 
ЛЫ)п\чтоп\ CPFO chrome progressive external ophihalmo 
plegia MLLAS miunhondnal im opat h ν enetphalopaihv lauu nido 
sis and sirokilike episodes OXPHOS oxidaiive phosphorvlation 2D 
two dimensional »ι ^ apparent molecular mass 
Biochemical analysis of muscle tissue varied from severe 
isolated or combined deficiencies of complex I and complex IV 
to no apparent defects [ 9 - 11] In a large proportion of patients 
wilh respiratory chain en/yme deficiencies no mlDNA mula 
tions have been found [12 Π ] These defects could have arisen 
from mutations in the nDNA although such mutations have not 
yet been identified 
In the present studv we used a quantitative two-dimensional 
elcctrophoretic procedure (blue native eleclrophoresis/Tncine 
SDS PAGE) to analvse the amount ol assembled OXPHOS 
complexes m mitochondrial encephalomyopalhy patients with 
mtDNA mutations and/or enzyme defects in the respiratory 
chain 
MATERIALS AND METHODS 
Chemicals. Dodecyl β υ maltoside was from Boehnnger 
Mannheim 6 aminohexanoic acid from Fluka acrylamide and 
bisacrylamide (the commercial twice crystallized products), and 
Serva blue G (Coomassie blue G 250) from Serva All other 
chemicals were from Sigma 
Fleclrophorelic techniques and sample preparation The 
sample preparation for blue native PAGE started from 20 mg 
muscle that was homogenized with 2 S 0 p | 440 m M sucrose 
1 mM EDTA 0 2 mM phenylmcthylsulfonyl fluoride 20 mM 
Na/Mops pH 7 2 by using a tightly fitting glass/Teflon homoge 
nizer After a 20 mm ceninlugaiion at 200Ш ц the supernatant 
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was discarded and the sediment was suspended in 40 μΙ 1 M 
aminohexanoic acid 50 mM Bistns/HCl pH 7 0 by twirling 
with a tiny spatula The membrane proteins were solubilized by 
adding 15 μΐ 10% (mass/voi ) dodecylmaltoside After a 15 mm 
centnfugation at 100000 g the supernatant was collected 7 5 μΐ 
5% (mass/voi ) Serva blue G in 1 M aminohexanoic acid 
was added, and the total volume was applied to gel wells 
(10 mm X 1 6 mm) in blue native PAGE that was performed as 
described [14] Second dimension Tncine SDS PAGE starting 
from individual lanes from blue native PAGE was performed as 
described previously [15] 
Staining and quantification. All two dimensional (2D) gels 
were stained with Coomassie blue G 250 [16] Densitometry 
quantification was performed with a personal densitometer 
(a laser scanning densitometer from Molecular Dynamics 
Krefeld) and a Quick Scan Jr filter densitometer (Desaga Hei 
delberg) using a 595 nm filter The personal densitometer al 
lowed one to use rectangles around individual bands and to 
quantify the absolute staining intensity of bands The filter den 
silometer was used for one dimensional scanning through the 
lanes of the characteristic polypeptide patterns A 5 mm broad 
slit was used in order to include the most intensely stained part 
of the bands Both quantification techniques essentially gave the 
same results 
Several successive steps were applied lor quantification of 
2D gels First the staining intensity ol selected protein subunits 
of complexes was measured The selected bands marked by ar 
rows in Fig 1 A were the 75 kDa the unresolved 51 kDa and 
49 kDa and the 39 kDa subunit of complex I [17] subunits α β 
¡ b d and a of complex V [18] core proteins I and II together 
cytochrome b iron suliur protein Π 4 kDa and 9 5 kDa pro 
teins of complex III [19] subunits II (jpparenl molecular mass 
mjpfl about 20 kDa) IV (m jpr 16 kDa) Va b (one band тлрр 
11 kDa) Via be (two bands m j p r around 9 kDa) of complex IV 
120) Then the average staining intensifs of each individual band 
Irom the control group was set to 1 00 and the staining intensity 
of individual bands Irom patient samples was compared to the 
corresponding average staining intensity from the controls The 
mean value of these percentages was taken as the percentage 
ol nolo complex in the patient sample One of the quantified 
complexes (complex V in the present work complex III in the 
studies of Al/heimer disease in the following paper in this vol 
urne) was then used as an internal relerence in order to obtain 
the mutual ratios of complexes in each individual gel 
Patients. Seven patients were selected lor this study based 
upon low respiratory chain enzyme activities and/or mtDNA 
mutations observed in skeletal muscle biopsies A brief over 
view of some clinical and laboratory data is presented in 
Table I 
The two patients with the MELAS s\ndrome (P3 and P4) 
earned the heleroplasmic A3243G mutation in 50% and 60% of 
their mtDNA respectively in their skeletal muscle Riboflavin 
therapy in patient P3 has been previously described [21] The 
two CPEO patients (P6 and P7) carried a large heteroplasmic 
deletion in 50% and 75%, respectively of their muscle mtDNA 
This deletion included the cytochrome с oxidase III gene (COX 
III) All other patients and controls were Iree of known mtDNA 
mutations associated with mitochondrial myopathies or respira 
tory chain defects [4] 
Control specimens for enzymic measurements were consid 
ercd those in which a mitochondrial defect had been excluded 
by normal substrate oxidation rates of intact mitochondria and 
individual enzyme activities as described previously [22] The 
control group for 2D eleetrophoretic analysis consisted of ten 
patients with normal individual OXPHOS enzyme activities 
Morphology and biochemistry All specimens of quadri­
ceps muscle were removed by surgical biopsy whereafter the 
fresh tissue was processed for histochemical and biochemical 
studies From patients PI and P2 autopsy specimens thai had 
been removed within 1 h of death were also studied The 
oxidation rates of radiolabeled substrates (pyruvate malate and 
succinate) and the activities of enzyme complexes of the respi 
ratory chain were measured in 600 g supemaiants of muscle 
homogenates [22 23] Cytochrome с oxidase (complex IV) 
was determined according to Cooperslein and Lazarow [24] 
and citrate synthase according to Srere [25] The rolenone sensi 
live NADH ubiquinone 1 oxidoreductase (complex I) and 
NADH О oxidoreductase (complex I III IV) were measured 
according to Fischer et al [22] Ubiquinone 1 was a giti from 
Hoffman La Roche Complex III was measured using decvlub 
iquinol and cytochrome с as substrates according to 7heng el al 
[26] All catalytic activities of OXPHOS complexes were fusi 
normalized for the citrate svnthase activity to account for differ 
enees in recovery of mitochondria (values not shown) The^e 
ratios then were expressed as the percentage of the mean value 
of the controls 
Western blotting Mitochondrial proteins isolated by dil 
ferential centri fugation ol homogenized skeletal muscle speci 
mens were fractionated (2 μg protein/lane) on 10% or 16 5% 
slab gels in a Mini Protein II apparatus (BioRad) according to 
Schagger and Von Jagow [16] Proteins were blotted onto 
0 2 μηι nitrocellulose paper [27] 
Rabbit antibodies raised against a synthetic peptide oí pre 
dieted internal epitopes ol the ND4 and ND6 subunits ol human 
complex I against the purified bovine adenine nucleotide trans 
locase or against the human ATPase β subunit were used The 
latter two were used as an internal standard tor mitochondrial 
protein recovery 
Cytochrome t oxidase (complex IVj was purified from 
human heart mitochondria by preparative blue native electro 
phoresis |I4J Antibodies were raised in rabbits by inoculahon 
of the purified complex into lymph nodes according to Sigel el 
al |28| 
The antibodies against the bovine complex I holo en/yme 
its 24 kDa subunit and the ND1 subunit of Neutospora ( ruwa 
[29] were kind gifls from Dr U Harnisch (Department ol Bio 
chemistry University of Dusseldorf) Dr J Walker (MRC Cam 
bridge) and Dr S Wemer (Department of Physiological Chemis 
try University of Munich) respectively 
All antibodies were used at a dilution ot 1 1000 except lor 
the antibodies against ND4 and ND6 which were used at a 
dilution of 1 100 The ECL kit (Amersham) was used for detcc 
lion of bound antibodies 
RESULTS 
Muscle morphology. Quadriceps muscle from six patients 
(P2 P7) was histologically examined From patient PI no histo 
logical report was available No ragged red fibers were observed 
in patients P2 (isolated complex 1 defect) and P5 (isolated com 
plex IV delect) The two patients with MELAS showed a higher 
frequency of these fibers (10 7% in P3 and 8 5% in P4) as 
compared to the two patients with CPEO (0 5% in P6 and 0 6% 
in P7) 
Cytochrome < oxidase activity was normal in most fibers of 
patient P2 whereas patient P5 had a complete lack ot this activ­
ity The activity in the ragged red fibers of the two patients with 
CPEO (P6 and P7) contrasted with that of the two patients with 
MELAS <P3 and P4) In the CPEO patients the majoritv ol 
ragged red fibers contained no cytochrome с oxidase wherca\ 
this was nol the case in the MELAS patients 
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Table I. Clinical, laboratory and morphological features of patients studied. Ages are given in years unless otherwise specified (d = days 
inf ~ infantile) Fur Progresión t = indicates death Other abbreviations na not available \ not applicable because of young age CT/MRI 
computerised tomography/magnetic resonance imaging 
Feature 
Sex 
Diagnosis 
Age at onset 
Age at biopsy 
Progression 
Hypotonia 
failure to thrive 
Stroke like episodes 
Seizures 
Retinopathy 
Deafness 
Respiratory distress 
MenUl retardation 
Plows 
Short suture 
Bram CT/MRI 
1 actic acidosis 
Ragged red fibers 
h a mil y history 
PI 
F 
entephalo 
myopathy 
inf 
12d 
t27d 
+ 
> 
η 
+ 
na 
na 
* 
> 
-
-
+/ + 
+ 
-
-
P2 
M 
failure 
to thnve 
inf 
1 
t4 
-
+ 
-
-na 
-
-
-
-
-
-/na 
+ 
-
+ 
P3 
M 
MELAS 
22 
25 
slow 
-
-+ 
+ 
-
+ 
-
-
-
-
+/na 
+ 
+ 
-
PA 
F 
MELAS 
22 
22 
t23 
-
-+ 
+ 
+ 
+ 
-
-
-
+/+ 
+ 
+ 
+ 
P5 
F 
encephalo 
myopathy 
inf 
3 
t5 
+ 
-
-na 
-+ 
-f 
-
na/na 
+ 
-
-
P6 
M 
CPEO 
12 
22 
-
-
-
-
-na 
-
-
-+ 
-
-/na 
-+ 
-
P7 
M 
CPEO 
5 
11 
-
-
-
-
-+ 
-
-
-+ 
+ 
-/na 
+ 
+ 
+ 
Table 2. Quantification of OXPHOS complexes after two-dimensional electrophoresis compared to enzyme activities in fresh 600 g superna· 
tanls of patients muscle Controls were set to I 00 their values are given as a range ± S D (no ) Slam absolute total amount of an individual 
complex in 20 mg muscle deduced from prolein stain in 2D gels ыаіп/ ratio of the absolute slain of an individual complex and complex V from 
the чаше gel the quantification being described in Methods act /CS ratio of catalytic activities of complexes and citrate synthase All values are 
normalised to the average values of the controls Underlined values are below the mean of the control group minus twice its standard deviation 
(P<005> nd not determined 
Sample 
Controls 
PI (complex 1 defeu) 
P2 komplex 1 deleu) 
PI (MFI AS) 
P4 (MELAS) 
PS (complex IV defeci) 
P6 (СРГО) 
P7 (CPfcO) 
Complex I 
sljin/V 
0 7S-1 42 
± 022 (10) 
<0.23 
<U24 
0 36 
<0.12 
0 94 
0 89 
1 09 
ait /CS 
0 1 7 - 1 93 
± 042 
0Δ2 
031 
0 27 
0 27 
1 60 
0 84 
0 96 
(26) 
Complex 111 
suin/V 
0 8 1 - 1 17 
i 0 16 (10) 
1 23 
0 96 
0 58 
й£2 
0 86 
1 03 
1 33 
ÌLI /CS 
0 6 0 - 1 39 
- 0 24 (24) 
nd 
0 53 
<L28 
0 55 
nd 
nd 
0 57 
Complex IV 
stai n/V 
0 90 -1 29 
± 0 14 (10) 
1 15 
0 97 
0 47 
0 26 
0 20 
1 22 
0 82 
act /CS 
0 4 2 - 1 71 
± 0 35 (10) 
0 88 
0 72 
0 58 
0.24 
0 23 
1 18 
0 72 
Complex V 
stain 
absolute 
0 56-1 74 
± 043 (10) 
0 66 
0 70 
1 49 
1 85 
0 50 
0 36 
071 
Complex 
1 Ш-І 
aclivily/CS 
0 62-1 87 
± 0 31 (25) 
0.16 
0 16 
£L22 
0 16 
0 36 
1 42 
0 53 
Biochemistry. Substrate oxidation rates in 600 # su pernal ant s of 
fresh muscle homogerutes were decreased in all patients, except 
for the two CPEO patients (P6 and P7. rcsulis not shown) 
Also the NADH 0 : oxidoreductase activity (complex 1 III IV, 
Table 2) was severely diminished in the same patients 
An isolated complex I deficiency could be clearly attributed 
to palient PI, as its activity m muscle was only 13% of the 
mean ol controls (Я<0 05) This observation was confirmed in 
muscle, liver and brain tissue obtained through autopsy after the 
child had died at the age of 27 days 
In patient P2 a decreased complex I activity was measured 
although this was not statistically significant because of the 
broad range of control values Since complex III activity was 
also below the normal range there was some ambiguity about 
possible complex I and/or complex III defects 
In the MELAS patients low activities of complexes 1 III. 
and IV were observed but only the complex III activity of 
patient P3 and the complex IV activity of patient P4 were signif­
icantly reduced 
In patient P5 a severe complex IV deficiency was found 
(23% of mean control value) 
The muscle of the two CPEO patients (P6 and P7) did not 
reveal any markedly decreased enzyme activities which was 
in accordance with the observed normal substrate oxidation 
rates 
Two-dimensional electrophoresis. The electrophoretic and 
quantification techniques were optimized and validated by using 
bovine heart mitochondria and human autopsy specimens The 
extraction of OXPHOS proteins from mitochondria and tissue 
homogenates and the protein recovery after 2D electrophoresis 
were almost quantitative The Coomassie staining intensity of 
complexes correlated linearly with the protein load over a much 
broader range than used for analysis of human biopsy specimens 
(experiments not shown) 
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-BLUE NATIVE PAGE • BLUE NATIVE PAGE • 
COMPLEXES 
V III IV II 
І 
— ? 
Fig. 1. Two-dimensional resolution of the OXPHOS complexes from muscle by blue native PAGE/Tricine-SDS-PAGE. 20 mg quadriceps 
muscle from (A) a control person. (B) patient PI (complex I deficiency). (C) patient P5 (complex IV deficiency), and (D) patient P4 (MELAS) 
were processed for blue native PAGE as described in Methods. For the second dimension Tncine-SDS-PAGE. 1657c acrylamide gels were used. 
The complexes were identified after Coomassie staining by their characteristic polypeptide patterns. Note the absence of complex I in B. the almost 
complete absence of complex IV in C, and the differential reduction of complex 1 (complete) and complex IV (partially) in the MELAS disease in 
D. Subunits marked by arrows were used for densitometry quantification (see also Methods). 
Fig. 1 shows four examples of the 2D resolution of 20 mg 
human quadriceps muscle. In muscle from a control person (A), 
four OXPHOS complexes could be identified after Coomassie 
staining: complex I, III, IV and V. Complex II was not seen 
easily because of large quantities of other unidentified proteins 
in the same region of the gel. Fig. 1 В and 1С represent examples 
for isolated defects of single complexes. Muscle of patient PI 
(Fig. 1 B) showed a complete lack of correctly assembled com­
plex I, i.e. complex I was below the detection limit at about 
20% of the mean control concentration. Muscle of patient P5 
(Fig. 1С) showed a severe reduction of complex IV that was 
just above the detection and quantification limit at about 10^ 
of the controls. Fig. 1 D shows the polypeptide patterns of the 
OXPHOS complexes of the MELAS patient P4 indicating 
multiple defects of complexes. The most obvious deficiency 
concerned complex I which was not detectable. However, a re­
duced amount of complex IV was also apparent when compared 
to the control in Fig. 1 A. A reduced complex III/V ratio could 
be revealed by densitometric quantification. 
The results of the quantification of the complexes are sum­
marized in Table 2. The staining intensities of the protein sub-
units of complexes were used to determine the absolute protein 
amounts of assembled complexes present in 20-mg muscle 
specimens as described in Methods. 
The absolute amounts, given only for complex V (Table 2), 
are expressed as the percentage of the average amounts of the 
controls. The absolute amounts of assembled complexes varied 
considerably within the control group, which resulted in broad 
ranges. Such broad normal ranges were only found in muscle, 
not in brain. These variations were not due to poor reproducibil­
ity of the electrophoretic technique as tested by repeated analysis 
starting from the same sample (see following paper in this 
volume); however, variable losses of water from frozen muscle 
and slight variations in Coomassie staining as additional factors 
cannot be excluded. The absolute amounts cannot be compared 
to the enzymic data which are normalized for the amount of 
mitochondria in the 600 g supernatant. In order to allow a com­
parison of electrophoretic and enzymic data, all amounts of 
OXPHOS complexes were expressed as the ratios to the com­
plex V amount in each gel. Thus, using complex V as an internal 
standard, the electrophoretic analysis also becomes independent 
of the absolute amount of mitochondria. 
These mutual ratios of complexes additionally had the ad­
vantage of being much more constant in the control group than 
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the varving absolute amounts ol complexes The standard de\ia 
lion e g ol the complex IV/V ratios in the control group 
( 1 ± 0 14) was much lower than that ol the ahsolute complex IV 
amounts (1 r 0 14) 
In muscle ol patients Pi and P2 isolated complex I defects 
were identified by the low absolute amounts (not shown) as well 
as b\ the low complex I/V ratios (Table 2) The results ol the 
electrophoretic and enzymic analysis were in parallel but due 
to the smaller standard deviations of the electrophoretic analvsis 
the complex 1/V ratios were clearly below the P < 0 0*> limit in 
both cases 
The two MELAS patients showed varving degrees ol de 
feet s Considering absolute amounts only a significant reduction 
ot comple\ I in patient P4 was observed (not shown) Complex 
V in contrast was normal or moderately increased as compared 
to the controls resulting in reduced ratios ol all individual com 
plexos relative to complex V Ratios ol complexes and en/vmic 
ictmties paralleled but onl\ the electrophoretic analysis re 
vLaled a significant reduction of all mutual ratios 
In patient PS the absolute quantities ol the complexes were 
ienerallv below the normal range but onlv the quantitv of com 
plex IV was significant^ reduced The ratios ol the complexes 
were normal except for complex IV (0 20) Thus a generalis 
low Lontent of OXPHOS complexes setmed to be accompanied 
by a st ν ere complex IV defect 
The two CPEO patients (P6 and P7) showed normal ratios 
ot (he complexes Only in patient Pf> were the absolute staining 
intensities ol all complexes below the normal range of controls 
without reaching the level of significance (not shown) 
The subunit compositions ol all visible complexes were 
lound to be normal and no partialis assembled complex could 
be identified in ап of the patients 
Western blotting. We tested whether the reduced amounts ol 
assembled complexes were caused bv a missing subunit i e 
whether individual subumts were present in abnormal ratios 
Mitochondrial proteins were separated bv one dimensional Trie 
inc-SDS/PAGE After the transler to nitrocellulose paper the 
blots were incubated with dillerenl antibodies 
Reactions of mitochondrial proteins from patients P I — P 4 
with antisera against holo complex 1 against single mito 
ehondrially coded subumts (ND1 ND-1 and ND6) and a 
nuclear coded subunit (24 kDa) were all diminished whereas 
the reactions with an antibody against the ATPase β subunit were 
normal (results not shown) Thus il seemed that the major por 
lion ol unassembled subumts was eomplelelv degraded 
Antibodies against human heart complex I\ that gave a 
strong reaction with all of the larger subumts including the 
mitoehondnally coded subumts I II and III were used to screen 
lor missing or proteolvtically fragmented complex IV subumts 
An anubodv against bovine heart adenine nucleotide translocase 
was used as a reference Patients P4 and Ve) who had strongly 
decreased levels ol assembled complex IV m the 2D electropho 
resis also showed reduced levels ol individual cytochrome с ox 
idase subumts Reactions with proteolytic Iragments were not 
observed indicating again that unassembled protein subumts 
were proteolytically degraded (results not shown) 
D I S C I S S I O N 
Morphological molecular genetic biochemical electropho 
retie and Western blotting techniques were applied to character 
i/e three groups of OXPHOS delects CPEO patients with dele 
tions in the mtDNA MELAS patients with a point mutation in 
the tRNA' l l K gene and patients with latal inlantile forms 
without known mtDNA mutations who suffered from isolated 
delects either ol complex I or of complex IV 
Our special interest was the study of the amounts of assem 
bled OXPHOS enzymes and the mutual ratios ol these com 
plexes using a new type of 2D electrophoresis (blue native 
PAGE/Tricine SDS PAGE) 
The enzymic and 2D electrophoretic approaches summa 
nzed in Table 2 gave similar results however the standard 
deviations ol controls in the electrophoretic analysis were mark­
edly lower than in the enzymic analysis allowing the results to 
be interpreted with greater statistical confidence Both tech 
niques should always be used in parallel because in rare cases 
which are under investigation normal amounts of correctly 
assembled complexes were observed at very low catalytic ac 
tivities 
Quantification of a 2Ü gel from a sample with lower content 
of OXPHOS proteins (around 509c in patient P5) allowed a sin 
gle detect ol complex IV ю be clearlv identified by a selectively 
decreased complex IV/V ratio Since the detection limit of abso 
lute amounts ot complex IV in the Coomassic-staincd gels was 
reached onlv at 10 r( of the mean oí the controls (approximately 
2 0 ^ in the case ol complex I delects) missing or hardly detec 
table polvpeptide patterns clearlv indicate a defect but enzyme 
activny measurements are required to quantity extremely re-
duced complexes more exactly More sensitive silver staining 
procedures were not found to be useful lor reliable quantifica 
tion This may be overcome by the use of suitable antibodies for 
quantitative immunodetection 
The eleetrophoretic technique using mutual ratios ol com 
plexes has the advantage of quant i s ing all complexes in one 
gel thus minimizing errors in comparing dillerent samples 
Since the г mos ol complex concentrations were lound to be 
lairlv constant in the control group and independent of the pro 
tein load divergent ratios in patients were tound to be a superior 
measure to detect OXPHOS detects Isolated delects ol 
OXPHOS complexes as in patients PI P2 and P5 could be 
clearly discriminated from multiple defects as in MELAS 
patients P I and P4 Furthermore complex V which is dillicult 
to quantity by en/ymic analysis was easilv quantified in 2D 
gels Complex V defects were not observed in the small number 
of patients studied but were found in Alzheimer ρ itients (see 
following paper in this volume) 
In the ease of the two MELAS patients (PI and P4) a re 
duced rate ol mitochondrial protein synthesis [10 11] would 
account lor a low amount of mitochondrial translaiion products 
and a decreased amount of those complexes that comprise at 
least one miiochondnallv coded protein subunit (all except 
complex II) The enzvmic analysis showed that the activities ol 
complexes I III and IV were differentially alteeted (Table 2) 
The electrophoretic analysis identified altered mutual ratios of 
complexes even more clearly and demonstrated a hitherto un 
identified ellect on complex III Complex I was more affected 
than complex IV and the ratio of complex Ш/ was also found 
to be reduced This order in the extent of the deficiencies seemed 
to parallel the number of subumts encoded in mtDNA of each 
complex seven three and one respectively However complex 
V also contains two subumts ATPase 6 and 8 encoded in 
mtDNA but was found to be normal or moderately increased 
(Table 2) It is not known whether this apparent discrepancy is 
based on differences at the transcription translation or protein 
turnover levels 
Three patients with fatal infantile mitochondrial encephalo 
mvopathy (PI P2 and P5) had no deletion depletion MELAS 
or MERRF mutation and their muscles lacked ragged red fibers 
which has also been observed in diseases caused bv nussense 
mutations in mtDNA like Leber hereditary optic neuropathy and 
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Leigh s syndrome [4] The localization of the delects (specific 
complex I or complex IV deficiencies) was achieved by using 
2D electrophoresis and enzyme activity measurements No dis 
ease related missense mutations ha\e been found in the ND 
genes of patient PI (DeVnes et al unpublished results) There 
fore the complex I deficiency in this patient is most probably 
caused by a mutation in one of the nuclear genes of complex I 
or in a gene specifically controlling the assembly of complex I 
These hypotheses are under present in\estigation No partially 
assembled complexes could be identified on the basis of their 
subunit composition (Fig 1) in any of the 2D gels from patients 
and controls not even by using more sensitive silver staining 
techniques 
An OXPHOS defect in CPEO patient P6 seemed to be appar 
cnt from the absolute amounts of complexes in 2D electrophore 
sis (12-449t ol the mean of controls) that seemed to be in good 
agreement with the observed 5 0 ^ deleted mtDNA However 
this correlation was not found in patient P7 wiih an even higher 
percentage of deleted mlDNA (75 *7c) but almost normal abso 
lute amounts of complexes The discrepancy between a high per 
centage ol deleted mtDNA and a hardlv detectable defect ean 
be explained b\ un uneven distribution ot deleted mtDNA in 
the muscle fibers [32 331 The few ragged red libers which 
predoininantlv lacked cytochrome с oxidase had inercased 
amounts of mtDNA and have been shown lo be almost com 
pletely homoplasmic for the deletion [34| while most other fi 
bcrs had normal amounts of heteroplasmic mtDNA This would 
result overall in a high percentage of deletion bui the ratio of 
deleted/wild l>pe mtDNA would slay below the threshold of 
phenotypic expression in most fibers In contrast to ihe CPCO 
patients the MCLAS patients P3 and P4 showed multiple de 
feels at onlv 50-60Я· mulaled DNA which is more even dis 
( n b u i e d [ 1 2 11] 
Western b l o t t i n g was p e r f o r m e d in order to detect potent ia l 
var iat ions in subuni t quant i t ies and s t o i c h i o m e t r i c s ι e to ana 
U s e both Iree and Lorrectlv assembled subunits In fact reduced 
react ions o f ant ibodies c o r r e l a t e d w i i h reduced m u t u a l rat ios o f 
c o m p l e x e s m ihe e l e c t r o p h o r e t i c and enzvmic analvsis bui no 
s ign i f ieant dev iat ions i r o m the n o r m a l rat io o f i n d i v i d u a l sub 
u n i t s in c o m p l e x e s were detected T h i s observat ion c o n f i r m s 
ear l ier results I r o m other g r o u p s e g [ H I i n d i c a t i n g that free 
subunits not assembled i n t o c o m p l e x e s are p r o t e o l v t i c a l l ) de 
g r i l l e d and shows that o n l y the assembled c o m p l e x e s are ana 
l v s c d by Western b l o t t i n g s i m i l a r to 2 D electrophoresis and en 
¿ymic analysis 
We conc lude that 2 D elect rophoresis (blue nat ive P A G E / 
T r i c i nc SDS P A G E ) is a c o m p l e m e n t a r ) sensit ive and valuable 
new method fo r the iden t i f i ca t ion o f O X P H O S delects in m i t o 
c h o n d n a l encepha lomvopath ies W o r k is in progress to use spe 
ci t ic ant ibodies and cel l cu l tures to a l low ident i f i ca t ion o f par 
t i a l l ) assembled complexes and free subuni ts w h i c h cou ld g i ve 
clues to the under l v ing gene defect in patients 
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1 Introduction 
Electrophoretic separation of multiprotein complexes 
from blood platelets and cell lines: Technique for the 
analysis of diseases with defects in oxidative 
phosphorylation 
A two-dimensional electrophoretic technique combining blue native Polyacry-
lamide gel electrophoresis (BN-PAGE) with Tricine sodium dodecyl sulfate 
(SDS)-PAGE was previously used for the localization of oxidative phosphoryl-
ation (OXPHOS) defects in human diseases starting from biopsy or autopsy 
tissues (Schagger, Η , Electrophoresis 1995, 16, 763-770) In the present work 
the technique was extended for the resolution of OXPHOS enzymes from 
platelets and tissue-cultured cells Silver staining is required to detect the pro­
tein subunits of OXPHOS complexes in two-dimensional gels However, the 
use of cultured cells has major implications for patients with mitochondrial 
encephalomyopathies since it will reduce the number of invasive muscle biop­
sies The ease of isolating the platelet membrane glycoprotein complex from a 
few milliliters of blood makes it possible to analyze this complex and its pro­
tein subunits in bleeding disorders like Glanzmann's thrombasthenia 
In the present work a special type of two-dimensional 
electrophoresis, combining blue native Polyacrylamide 
gel electrophoresis (BN-PAGE) in the first dimension 
with Tricine-SDS-PAGE in the second dimension, was 
used Major principles of BN-PAGE are as follows 
Membrane proleins are solubilized from biological mem­
branes by neutral detergents Coomassie blue dye is 
added to the cathode buffer and to the protein solution 
before it is applied to an acrylamide gradient gel buff­
ered at pH 7 Negatively charged Coomassie dye binds to 
hydrophobic protein surfaces, keeps membrane proteins 
soluble in the detergent-free gel, drags proteins to the 
anode, and makes nalive proteins visible during the run 
Protein migration slops when a limiting pore size of the 
gradient gel is reached Therefore, a separation of pro­
teins according to iheir molecular masses is achieved 
Tncine-SDS PAGE, used in Ihe second dimension, then 
resolves the subunils of protein complexes 
This two-dimensional (2-D) technique has been used for 
the quantification of oxidative phosphorylation 
(OXPHOS) complexes in Parkinson's disease [1], in 
mitochondrial encephalomyopathies [2], and for the 
detection of specific complex V deficiencies in 
Alzheimer's disease [3] All these studies used tissue 
specimens from biopsies (skeletal muscle) and autopsies 
(brain, liver, heart) Any technique thai allows the use of 
patient cell lines, eg skin fibroblasts and lymphoblasls, 
or the use of the platelet fraction from blood would be 
of great benefit for patients and researchers because less 
muscle biopsies would be required, and sufficient 
sample would be available for the analysis of the molec-
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ular basis of the defect The enzymatic analysis of 
OXPHOS enzymes in fibroblast cell lines and in plate­
lets from patients with encephalomyopathy, Parkinson's 
or Alzheimer's disease, showed already that OXPHOS 
defects are also often detectable in fibroblasts [4, 5] and 
platelets [6, 7] 
Direct application of the electrophoretic technique devel­
oped for skeletal muscle to cultured cells or blood plate­
lets is problematic because these cells have an approxi­
mately tenfold lower mitochondrial content compared to 
skeletal muscle This would lead to overloading of gels 
and smearing of protein bands On the other hand, a pre­
ceding preparation of mitochondria from cells is also 
problematic because the yields of mitochondria obtained 
by conventional homogenization-cenlnfugation proce­
dures can vary considerably Variations in protein quanti­
ties would then lead to variations in detergent/prolein 
ratios used for membrane protein extraction, and to con­
siderable variations in the performance of 2-D gels The 
major problem to be solved therefore was the develop­
ment of a protocol for the preparation of mitochondria 
from cells wilh reproducible yield 
2 Materials and Methods 
2.1 Cell lines 
Murine L-929 fibroblasts, human FL amnion cells, HeLa 
cervix carcinoma epithelial cells and primary fibroblasts 
from healthy individuals and from one patient with 
cytochrome oxidase deficiency were grown in Eagle's 
minimal essential medium in the presence of fetal calf 
serum and penicillin/streptomycin Murine NIH/3T3 
fibroblasts and human Molt-4 T-cell lymphoblasts were 
grown in RPMI 1640 medium with fetal calf serum and 
penicillin/streptomycin 
68 Chapter V 
stocks in 0.9% NaCl, pH 7.4. Four mL of EDTA- or cit­
rate blood, stored at 4°C for maximally two days, was 
diluted with 2 mL of 0.9% NaCl solution, loaded onto a 
6 mL cushion of Histopaque 1.077 (Sigma) in a 14 mL 
plastic tube, and centrifuged at 20' С for 30 min at 680 g 
(2500 rpm in a Beekman JS 13.1 swinging bucket rotor). 
The cells at the interphase, mostly platelets and some 
lymphocytes, were harvested and diluted with a twofold 
volume of a buffer containing 150 т м NaCl, 150 гам 
Na-phosphate, pH 7.2, at 20'C. After centrifugation for 
15 min at 1750 g at 20"C the sedimented cells were sus­
pended with 0.5 mL sucrose bufTer (250 т м sucrose, 
0.5 т м EDTA, 10 т м Tris-HCl, pH 7.4, at 4"C) and 
centrifuged 15 min at 10000 g. The sediment, usually 
around 10 mg, was rapidly frozen in liquid nitrogen and 
stored at — 80'C. The subsequent isolation of a mitochon­
drial fraction, the solubilization of membrane proteins, 
and the processing for application to BN-PAGE followed 
the protocol outlined below. 
2.2.2 Sample preparation from sedimented cells and 
protein load to BN-PAGE 
Ten milligrams of sedimented cells (wet weight) isolated 
either from blood or from cell cultures (around 5 X 10' 
cells) were used for one electrophoretic analysis. Frozen 
cells were used because direct use of non-frozen cells 
led to considerable losses. The initial protein amount, 
determined by a modified Lowry procedure [81, was in 
the 1.5—1.7 mg range with blood platelets and with cul­
tured cells. The frozen cells were suspended in 500 pL of 
a hypotonic buffer (83 т м sucrose, 10 т м Na'/Mops, 
pH 7.2), homogenized extensively in a tightly fitting 1—2 
mL glass-Teflon homogenizer (15 cycles at 2 000 rpm), 
and collected by rinsing the homogenizer with 500 μ ι of 
250 т м sucrose buffer. After a 15 min centrifugation at 
600 g (4'C) a mitochondrial fraction was collected 
through 15 min centrifugation at 15 000 g. The sediment 
contained 0.10—0.15 mg total protein. I.e., around 6—9% 
of the starting material, but about 70% of ubiquinol-
cytochrome с reductase activity. The mitochondrial-
enriched pellet was suspended in 15 pL of 1 м 6-amino-
hexanoic acid, 50 т м Bistris/HCl, pH 7.0, before the 
membrane proteins were solubilized by addition of 5 pL 
of 10% w/v dodecylmaltoside. After centrifugation for 
15 min at 100000 g, 60-70% of ubiquinol-cytochrome с 
reductase activity was found in the supernatant. After 
addition of 2.5 pL of 5% w/v Serva Blue G dye in 1 м 
6-aminohexanoic acid to the supernatant, the total 
volume was applied to 5 X 1.6 mm gel wells in 
BN-PAGE. The total protein amount applied to the gel 
could not be determined directly, because protein deter­
minations are disturbed by 6-aminohexanoic acid. Using 
sodium chloride for solubilization instead of 6-amino­
hexanoic acid, the total protein was always in the 
50—100 pg range. The mitochondrial protein fraction 
thereof was estimated to be in the 10—20 pg range 
because the staining intensities of OXPHOS complexes 
during BN-PAGE (Fig. 1) were lower than those from 
28 pg, but higher than those from 9 pg of isolated 
bovine heart mitochondria (cf. [1], Fig. 1, lanes 6 and 9). 
Using isolated mitochondria, up to 150 pg protein can be 
applied to 5 X 1.6 mm gel wells in BN-PAGE without 
provoking severe overloading effects. However, starting 
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higure I. Resolution of native protein complexes from a mnothon-
dnal-enriched fraction from human platelets by BN-PAGE (lane 2) 
OXPHOS complexes from solubilized bovine heart mitochondria 
(lane 1; 200 ug of total mitochondrial protein [1]) and from 20 mg 
human skeletal muscle (lane 3: prepared as described in |2]i were 
used as references for molecular mass calibration, and to help identify 
the location of faint bands of OXPHOS complexes in lane 2. Lane (2): 
a mitochondnal-ennched fraction (100-200 ug total protein com­
prising around 20—40 pg mitochondrial protein) prepared from 20 mg 
of sedimented platelets from 8 mL of blood of a heallh> individual 
was applied to a 10 X 1.6 mm gel well The prominent band in (2) was 
identified as platelet glycoprotein complex (cf. Section 3.1). A linear 
acrylamide gradient gel from 6 to 13% acrylamide was used [1] The 
photograph was taken directly after the run when the gel was still 
between the glass plates. 
from sedimented cells, not more than 50—100 pg of total 
protein (isolated from 10 mg celfs) should be applied. 
Increasing the protein load would not help to approach 
the detection limit of protein subunits by Coomassie 
staining, but would lead to a further increase of 
streaking of bands. At a lower protein load, on the other 
hand, some of the small subunits, e.g. the small subunits 
of complex II, might not be detectable after silver 
staining. 
2.2.3 Electrophoretic techniques, staining, and 
quantification 
Chemicals, first-dimensional BN-PAGE, second-dimen­
sional Tricine-SDS-PAGE, staining and quantification 
techniques were used as described recently [1]. 
3 Results and discussion 
3.1 Native resolution of multiprotein complexes by BN-
PAGE 
Figure 1 shows the native resolution of a mitochondrial-
enriched protein fraction isolated from blood platelets 
(lane 2), compared to bovine heart mitochondrial pro-
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Figure 2. 2-D resolution ol'platelet multi-
protein complexes Lane (2) from Fig. 1 
was cut into two equal parts, and the two 
halves were processed by Tncinc-SDS-
PAGE using 16%C. 3°'oT acrylamide gels 
as described previously [1]. One 2-D gel 
was silver-stained as shown. The second 
2-D gel was used for protein sequencing. 
Protein subunits of complexes V, III. [V. 
and two protein spots of the platelet gl>-
coprotein complex (GP) could be identi­
fied by their characteristic polypeptide 
patterns in the silver-stained gel. and by 
Л'-ierminal protein sequencing, respec­
tively Complex I and II protein subunits 
could not be identified unambiguously 
Most probable bands compared to the 
patterns from human heart [2] and from 
bovine heart mitochondria [10] were also 
marked. 
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teins (lane 1) and to the proteins from human skeletal 
muscle (lane 3). Complex I can be detected as a strong 
band in the lane of bovine heart mitochondrial proteins. 
Human complex I generally gives rise to a much broader 
band than the bovine enzyme. It can hardly be detected 
in human skeletal muscle and not at all in the lane from 
human platelets. Complexes III. IV. and V from skeletal 
muscle and also from platelets can be detected on the 
ligth screen. The position of complex II. as deduced 
from two-dimensional gels, is also indicated. The perfor­
mance of BN-PAGE with human Molt-4 lymphoblasts. 
HeLa cells, skin fibroblasts, and FL amnion cells was 
similar to that of platelets, i.e., only faint bands were 
detectable (not shown). However, only platelets con­
tained a prominent band at an apparent molecular mass 
Figure J. 2-D resolution of OXPHOS 
complexes starling from IO mg of sedi-
mented Moll4-l>mphoblasts First dimen­
sion: BN-PAGE using a 6-13°o acryl­
amide gradient gel The total protein 
load was in the 50-100 ug range, com­
prising about 10—20 ug mitochondrial 
proteins. Second dimension: Tncine-
SDS-PAGE using 16.5°bT. 3°»C gels. 
Except for complex I. all OXPHOS com­
plexes could be detected after silver 
staining (c/ Section 3 22) On the left 
and right sides the apparent molecular 
masses of complex IV and complex II 
subunits respectively, were indicated. 
of 330 kDa. Further resolution in the second dimension 
(Fig. 2) identified this band as the human platelet glyco­
protein Ilb-IIIa complex (see section 3.2.1). This com­
plex is a receptor for adhesive proteins; it binds fibrin­
ogen, providing interplatelet linkages, and the von Wille-
brand factor as a molecular anchor between the subendo-
thelium and platelets [9]. The blue band of the platelet 
glycoprotein complex can be excised and electroeluted 
as described previously [10]. This is an alternative isola­
tion method to the commonly used immunoprecipita-
tion or affinity chromatography with antibodies against 
single subunits [11]. A protein extract from 200 mL of 
blood can be applied to one preparative gel (3 mm X 
120 mm gel wells) and about 0.5-1.0 mg of electro­
eluted platelet glycoprotein complex is obtainable, e.g. 
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Figuri' 4. Comparison of OXPHOS complexes from control (A) and patient fibroblasts (B) in silver-stained 2-D gels. OXPHOS abnormalities 
concerning complexes [V and V (synonymous to F|F„ complex) were observed in fibroblasts of this patient suffering from a mitochondrial ence-
phalomyopathy without known genetic origin. Gel types and protein load as in Fig. 3. 
for protein chemical work, for studies of glycosylation, 
and for isolation of antibodies. It can be applicable also 
in the analysis of diseases with alterations in the platelet 
glycoprotein complex, e.g. neonatal alloimmune throm­
bocytopenia [12] and Glanzman's thrombasthenia [13]. 
3.2 Resolution of subunits of multiprotein complexes by 
SDS-PAGE 
For analytical applications 0.5 cm lanes from the first-
dimensional BN-PAGE (Fig. 1) can be processed 
directly by SDS-PAGE in the second dimension. After 
Coomassie staining of the 2-D gels the largest subunits 
of complex V and III, and subunit IV of complex IV can 
be detected and quantified (Coomassie-stained gels not 
shown). For detection of the characteristic polypeptide 
patterns of complexes, silver staining is required (Fig. 2). 
We stopped silver staining only when the small subunits 
of complex II could be detected, because complex II is 
the only one of the five OXPHOS complexes that com­
prises no mitochondrially coded protein subunit. It there­
fore serves as a mitochondrial marker that is not directly 
influenced by alterations in the mitochondrial genome. 
However, this additional information was obtained at the 
cost of a lower quality of 2-D gels. The prolonged 
staining led to a high background stain and empha­
sized the presence of horizontal streaking of bands. 
Detailed information about the subunit compositions of 
OXPHOS complexes is given in [14-18]. 
3.2.1 Two-dimensional platelet protein analyis 
A typcial 2-D resolution of platelet proteins from a 
healthy person is shown in Fig. 2. Silver staining 
revealed the typical polypeptide patterns of OXPHOS 
complexes III, IV, and V. Subunits of complexes I and II 
could not be identified unambiguously. This would 
require the use of specific antibodies. However, a tenta­
tive assignment of polypeptide bands similar to the pat­
terns from heart and other tissues [1] is given. The pro­
minent native glycoprotein complex from platelets (lane 
2 in Fig. 1) was resolved into two protein bands with 
molecular masses around 100 kDa and 22 kDa, which 
were intensely stained by Coomassie dye (not shown), 
but negatively stained in silver-stained gels (Fig. 2, 
arrows below GP). Using 10% acrylamide gels the larger 
band could be resolved into two bands (not shown). 
After electroblotting onto PVDF membranes the sepa­
rated bands were identified by ЛЧегтіпаІ protein 
sequencing (15 amino acids each) as integrins lib-alpha 
and Ilia with molecular masses of 114 and 84.5 kDa [19, 
20]. The 22 kDa band was not identified by sequencing. 
We expect that it represents integrin lib-beta, the third 
component of the glycoprotein complex, with a molec­
ular mass of 22.5 kDa [19]. Considering the 15% contri­
bution of carbohydrate [11], a total molecular mass of 
255 kDa for the hologlycoprotein complex is calculated. 
The apparent molecular mass of 330 kDa, determined by 
BN-PAGE (Fig. 1 and [21]), is in reasonable agreement 
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with the molecular mass of 265 kDa determined by ana 
lylical ultracentrifugation [11] and confirms the mono 
mene structure of the glycoprotein complex by an inde 
pendent method 
3 2 2 Analysis of OX PHOS proteins from cell lines 
Figure 3 shows the protein patterns in 2 D gels from 
Molt 4 lymphoblasts The patterns from human cell 
lines such as FL amnion cells and HeLa cells look very 
similar (not shown) Complex I could rarely be identified 
in silver stained 2 D gels from human cells although it 
could be easily identified in murine cells (not shown) 
Complex II comprises four different protein subunils in 
mammals with molecular masses of 70 27 13 and 9 0 
kDa although five protein binds can be detected as 
indicated by the arrows (Fig 3) Amino terminal protein 
sequencing revealed that the additional 9 3 kDa com 
ponent is the preprolein to the 9 0 kDa protein that is 
not yet processed to the mature 9 0 kDa form (Schaggcr 
H unpublished) Complex IV is present in two forms 
the major monomenc form wilh the normal apparent 
molecular masses of 200 kDa ind a minor IV lorm with 
an apparent mass of about 150 kDa Several protein sub 
units f ( the 9 5 kD ι subunit VI ι and the 7 0 kDa sub 
unit are missing in the IV form This can be caused by 
dissociation from the holo complex al the high deter 
gent/protein ratio required for solubilization Complex 
V monomer and complex III dimer with apparent molec 
ular masses of 600 kDa and 500 kDa in the first dimen 
sional BN PAGE (not shown) seem to be less sensitive 
to high detergent and only one form each with the 
normal polvpeplide composition [1 3] is observed in the 
second dimensional SDS PAGE 
3 2 3 Deviations from normal OXPHOS protein patterns 
in fibroblasts 
A normal OXPHOS protein pattern from primary skin 
fibroblasts of a heallhv individual is shown in Fig 4A 
Complex I again is the only complex that is usually not 
delected in Coomassie and silver stained 2 D gels A 2-D 
gel of a patient with mitochondrial encephalomyopathy 
is shown in Fig 4B Complex IV was hardlv detectable 
in the patient s fibroblasts This is in agreement with the 
low complex IV catalytic acilivity measured in fibro 
blasts and muscle of the patient The most prominent 
alteration however concerned complex V The largest 
subunits of complex V the alpha and beta subunils 
were detected at two different locations at the normal 
position of complex V also called F F ATPsynlhise 
(600 kDa) and at the position of the Tree F subcomplex 
(400 kDa) Since BN PAGE separates proteins according 
to their molecular masses [21] the F subcomplex will be 
found in the vicinity ol complex III which has an 
apparent molecular mass of 480 kDa [22] This complex 
V abnormality characterized by the presence of a consi 
dcrable portion ol an F subcomplex was detected nei 
ther in skeletal muscle samples nor in fibroblasts from 
control individuals It was also absent in muscle samples 
from patients with deletions or individual defects of 
either complex I or complex IV [2| However it was 
found recently in muscle of patients with Leigh s disease 
with normal complex IV and a point mutation (T — G at 
position 8933) in the mitochondrial ATP 6 gene [23] The 
single amino acid exchange in a protein subunit of com­
plex V seemed to selectively influence the structural sta­
bility or assembly of this complex In the present case a 
point mutation in any gene of a complex V subunit is 
unlikely since additionally the amount οΓ assembled 
complex IV was reduced by 80% We therefore suspect 
that a novel point mutation in either one of the mito­
chondrial tRNAs could be responsible for the simulta 
neous expression of the complex V abnormality and the 
complex IV deficiency 
4 Concluding remarks 
OXPHOS deficiencies present in skeletal muscle can 
also be expressed in skin fibrobl isls in some forms ol 
mitochondrial enceph ilomvop unies |24] If OXPHOS 
deficiencies arc not delectable in fibroblasts of patients 
with mitochondrial encephilomyopathy a needle or sur 
gical biopsy ol skeletal muscle will still be required The 
possibility to use cell lines from control individuals and 
Irom patients oilers the chance for studies ol OXPHOS 
complexes under varying conditions ι e there is more 
flexibility in probing the influence of inhibitors hor 
mones and transcription factors It seems possible to 
study the biogenesis assembly and turnover of 
OXPHOS complexes in cell cultures and the influence 
01 thyroid hormones stenod hormones and cytokines 
on the OXPHOS system 
OXPHOS analysis in blood ol patients certainly mav 
h îve the same or even stronger restrictions as the anal 
ysis of cell lines The percentage of the MELAS point 
mut mon in mitochondrial DNA For example was Found 
to be 90°o in muscle but onlv 25% in blood [з] Sim 
il irly Ihe chronic progressive external ophihalmoplegia 
(CPLO) and Kears Sayrc syndrome (KSS) forms of mito 
chondrial encephalomyopathies are ch iractenzed bv 
deletions in muscle mitochondnil DNA but these dele 
tions are hardlv detectable in blood cells Therefore the 
2 D eleclrophorctic approach will not detect OXPHOS 
alterations in these cases (</ references in [2i]) In 
Pearson marrow pancreas svndrome however the gene­
ralized evtopenia correlates with a high percentage of 
miDNA deletions in penpheril blood [26] and enzy­
matic anaKscs revealed a complex IV deficiency in libro 
blasts and lymphoblastoid cell lines [27] Future cxperi 
menls will show if these genetic and enzv malic defects 
arc also expressed by reduced amounts ol assembled 
complexes or by altered ratios of complexes in platelets 
We would like to stress Ihe potential use of the 2 D elee 
trophorctic technique for the analysis of Glanzmann s 
thrombasthenia [13] or other diseases with defects in the 
platelet glycoprotein complex eg neonatal alloimmune 
thrombocytopenia [12] 
These in\es!if,anons неге supported M а цгат ot the 
Deutsche rorschumisnememschaft to Hirmunn Schagner 
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Abstract 
A 2-month-old boy died of a lethal infantile mitochondrial disease with severe lactic acidosis 
and involvement of the CNS Histochemical analysis of skeletal muscle showed that cytochrome с 
oxidase staining was lacking in all muscle fibers, but was present in arterioles Ragged red fibers 
were not seen, but some fibers showed excessive staining for succinate dehydrogenase Biochemical 
analysis revealed a combined complex I and IV deficiency in skeletal muscle but only a complex I 
deficiency in his fibroblasts Two-dimensional native SDS electrophoresis confirmed these enzymatic 
findings at the protein level Analysis of mitochondrial translation products in fibroblasts revealed no 
abnormalities, and analysis of mitochondrial DNA in muscle showed no depletion, large-scale 
deletions, or frequently occurring point mutations 
We conclude thai this disease must have been the result of either a nuclear DNA mutation in a 
gene controlling the expression or assembly of both complex I and the muscle-specific isoform of 
complex IV or, alternatively, a heteroplasmic point mutation in a mitochondrial tRNA, which codon 
is used more often by mtDNA encoded subunits of complex I than by mtDNA encoded subunits of 
complex IV A different degree of heteroplasmy in skeletal muscle and fibroblasts would then explain 
the curious heterogeneous tissue expression of defects in this patient 
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Introduction 
Mitochondrial encephalomyopathies are a heterogeneous group of disorders in which various 
tissues are affected, predominantly skeletal muscle and the central nervous system (CNS) ' The 
primary cause of disease is thought to be a defect in the mitochondrial energy metabolism The five 
enzyme complexes (complexes I to V) of oxidative phosphorylation (OXPHOS) play a crucial role 
in this ATP generating system Each mitochondrion contains its own mitochondrial DNA (mtDNA) 
which is maternally inherited The mtDNA encodes seven subunits of NADH ubiquinone oxidore-
ductase (complex I), one subunit of ubiquinol cytochrome с oxidoreductase (complex III), three 
subunits of cytochrome с oxidase (COX) (complex IV), and two subunits of ATP synthase (complex 
V), two nbosomal RNAs and 22 transfer RNAs necessary for mtDNA gene expression 2 The genes 
of complexes I, III, IV and V are located in both the mtDNA and the nuclear DNA (nDNA) Succi­
nate ubiquinone oxidoreductase (complex II) contains only nDNA encoded subunits All nDNA 
encoded subunits are imported into the mitochondria where they are assembled together with the 
mtDNA encoded subunits Deficiencies in complex I and complex IV, either alone or combined, are 
found most frequently 3_6 
A growing number of mitochondrial encephalomyopathies or other neurological disorders 
have been associated with deletions, depletions or more than 30 point mutations in the mtDNA 7 
These mutations are often found only in a proportion of the mtDNA molecules (heteroplasmy) Also 
nDNA mutations affecting OXPHOS are expected to cause these diseases, but have not been 
described so far 
We present a patient who immediately after birth had a severe lactic acidosis Biochemical 
analysis revealed a combined deficiency of complex I and IV in muscle tissue but only an isolated 
complex I deficiency in fibroblasts 
Case report. 
A boy was born by normal delivery after an uncomplicated 39-week pregnancy Birth weight 
was 3680 g, length was 54 5 cm and head circumference was 35 cm His unrelated parents and a 4-
year-old sister are in good health 
Within 18 hours after birth the baby became tachypnoeic and developed an overwhelming 
lactic acidosis (blood pH 7 02, base excess -25 3 mmol/1, blood lactate (88-147 mg/dl, normal <16 
mg/dl) and pyruvate (1 13 mg/dl, normal <0 59 mg/dl)) There were no signs of an infection Plasma 
amino acid analysis revealed hyperalaninemia Repeated urine analysis showed variable increased 
excretion of lactate, ethylmalonate and 3-hydroxybutyrate In CSF, lactate was elevated (42 mg/dl, 
normal 11-19 mg/dl) Despite continuous buffering, severe acidotic periods recurred Gradually, a 
developmental delay, hypertonicity, and occasionally seizures occurred (signs of CNS involvement) 
Because of suspicion for a mitochondrial disorder, a surgical muscle biopsy of the quadriceps 
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was performed at age 29 days During this time, blood lactate was 230 mg/dl and pyruvate was 3 52 
mg/dl Multivitamin therapy was started thereafter A biopsy of the skin was taken at age 42 days 
When the child was 58 days old, his condition suddenly worsened and he died from respiratory and 
cardiac arrest Autopsy was not allowed 
Methods. 
Histologic and electron microscopic analysis Light microscopy, histologic stains, and 
electron microscopy of the muscle biopsy were done according to standard procedures 
Biochemical analysis of muscle tissue The oxidation rates of radiolabeled substrates 
(pyruvate, malate and succinate), the ATP + creatine phosphate (CrP) production rates from 
pyruvate and succinate, and the mitochondrial enzyme activities were measured in 600 g supernatant 
of muscle homogenates as described previously β Control specimens were considered those patients, 
ages 4 to 56 years, in which a mitochondrial defect had been excluded by substrate oxidation rates 
and individual enzyme measurements comparable to persons having restorative surgery Complex III 
activity was measured using decylubiquinol and horse heart cytochrome с (both Sigma) as substrates 
according to Zheng et al ' Tween 20 (0 04% v/v) was added to the assay mixture to reduce the non­
enzyme reaction All biochemical values are expressed per mU citrate synthase (CS) to correct for 
mitochondrial recovery in the 600 g supernatant of muscle or in the mitochondria enriched fraction 
of fibroblasts (see below) 
Fibroblast studies Human skin fibroblasts were grown in M199 (GIBCO) medium 
supplemented with 20% (v/v) fetal calf serum Control specimens were obtained from healthy 
volunteers Enzyme activities were measured in mitochondria enriched fractions, which were 
prepared as described previously10 with the following modifications Approximately 20 χ 106 cells 
were homogenized in 10 mM Tris HCl (pH 7 6), thereafter adjusted to 0 25 M sucrose and 
subsequently differentially centrifuged (600 g and 14,000 g) The formation of lactate and pyruvate 
from glucose was determined in monolayer grown fibroblasts as described", except that fibroblasts 
were cultured in M199 medium 
Two-dimensional electrophoresis The amounts of assembled OXPHOS enzymes in muscle 
homogenate (20 mg) or frozen fibroblasts (4 χ 106 cells) were quantitated by two-dimensional 
Polyacrylamide gel electrophoresis (PAGE) (blue native/Tncine-SDS-PAGE) and subsequent 
densitometry analysis of Coomassie stained gels 6 
Mitochondrial protein synthesis Mitochondrial translation products of fibroblasts from the 
patient and two control subjects were labeled in near confluent six-well plates (diameter 1cm) for 2 h 
with [35S]methionine (0 4 mO/ml, 1200 Ci/mmol) in the presence of emetine, an inhibitor of 
cytoplasmic protein synthesis, at 100 μ^πιΐ l : After the labeling, the cells were washed twice with 
phosphate-buffered saline (pH 7 4) and detached by treatment with trypsin Cells were lysed in 10 
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raM Tris-HCl (pH 7.4) with 0 1% (w/v) SDS Equal amounts of cell lysates (20 μg per lane) were 
analyzed on 16.5% minislab gels13 and prepared for fluorography 14 
MtDNA analysis. MtDNA was analyzed in total DNA isolated from muscle as reported 
previously.15 The mtDNA content in muscle tissue was quantitated by Southern blotting analysis 
using probes for the total mtDNA and the nuclear 18S rDNA gene. Control specimens were obtained 
from patients aged 4 to 56 years. 
Results. 
Histochemistry and electron microscopy. Morphological examination of the patients skeletal 
muscle revealed no ragged red fibers, but the staining for succinate dehydrogenase (SDH) showed a 
few large fibers with exceptionally high activity (figure 1A and IB) COX activity was absent in all 
Figure 1. Skeletal muscle sections of the patient (A and C) and an age-matched control (B and D) were stained 
for SDH activity (A and B) and COX activity (C and D) Note the exceptionally high SDH activity in one fiber 
in A and the complete lack of COX activity in all muscle fibers in С Smooth muscle cells of arterioles have 
normal COX activity in С (arrow) and D (the arteriole is longitudinally cut). Bars represent 50 \xm 
muscle fibers, but was present in smooth muscle cells of arterioles (figure 1С and ID) There was no 
glycogen or lipid accumulation Electron microscopy revealed no structural abnormalities of the 
mitochondria. 
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Biochemical studies. Biochemical investigation in fresh skeletal muscle 600 g supernatant 
revealed that oxidation rates and ATP + CrP production rates with pyruvate, malate and succinate as 
substrates were all significantly diminished (p<0 05, table 1) Complex IV activity was most severely 
decreased (11% of the mean of control subjects, p<0 05) The activity ofNADH Q, oxidoreductase 
(complex I) was decreased 24% of the mean of control subjects and the activity of NADH 0 2 
Table 1. Biochemical measurements in fresh skeletal muscle. 
Oxidation rate' for 
[1-'^pyruvate + malate 
[U-HC]malalc + pyruvate + malonate 
ATP+CrP production rate2 from 
pyruvate + malate 
succinate + acclylcamiline 
Activity6 of 
NADH Q, oxidoreductase 
succinate cytochrome с oxidoreductase 
dcc>lubiquinol cytochrome с oxidoreductase 
cytochrome с oxidase 
NADH 0 2 oxidoreductase 
p>Tuvale dehydrogenase' 
citrate synthase (CS)d 
Patient 
0 60 
1 16 
5 8 
5 3 
0 036 
041 
2 78 
0 19 
0 12 
0 051 
67 
(%)' 
( H ) 
(16) 
(9) 
(40) 
(24) 
(78) 
(62) 
(11) 
(27) 
(63) 
(64) 
controls' 
5 52 ± 0 99 
(3 61-7 48) 
7 18± 1 28 
(4 68-9 62) 
6 3 9 ± 10 1 
(42 1-812) 
13 1 ± 3 7 
(7 2-18 4) 
0 153 ± 0 061 
(0 061-0 276) 
0 5 6 ± 0 13 
(0 31-0 84) 
4 52 ± 0 99 
(2 85-6 61) 
1 78 ± 061 
(0 81-3 13) 
0 4 4 ± 0 14 
(0 28-0.84) 
0 081 ± 0 024 
(0 034-0 122) 
104 ±29 
(65-162) 
N 
14 
20 
16 
13 
21 
26 
16 
28 
20 
25 
28 
a
 nmolcs hr 'mU ' CS, bmUmU "' CS, ' in homogenate, dmUmg ' protein, 
' % of mean of controls,r mean ± SD, range in brackets 
oxidoreductase (complexes I+III+IV) was also decreased, 27% of the mean of control subjects 
Complex III and other enzyme activities were nearly normal (table 1) 
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In the patients fibroblasts, on the contrary, complex IV activity was in the normal range, both 
in whole cell homogenate and in the mitochondria enriched fraction (table 2) Here, only complex I 
activity was significantly decreased (39% of the mean of control subjects, p<0 05) An increased 
lactate/pyruvate ratio after glucose conversion in these cells (42, normal <25) pointed also towards a 
respiratory chain defect 
Table 2. Enzyme activities' in mitochondria enriched fractions of fibroblasts. 
NADH Q| oxidoreductasc 
succinate cytochrome с oxidoreductasc 
dccylubiquinol cytochrome с oxidoreductasc 
cytochrome с oxidase 
cytochrome с oxidase*1 
citrate synthase' 
Patient 
0 05 
0 23 
1 87 
0 78 
0 63 
203 
(%) d 
(39) 
(94) 
(98) 
(92) 
(91) 
(90) 
controls 
X ± S D 
0 13 ± 0 03 
0 24 ± 0 04 
I 90 ± 0 31 
0 85 ± 0 13 
0 69 ± 0 11 
226 ± 2 3 
(N=8) 
range 
(0 10-0 20) 
(0 20-0 31) 
(1.56-2 61) 
(0 68-1 05) 
(0 54-0 89) 
(189-257) 
1
 mU-mU •' citrate synthase,b in whole cell homogenale, ' mU mg ' protein,d % of mean of controls 
Two-dimensional electrophoresis. Analysis of muscle homogenate of the patient showed that 
both complex I and IV were nearly absent (figure 2) Complex I could not be detected, even by more 
sensitive silver staining of the gels Densitometrie analysis of Coomassie stained gels revealed that 
the amount of correctly assembled complex IV was decreased (23% of the mean control subject 
concentration) Complex I was below the detection limit, i e less than 20% of the mean control 
subject concentration Complex III and V were present in normal amounts, whereas the complex II 
amount (visible after silver staining, results not shown) was slightly increased In fibroblasts of the 
patient normal amounts of assembled complexes II, III, IV and V were detected (results not shown) 
Complex I is very difficult to detect in fibroblasts, even in control subjects 
Mitochondrial protein synthesis Metabolic labeling of the patient fibroblasts revealed that all 
detectable mitochondrial translation products were present in amounts equal to two control subjects 
(figure 3). 
MtDNA analysis. Investigation of mtDNA in the patients muscle revealed no mtDNA 
depletion, large deletions, or point mutations, which are frequently associated with mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS, position 3243), myoclonic 
epilepsy and ragged red fiber disease (MERRF, position 8344), and neurogenic weakness, ataxia, 
and retinitis pigmentosa (NARP, position 8993)7 
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Figure 2. Two-dimensional electrophoresis of 
OXPHOS complexes in muscle. 20 mg quadriceps 
muscle from a control (A) and the patient (B) were 
processed for the first dimension (blue native 
PAGE, horizontal direction). For the second 
dimension Tricine-SDS-PAGE, 16.5% acrylamidc 
gels were used (vertical direction). The complexes 
were identified after Coomassie staining by their 
characteristic polypeptide pattern and quantified by 
densitometry. Note the complete absence of 
complex I and near complete absence of complex 
IV in B. 
ю' 
Figure 3. Metabolic labeling of mitochondrial 
translation products in fibroblasts. Cells of the 
patient (lane P) and two controls (lanes C¡ and C2) 
were labeled for two hours with [35S]methionine in 
the presence of emetine Whole cell lysates were 
analyzed on a 16.5% Tricine-SDS minigel, followed 
by fluorography. The dried gel was exposed for 4 
days. On the right the migration positions of 
molecular weight marker proteins (M) are indicated. 
The 13 subunits encoded in the mtDNA are 
indicated on the left. 
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Discussion 
Our patient had a lethal infantile mitochondrial disease (L1MD)16 with lactic acidosis dominating the 
clinical presentation Involvement of CNS pathology became apparent because of developmental 
delay, hypertonicity, an increased lactate level in cerebrospinal fluid and the occurrence of seizures 
Other organs appeared normal 
Extensive biochemical analysis revealed the presence of a severe deficiency of both complex I 
and IV in skeletal muscle tissue, but only of complex I in cultured skin fibroblasts Other enzyme 
activities were not significantly decreased These findings were confirmed by histochemical analysis 
of COX in muscle sections and by two-dimensional native/SDS electrophoresis of all five OXPHOS 
enzymes in both muscle and fibroblasts 
Age differences between the patient ( 1 month at the time of muscle biopsy) and the controls 
(range 4-56 years, n=28) are not relevant since the enzyme activities are normalized for citrate syn-
thase activity 17 
There are reports of two similar cases of LIMD with a combined deficiency of complex I and 
IV in muscle18 " Both patients suffered from muscular hypotonia and tachypnoea, but no 
encephalopathy The first patient died 4 months old and the combined deficiency was found in 
skeletal muscle, heart and liver, but no deficiency was found in kidney and brain,18 fibroblasts were 
not investigated The authors postulated a nuclear DNA mutation in a developmental stage-specific 
and tissue-specific OXPHOS gene 'B The second case died at the age of 53 days because of 
respiratory failure with lactic acidosis and had a combined defect in complexes I and IV in skeletal 
muscle mitochondria " We analyzed the respiratory chain enzymes in cultured fibroblasts of the 
latter patient and found no defect in complex I or IV (unpublished results) Both reported cases1819 
showed ragged red fibers in their muscle, whereas these were lacking in our patient However, the 
excessive staining for succinate dehydrogenase in some fibers could point towards the development 
of ragged red fibers in our patient Thus there are many clinical and biochemical similarities between 
the two reported cases and the one presented here By contrast, the two reported cases1819 had no 
apparent CNS involvement and we found a normal complex I activity in fibroblasts of the second 
19 
case 
There are previous reports on heterogeneous tissue expression of OXPHOS defects in 
mitochondrial encephalomyopathies 20~22 In some cases this was associated with mtDNA depletion21 
or the MELAS 3243 mutation 22 Both mutations were excluded in our patient We examined 
fibroblasts of 10 other patients with combined complex I and IV defects in muscle tissue, including 
some previously reported,5,20 and found only in one case a complex IV defect All other fibroblasts 
did not show a respiratory chain enzyme defect We demonstrated an isolated complex I deficiency 
also in fibroblasts of eight other patients, most of them having LIMD All showed only a complex I 
deficiency in their muscle tissue (H Bentlage, unpublished results) This illustrates the uniqueness of 
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the case presented here 
Robinson et a l 2 3 reported a complex I deficiency in fibroblasts of four patients with the clinical 
picture of LIMD Three patients had signs of CNS involvement such as hypertonia, seizures and an 
abnormal EEG Unfortunately, they did not mention the biochemical investigation of muscle tissue, 
thus it is unclear whether these patients also had a combined complex I and IV defect in their muscle 
A unique Chinese hamster mutant lung cell line, Gal 32, also exhibits extremely low activities 
of both complex I and IV, at moderately decreased activities of other respiratory chain complexes24 
Simultaneous correction of this pleiotropic phenotype in a spontaneous revenant suggested the 
presence of a single nDNA mutation in Gal 32 2 5 Mitochondrial protein synthesis revealed low 
amounts of mtDNA encoded complex I and IV subunits in this cell line, whereas the amounts of 
mitochondrial RNAs were increased but of correct size Therefore a mutation altering mitochondrial 
tRNA structure or base modification was assumed 2S However, our patient had normal biosynthesis 
of all mitochondrial translation products in his fibroblasts, despite the reduced complex I activity 
Thus the phenotype of our patient probably arose from a different mutation 
In humans there are tissue specific isoforms of subunits Via27 and Vila28 of complex IV, a 
heart (H) and liver (L) form In human heart there are equal amounts of H- and L-forms, while in 
skeletal muscle there is mainly the H-form " 3 0 The L-form is exclusively present in liver, brain, 
kidney, smooth muscle,30 and in cultured fibroblasts31 and myoblasts 32 During myogenesis32 and 
during fetal development13 both subunits switch from liver-type to heart-type in human heart and 
skeletal muscle Complex I possibly also has isoforms,3,135 but there are no data at the molecular level 
yet A mutation in one of the heart-type subunit isoforms of COX would account for the normal fetal 
development (L-form) and the heterogeneous tissue expression of the complex IV defect in the 
presented patient, ι e normal activity in arterioles (mainly smooth muscle) and fibroblasts (both L-
form), and a deficiency in skeletal muscle (Η-form) However it does not explain the complex I 
defect in skeletal muscle and fibroblasts of the patient A nuclear DNA mutation in a communal gene 
controlling both the expression or assembly of complex I and of the heart-type isoenzyme of complex 
IV could explain the phenotype in our patient Analysis of pel mutants in yeast identified several of 
such genes [review36] A candidate gene could be the human homologue of the yeast gene oxaJ,31 
which is essential for cytochrome с oxidase assembly in yeast However, there is no complex I in 
yeast, thus the involvement of ara/ in complex I expression remains to be established 
Alternatively, the pleiotropic defect and tissue heterogeneity can be explained by a point 
mutation in a mitochondrial tRNA and a different degree of heteroplasmy in muscle and fibroblasts, 
similar to patients with the 3243 MELAS mutation6 2 2 Thus the mutation must be in a mitochondrial 
tRNA whose codon is used more often by subunits of complex I than of IV and less by subunits of 
complexes III and V Fibroblasts and cybnds with near homoplasmic point mutations at position 
326038 and 3243 of the tRNAUu<UUR) gene (Bentlage and Attardi, unpublished results) can also exhibit 
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a normal mitochondrial protein synthesis as is the case in our patients fibroblasts 
We are presently developing techniques to test both hypotheses in muscle tissue or fibroblasts 
of the presented case 
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Abslrjct A patient with neonatal 
expression ol seveie De Tom-Debie-
Fanconi svndiome is presented Be­
cause ol eai I) signs of renal tubu-
lopalhy together with a large urinar) 
e iue l ion ol lactate Vhydroxybu-
t)ratc anil e in к ас iti cycle intermedi­
ates a mitochondnal disorder was 
suspected and muscle and liver biop­
sies »ere perlormcd Biochemical 
investigations in both tissues re­
pealed a delect in the respirator) 
chain at the level ol complex III In 
this patient renal dysfunction was the 
pnmar\ svmptoni and hvperlac 
tataemia an impottant clue fora mi 
tocliondnal disorder was lacking 
Conclusion Complex III defi­
ciency should be included in the 
diflerenlial diagnosis of neonalal 
De Toni Debre-Fanconi syndrome 
Key words De Toni-Debré-Fanconi 
syndrome Respiratory chain 
delects Complex III 
Abbreviation ATP adenosine 
triphosphate 
Introduction 
The renal lubulopalhy De Toiii-Debre-Fancom syndrome 
is seen in dilleienl disorders ol ihe mitochondnal lespna-
lor> chain with impaired adenosine triphosphate (ATP) 
production required tor proper renal tubular transport ac-
tivity (Fig 1) It is relatively common in fatal inlanlile 
myopathv due to cytochrome с oxidase {complex IV) de-
ficienc) |2 . У И | and has also been reported as a teatuie 
ol complex I and combined complex I1I/IV deliciencies 
[6 7, 111 Moieover De Γοηι-Debre-Fanconi syndrome is 
invariable involved al a late stage of Pearson syndrome a 
mitochondrial disotdet with a mitochondrial DNA dele­
tion aflecling dillerctil oigans including the kidneys |4 . X. 
10 Π | Here we report the neonatal expression ol severe 
renal lubulopalhy associated with complex III deficiency 
ol the rcspnatoty chain in muscle and liver 
Case report 
A 2 month old babv was admitted to the hospital because ol lail 
ure to thrive He was bom bv normal dehverv .(Her an шкошріі 
caled -12-week pregnant ν Rirth weight was 2 S kg length was 4X 
cm He was the loiirlll child ol a consanguineous Turkish couple 
FamiK hislorv was unremaik ible 
On idmission the child presemeli w uh a mild upper respiratene 
tract inlection larvngeal stneloi eluc to tracheomalacia hv pe ι 
pnoea w ide open lonlanelles and sutures rickets irritabilité mus 
ele weakness and insutlieieiit lespemse to stiniuh He ve is miKllv 
dellvdiatcd weight was ι 0 ky I aboratoiv tests shoeeed melabolie 
acidosis (pH 7 28 bieaibonale Is niLe|/l base excess II) with 
euherwise normal serum tleclreilvtes gluceise and creatinine 
Trins.inunases (about IM) L/l) jnd jlk.ihne phosphatase (I2s() 
U/l> were elevateti The Liner indicated active rickets Inorganic 
phosph не (0-16 llliliol/l and I 4 m»/dl) and une acid (SI μιηοΙ/Ι 
and 0 K9 mg/dl) were deeieased Sciuni triglveentles I7? 1 mmol/i 
and 2 92 mg/dl) were mixleralely elevated Blood latíale (1 7-2 9 
normal < 2 0 mmol/i) and pvrueale (0 077 norm il < 0 ObS 
mmol/1) concentrations were normal or nlildlv elevated Serum 
aminoacidi including alanine were normal The unnarv hvperes 
eiction ol amino acids ol all classes glucose bicarbonate and 
phosphate indicated proximal tubultipathv 
Al the age ol 4 months biochemical investigation also included 
the .inalvsis ol urinarv ornarne ucitls There were markedlv in 
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bip 1 Schematic presentanoli 
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creased amounts of lactate and 1 h\drox> hut} rate (Table 1) to-
ІІСІІКГ with a complex pattern ol organic acids (lumaratc succi-
n.ne and maiale) suggestive ol a respirami chain deled In CSF 
láclale and amino acid concentrations were normal Scruni total 
and free carnitine levels were also normal 
From (he aee of 4 months the patient was treated svmpioinali-
calh with bicarbonate, phosphate 'supplements I 2^ dihydroxy-
cholecalcilerol and carnitine Later he also received \ iiamin К (40 
mg/dav ) and riboflavin ( 100 mg/da'» ) However his clinical condi­
tion deteriorated and the child died of respiratory distress at the age 
ol 7 months No autopa was performed and no post mortem kid­
ney tissue wjs available 
Methods 
Because of ihe earlv occurring De Tom Debre-Faneoni s\ndrome 
and massive иппагч excretion of lacune л miloehondrial disorder 
veas suspected In order to obtain mitochondrial material for bio­
chemical and morphological investigations a surgical muscle 
biops> ol the quadriceps and a needle biopsv ol the h\er were per­
formed 
Substrate ovulation rates ATP pioduclion rales mitochondrial 
en?vme activities and carnitine content were measured in 6CK) g 
supernatants ol mustie homogenates as described previously [1 
12] Complex 111 aclivitv was measured using decvlubiquinol as a 
substrate ace οι ding to 7henp et al | ]6| vvilh inodilic allons Light 
nncroscop) histochetnical and hisio-enzvmolooical stainings 
were done according to standard procedures Milochondlial DNA 
veas an.iKsed .is reported earlier | l | Other laborators investiga 
lions were perlorincd according to routine procedures 
Results 
Biochemical investigation in fresh skeletal muscle super 
nolani revealed that ox idat ion rates w i t h pyruvate maiale 
and succinate as substrates and ATP+crealtne phosphate 
production rales w i t h pyruvate and inalale were both se­
verely diminished (< 20'/с o f l o w e s t control \alucs) I hese 
dala, as wel l as the a d i v i n e s of the respirators chain sub 
units in muscle and l iver and carnitine concentration in 
muscle, are listed in Table 2 Due to (he small amount o l 
l iver tissue, o n l y few activit ies could be measured Table 
2 shows that complex 111 act iv i ty was most severely de­
creased ( in muscle \УЛ of the lowest control value) The 
activit ies of succinate cytochrome с oxidoreduciasc and 
N A D H CK oxidoreductase. which both measure also 
complex Ml act iv i ty (14|. were less reduced (5()'/r ol the 
lowest control values) These values point to a severe de­
ficiency o f complex I I I o f the respiratory chain A com­
plex 111 deficiency (59c/c of the lowest control value) was 
also found in the l iver Carnit ine concentration (total and 
free) was reduced in muscle 
Histopathologic. i l Itndtngs in muscle revealed a nor 
mal l ibre structure w i t h an increased l ip id content in t>pc 
I fibres Ragged red l ibres were not seen On electron m i ­
croscopy there were no structural abnormalities ol the mi 
Fanconi syndrome due to complex III deficiency 91 
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p\ru\ ali + malate 
suiLinue + аиічкагпіипе 
Am\ it\ h öl 
utr ne s\nthasL' 
i \ toiliioine L OMil i^ e 
suii inati iMoilutMin ι oxidoreduita^e 
de*.\ІпЬицііпоІ iwoihronie ι oxidonduiiaM" 
NADU Q, oMiloiitint.Use 
NADH O ovidoreduclasi 
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Conn tur it inn ol 
ι inuline total 
ι i init ini non eMii i l i id 
ι ΐ ι nine toi il 
imi 
Cwoihronii ». oxidase 
SUIL inali iWoihronii oxidoreduclase 
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S IS 
142 
4S 
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1 (ι 
1 2 
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2 7-8 2 
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2 2-4 2 
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in = 
VI = 
{η = 
(/ι = 
In = 
(/1 = 
(// = 
{Il = 
(// = 
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{Il = 
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19} 
191 
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28} 
9 } 
14) 
21) 
2I> 
17-41 
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( i l = J l 
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tochondna Some muscle fibres u n i t a m e l i Ut vacuoles 
close lo the mitochondria L iver m o i p h o l o g ) was without 
spec il ic abnormalit ies No mitochondrial D N A deletions 
οι l iequent l) occurr ing mutations weie lound 
Discussion 
We describe a patient in w h o m onset ol severe De Toni 
Debre banconi sunchóme in earls intanc) lead us above 
all to look loi a biochemical defect at the le\el of unto 
choiulr ial ox ídame phosphor) lal ion This was done under 
ihe assumption that the energy requir ing process o l renal 
tubular transport might be severely disturbed due to a fa i l -
ure ol the respuator) chain to produce adequate amounts 
ol ЛТР Since kidney tissue could not be obtained for b i o ­
chemical investigations we stnved to demonstrate the as­
sumed respiratory chain defect in other organs such as 
muscle and l iver In both tissues a severely decreased ac 
l i v i t ) o l complex I I I of the respirators chain was found 
g iv ing use lo a s ignif icant i) impaired o x i d a n t e phospho-
iv lat ion in whole mitochondria 
Usuali) patients suspected o l haxing a mitochondrial 
disorder are selected after demonstration ol elevated lac 
tate concentiations in blood and/or CSF Due to the ab­
sence ol evidently increased lactate concentrations in both 
bod) f luids a d e l e d in the respiratory chain could have 
been overlooked in our patient It might be possible that 
the high renal clearance ol lactate (dai ly loss 14-20 
inmoles) caused by the disrupted tubular reabsorption was 
responsible lor the alinosi normal lactate levels Interest­
ingly another case o l severe respiratory chain defect in 
muscle (deficient c\tochrome-c-oxidase act iv i ty) and De 
Ton ι- Debre- Kinc on ι s)ndrome also w n h absence of sc-
\ c r c l ) elevated blood lactate levels has been reported [У| 
However w i t h respect to the extreme amounts of urinarv 
lactate ^-hydroxybut)rate and other organic acids as 
compared w i t h other palienls w i t h a serious t o n n of tubu-
lopath) due to c)st inosis or i fosfamide t o x i c i t ) (Table I ) 
it seems that pari o l these metabolites originates also I rom 
high production ш the kidney itself A c c o r d i n g to eail ier 
reports [ 4 . M | an increased production and excretion ot 
lactate and part icularly o f intermediates of the cit i re acid 
cycle was expl ic i t ly attributed to tubulopath) due to nulo 
chondnal disorders 
The block at the complex I I I level impairs oxidat ion ot 
both N A D - h n k c d and T A D l inked substrates (F ig 1) In 
most previous publications the diagnosis o l complex I I I 
(ubiquinol cv locfuome с oxidoreduclase) del ic ienc) was 
concluded indircel i ) t r o m a reduced a c l i v i i ) for both suc­
cinate cytochrome с oxidoreduclase and rotenone-sensi-
tive N A D H 0 ; oxidoreduclase and a normal activity ol 
succinate dehydrogenase [4. 14J In our patient complex 
I I I activity was measured directly by a spectrophotometry 
assay using dccylubiquinol as a substrate This activity 
was severely reduced in skeletal muscle and l iver The re-
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i luccd M I L o l pxruxatc m.i l j te and succinate oxidat ion as 
wel l .is o l Α Ι Ρ production in I resit muscle s u r e s t i l l it the 
oxer i l l respuaUirx (.hint i c l m l x in \ i\o was sienil ic intK 
i m p med b\ the complex I I I dcl icienc\ The loec musLle 
carnitine concentration is a secondare phenomenon which 
is Irequenllx lound in respir ilor\ chain disorders 
Complex I I I delie iene \ is a iel i t i \ c l \ ι nc txpe ol mi 
t o c h o n d r n l disoider \1oieo\ei among the small number 
ot patients (ca 20) descnbcd w i t h a delect ol complex I I I 
there is етеаі \ a n a b i l i l \ in the cl in ical presentation in 
c ludi i iL tissue speul ic detects such is pine skelet il mus 
ele disease and puic latal cardionmipalhx as « e l l as p io 
pressi le ciiccpltalopathx |S| A severe complex I I I del i 
ctence in muscle mei l ixer could recenllx also be demon 
stralci! in tissues (s io icd it - M l C i l i o m Mie neon He eeith 
sexere lactic acidosis and lenal tubulopathx desenbed b> 
Speri et al 1111 b\ u s i n j dec\ lubiquinol is ι substrate in 
the measurement ol complex 111 a d m i x decidual a d m i x 
ldr/f of the lowest c o n i m i \ due ) Thus the piesent md 
the p i e x i o u s h lepoited с isc expand the clime ι) s p e d a m i 
ol complex 111 deleci to include neonat j l expression ol se 
\ere renal tubulopathx 
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Transmitochondrial cell lines were isolated by fusing 
mtDNA-less ρ 206 cells with enucleated fibroblasts 
derived from four members of a pedigree carrying in 
their muscle varying proportions of the mutation at 
position 3243 In the tRN ALeu(UUR)
 g e n e associated with 
the MELAS encephalomyopathy. The mitochondrial 
transformants derived from an asymptomatic individ­
ual were all homoplasmic for wild-type mtDNA. The 
proportion of wild-type transformants derived from 
clinically affected members of the pedigree appeared 
to decrease in correspondence with an increase in 
severity of the clinical symptoms of the cell donor. Fur­
thermore, the average proportion of wild-type mtDNA 
in the transformants derived Irom each member ol the 
pedigree was very similar to that found in mtDNA from 
the fibroblasts of that individual, suggesting that the 
distribution of genotypes in the transformants re­
flected fairly closely that in the fibroblasts. The geno­
type and phenotype of ten transformants derived from 
one severely affected individual were investigated dur­
ing continuous culture up to 17-24 weeks after the 
transformation step. Six heteroplasmic clones showed 
a progressive increase in the proportion of mutant 
mtDNA, whereas the mitochondrial genotype re­
mained constant in four clones apparently homo­
plasmic for wild-type mtDNA or nearly homoplasmic 
for mutant mtDNA. An analysis of the rate of repopula­
tion of ρ 206 cells with fibroblast-derived mtDNA re­
vealed a large variability among different 
transformants, with the full re-establishment of the 
control ratio of mtDNA to nuclear DNA being observed 
between 6 weeks and more than 22 weeks after the 
transformation step. An increase in rate of 0 2 con­
sumption generally accompanied the increase in 
mtDNA copy number of the transformants, pointing to 
the important role of the mtDNA copy number in deter­
mining the phenotype of a cell. The observation that a 
very small amount of wild-type mtDNA (2 to 5% of the 
control level), coexisting with strongly predominant 
mutant mtDNA, conferred upon the transformants a 
substantial respiratory capacity (50% or more) and the 
evidence of proportionality between 0 2 consumption 
rate and mtDNA copy number, which occurred at wide­
ly different mutant to wild-type mtDNA ratios, strongly 
suggest a contribution of the mutant mtDNA to the cell 
respiratory competence. 
INTRODUCTION 
Deletions point mutations and depletion ot mtDNA have been 
described in association with myopathies encephalomyop.uhies 
andavanety ofoiherdisorders(1orre\ievvs seereK 1 and2) The 
phenol)pic manifestation ot the so-called common miDNA 
deletion (4977 base pairs) associated with chronic progressive 
e\iemal ophthalmoplegia (CPEO) and with Pearson sindrome 
and of some point miDNA mulaiions has been studied in clonal 
cell lines derived trom patients cells ( V i ) and in human 
mtDNA-less (p° ) cells (6) repopulated with mutant mitochondria 
through fusion with enucleated patient-derived cells ( 7 - Π ) The 
point mutations investigated included those in the tRNA1 >4 gene 
(at positions 8444 and 8156) associated with the MERRF 
(myoclonic epilepsy and ragged red liber) syndrome (1.7) those 
in the t R N A L e u l L U R l gene (at positions 1241 and 1271) 
associated with (he V1ELAS (myopathy encephalopathy, lactic 
acidosis and siroke-hke episodes) syndrome (4.9.10 I I ) that in 
the same gene (at position 1260) associated with myopathy and 
cardiomyopathy (12) and that in the A l Pase 6 gene (at position 
8991) associated with the Leich svndrome (11) These studies 
" To whom ч-ЧТ^ршикии shnulil гк K U U *SM1 
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have demonstrated that the mtDNA mutations mentioned above 
cause defects in mitochondrial protein synthesis and cell respir­
ation: in particular, the biochemical detect underlying the protein 
synthesis impairment in the MERRF syndrome caused by the 
8344 mutation has been elucidated ( 14). Furthermore, it has been 
shown that these mutations are functionally recessive, since 
wild-type mtDNA. even when present in relatively small 
proportion, can protect a cell against the phenotypic effects of the 
mtDNA mutation (3,8.10). A useful extension of the p° cell 
repopulation approach has involved the use of platelets, which are 
naturally occurring anucleate derivatives of megakanocytes. as 
mitochondria donors (15). 
A propagative advantage of mutant mtDNA molecules over 
wild-type molecules, leading to a segregation of the genotype 
towards the pure mutant type, has been observed in genotypically 
unstable transmitochondrial cell lines carrying in heteroplasmic 
form the "common' 4977 bp deletion (8). or the 3243 
tRNA LeutUUR) mutation ( 16. ! 7 ). or the 8344 tRNAL>s mutation 
(18). However, evidence has also been reported indicating that the 
direction of segregation towards the mutant or the wild-type 
genome is influenced by the nuclear background (17). Skin 
fibroblast cultures from a patient with Pearson syndrome have 
been reported to exhibit a loss of the 4977 bp deletion when 
cultured in the absence of undine, and amplification of the deleted 
mtDNA in the presence of uridine (5). A loss of the deletion 
dependent on the absence of undine was. on the contrary, not seen 
in lymphoblastoid cell lines from two Pearson syndrome patients 
(5). 
In the present study, a shift of the mitochondrial genotype 
towards higher levels of the tRN AL e u ( L L R ) (3243) mutation was 
found in all genotypically unstable heteroplasmic transmitochon­
drial cell lines derived from fibroblasts of one member of a 
previously described MELAS pedigree ( 19). However, the rate of 
this shift was much slower than previously observed in unstable 
transformants derived from myoblasts of MELAS patients 
(16.17). The re-establishment of the parental mtDNA copy 
number was in general slow in the p° cell transformants and 
accompanied by an increase of rate of ΟΊ consumption. Very low 
proportions of wild-type mtDNA (possibly as low as 29c) were 
able to protect against the deleterious effects of the mutation. 
Thus, both the proportion of wild-type mtDNA and the mtDNA 
copy number play a role in the phenotypic manifestation of the 
mutation. 
RESULTS 
Mitochondria transfer from fibroblasts to p°206 cells 
Figure la shows the MELAS pedigree investigated here (19). 
This included a 56 year old woman {b) and her five daughters (II] 
to II5). The clinically unaffected mother had 35% mutated 
mtDNA in her muscle, but no mutated mtDNA in her blood and 
fibroblasts. The daughter II1 only suffered from deafness, 
whereas the daughters II^ and lis both exhibited the MELAS 
syndrome: the latter showed higher percentages of mutated 
mtDNA in their tissues than the former one. The other two 
daughters (lb and II4) were clinically unaffected, and showed no 
or only minor proportions of mutated mtDNA in her tissues ( 19). 
Figure 1 b shows the proportion of the MELAS 3243 mutation-
carrying molecules in mtDNA from fibroblast cultures derived 
from different members of the MELAS pedigree. One can see that 
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Figure 1. (a) Pedigree of the MELAS family analyzed in this work. (O). 
clinical!) unaffected: (Ш). mildly affected: · severely affected; ( · > 
deceased, (h) Detection of the MELAS mutation in fibroblast cultures trom 
different members ot the MELAS pedigree indicated are the expected si/es of 
the PCR product (330 bp)and of fragments produced b) Apa\ digestion ol both 
the МП.AS mutation-containing PCR product (214 und llf> bpl and ot 
ХнніІ-linean/ed pBluescnpt II KS( + 1 DNA (1842 and 1064 bp). used as an 
internal digestion marker: the migration position ot the latter undigested 
fragment (2461 bp) is indicated by an arrow. The 2УЫ bp fragment was not 
detectable in the digested samples The signals were quantified b\ densito­
metry, and corrected tor heteroduplex formation on the basis ol a mixed-tem­
plate standard curve (16). as detailed in Materials and Methods M. 
Μψ\-digested pBluescnpt II KS<+) DNA. Percentages of wild-type (WT) 
mtDNA are indicated below each lane. 
the fibroblasts from the mother showed no delectable amount of 
mutant mtDNA. while those from the three affected daughters 
exhibited a variable proportion of wild-type molecules (from 38 
to 1007i ). with the cells from the least affected siblings carrying 
the lowest levels of the mutation. 
Fibroblasts from four different members (b. II|. II3 and ІЦ) 
were enucleated, and subsequently fused to a large excess of cells 
of the mtDNA-less human cell line p°206. a derivative of 
143B.TK" cells (6). The transformation efficiency, i.e., number 
of colonies growing in selective medium, containing BrdU and 
lacking uridine (6). relative to the number of enucleated 
fibroblasts, was between 0.29 and 0.957c Between 27 and 53 
days after fusion. 12. 14. 25 and 16 presumptive mitochondrial 
transformants derived from patient b . IIь Из a n u" II5. respective­
ly, were isolated and analyzed for the presence and level of the 
Iransmitochondrial cell lines with the 3243 mutation 97 
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MI I \S mutation figure 2 shows ihi percentage ul wild tvpe 
mtDNA in ihe tr tnslormanls Irom the lour lamilv members Al l 
12 ir insilimi mis hom the unallecud moiher ( l · ) contained onlv 
wild tvpe niiDNA as was also shown lor her libroblasts (Fia I 
nul Γι_Ι 19) The trmslormanis derived hom her ihree daughters 
(II l I h and Il-J showed variable UL mil) pes ihe distribution ot 
which appL tred to correlile with the seventy ol their clinical 
plunoivpc Thus H) who had the mildest s)mptoms contained 
74'r wild tvpe mlDNA in her libroblasts (I u I) and 10 ol M 
(7 l ' í ι l i aiisloi niants derived trom her cells were also complete!) 
wil i l i\pc in the i rmiDNA(f m 2) Ρ iiicnis II ι and I I- whowere 
SL\LTLK allccted contained i 4 f f and rcspeelivelv 4Hfï wild 
tvpc miDN \ m their tihrohl isis (bo M and 20Γΐ and 
ics|Kcti\cK H f r of the tr iiisloini mis derived there trom were 
appaienti) homoplasmic lor wild t\|x m i D N A l f ig 2) Tunher 
moie it is sinking that ihe avetaiie pcicciiiages ol wild type 
mi DNA in the' traiislormanis dctived Itoni ihe lour members ol 
ihe pedigree i e lOOVr 77 ±-MI'r -I2± W and 4 6 + 1 2 ^ lor 
individuals b II] II and 11> icspcctivck (Fig 2) were nearly 
identical to those lound m the patentai libroblasts ie 1(X) 74 
1У and W r respOetivel) (Fig 1) These obsci\ ltions suggest 
i lu l ihe parental libroblasts have adisinbuiionol genotvpes 1 airly 
similar to thai observed in the iransloinianis derived Irom the 
vanous members ol ihe pedigree 
Quantification of m l D N A ιυρ\ number in 
mitochondrial transformants 
1 he ratio ol mlDNA to nuclear DNA irelleeung the ìntDNA cop> 
number) in mitochondrial iransloinianis Irom three tamil) 
members ( l · (1| and №%) was measured at different times after 
lusion b> slot blot analysis using a mtDNA probe and a 28S 
rKNA probe respectnel) They are expressed relative to the 
mlDNA/mulear DNA ratio in І - И В Т К cells which ha«, 9700 
molcnilesrniDNApercell (6) and is the parental line Irom which 
ihe ρ 206 cells were derived As shown in 1 igure ^ the relative 
miDN \ copv number ol the iransiornunls surprisinglv varied 
grcallv when measured 6 lo I I weeks .liter lusion The variation 
covered a range between 6 and I7K'* ol ihe І -ИВТК 
mlDNA/iiuelcar DNA ratio (set equal lo I) in the 12 wild ivpe 
Mansioni! mis derived Irom the asvmptomalie mother ( b ) ihe 
mlDNA copv number Ьеіпц >7V/r ol Mie 141H I К level in the 
ma|oriiv ol them Two translormants derived trom patient II] C\ 
and CIO cxhibilcd a mlDNA copv numher corresponding ю 8*S 
and 97V ol ihe relativ e I-ИВ Т К " mlDNA level al 102 das s aller 
fusion having a proportion ol I'Kind ΙΟΟ'/ί wild ivpe mtDNA 
respcctivel) In eleven translormanis derived Irom IU (named 
A l A4 A'S A7 AIO В1 B I В4 Вб B U nul В12) the mtDNA 
copv number varied between -2 and -MO'r ol the relative 
14ЯВТК mtDNA level without anv obvious relationship to 
their pjopomon ol mutant mtDNA One iraiislormant <A7) 
which had a mlDNA copy number concspoiulmg to onlv 2(/( of 
the 141BTK level with 2</r ol ihe iniDNA molecules beim: 
wild type grewonlv in the presence ol ^Ομμ/ιηΙ undine Thiscell 
line icsembles the previously described human cell mutants 
which aie severely depleted of mtDNA (20) Dunng continued 
growth in medium not supplemented with undine the mlDNA 
cop) number ot all the lis derived iransloinianis below the 
I 4 4 B T K level showed a lendencv ю increase slowly and to 
approach or slightly surpass that level between 90 and ISO da\s 
alter lusion (setto I in Fig Ì ) The onlv exception appeared to be 
clone II-, B6 whose mtDNA cop) number rose trom I 1 times the 
14^B TK level measured S\ davs after lusion to 1 9 times that 
level measured HO da>s atter fusion 
Karyotype anal>sis of 16 transformants carried out at various 
times alter lusion revealed ranges of chromosome numbers very 
similar to that observed in р э 206 cells (7Ì-R9 per cell) 
confirming the c)brid nature of the translormants and arguing 
against the possibility that the low mtDNA copy number in some 
ol these translormants may have been caused b) a high number 
ol chromosomes carrying rRNA genes Only three с Iones II] C i 
ils B l and IU-B4 contained a certain proportion of cells 16 28 
and 1W< respectively with a somewhat higher chromosome 
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number than in p°206cells (covering the range o( 101 to 161 per 
LCII) However the mtDNA copy number in these three (Jones 
was very similar to thai οί ΙΉΒΤΚ cells 
Segregation of mtDNA towards the mutant type in 
MFI AS transformants from patient \U 
In previous work (16) к was found that among Π myoblast 
derived ρ"206 cell transformants that were heteroplasmic tor the 
MELAS Ч2-И mutation five underwent a rapid shilt ol their 
mitochondrial genotype towards the pure mutant type whereas 
the other eight cell lines which included six exhibiting nearly 
homoplasmic mutant mtDNA and one carrying nearly homo 
plasm к wild type ml DNA maintained a stable genotype Inno 
case a shift ul mtDNA towards the wild type torm was observed 
We have reinvestigated this behav юг in ten transformants derived 
from libroblasts of patient lis The proportion ol mtDNA with the 
MELAS mutation was determined with the last radioactive cycle 
PCR which excludes the possibility ot heteroduplex lormation 
between wild type and mutant mtDNA lollowed bv Лри\ 
digestion The autoradiogram of one such experiment is show η in 
Figure 4 A weak band wiih an intensity proportional to ihe level 
ol mutant mtDNA was seen moving slightly faster than the 
expected 158 bp band We believe that this extra band is derived 
trom the band above и probably by partial denatural ion in ihe 
Polyacrylamide gel due to its lower GC content as compared to 
the 214 bp band (49 9 и 44 97r) The shift towards mutant 
mtDNA can be clearly seen in clones B4 and Al (Fig 4) Two 
clones (A4 and AIO) exhibited apparently pure wild type 
mtDNA and two clones (Bl and B6) exhibited nearly homo 
plasmic mutant DNA The other six clones were heteroplasmic 
lor the mutation The proportion of mutant mtDNA was 
quantified by a Phosphonmager As shown in Figure ^ all 
heteroplasmic transformants exhibited a decrease in the propor 
tion ol wild type mtDNA whereas this remained constant in 
clones with apparently homoplasmn. wild type or nearly homo 
plasmic mutant mtDNA In no case was a shift towards the 
wild type mtDNA observed Furthermore it was noted that the 
shift to the mutant genotype in ihe heteroplasmic clones was 
remarkably slower almost by a factor of 7 than previously 
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iKmcd ir invi, ш и ш ·ΜΗ VST wild tv pe 
observed in myoblast derived p°cell iranslomiants (16 17) as 
exernphlicd hy the behavior ot clone 94B in Figure i 
Relationship between genotype and phenol ν pe in 
long-term cultured heteroplasmic transformants 
Eleven transformants derived Irom patient lis maintained in 
culture over a long time were invesiigaled indelail io determine 
their phenotvpe to genotype relationship The respiratory capac 
ity ol nine transformants was measured both riiher early (41 80 
days) and late (94-148 days) alter the mitochondria transfer into 
p° cells A diagram illustrating the relationship between propor 
tion of mtDNA carrying the MELAS mutation and degree of 
respiratory activity in the p c cell translormants derived from 
patient lis is shown in Figure 6a It appears thai ihe O^ 
consumption rate rises sharply with the percentage of wild type 
transmitochondrial celi Unes with the 3243 mutation 99 
nilDN \ until it reaches 2 tmol/min/cell ι e -*4)f < ot the normal 
le\el around 2*( wild t\pegenomes asohserved intwodiflerent 
slaves ol ihe ВI iranslonium The O: consumption values ol the 
Hft transformant which are presumablv high due to the Mgmli 
tant increase in its mtDNA cop> number ( 1 ì to 1 9 IIIIILS the 
14ЧВТК level ) ( i 8) after correction tor this tactor would also 
tit a threshold around 2f7r ot wild type mtDNA The ( b 
consumption rates continue to rise w ith increasing proportions ol 
wild tvpemlDNA to reach ~4 Imol/min/cellby -IOr/r wild type 
mtDNA remaining thereafter more or less constant up to l(X)'/f 
wild-type genomes Note that the early clones ot A^ B4 and Л10 
having mtDNA copv numbers ot 57 41 and 2b{/< ol the 
1-ПВТК kvel respectively and a proportion ol wild l>pe 
miDNAolS* 76andlOO fi respectiveh have 0> consumption 
rales below 2 Imol/min/cell The relativelv low number ol 
translorm.ints with verv high proportions ot mutant mtDNA 
makes it dillicult to define preciséis the threshold level tor 
protection against the etlectsofthe MhLAS mutation However 
il would appear that in the fibroblast derived ρ 206 cell 
transformants investigated here such threshold is lowei ih.m 
preuouslv reported for mvoblast derived transformants Larryimz 
the MELAS mutation (-64 rel 10) This dilterence is possiblv 
due to methodological tactors In fact in the present work the 
mutant mtDNA proportions were determined with a phosphon 
mager using the last radioactive c>cle PCR niellimi (see 
Materials and Methods below) whereas previously correction 
for heteroduplex lormation was made by laser densitometry ot 
ethidiuni bromide stained gels on the basis of a mixed template 
siandaid curve ( 10) 
In order to in\ estigate whether the absolute amount ol 
wild ivpe miDNA rather than or in addition to Hs proportion 
played a crucial role in determining the respiratory activity ol the 
translormants the Ob consumption rates ol these were plotted 
against the absolute levels ot wild type mtDNA As shown in 
figure 6b a verv small amount ot wild t\pe mtDNA coirespon 
ding to -*»f/r of that the I-ИВ TK" parental line was sulliuent to 
support ~4Y/c of the normal level ol respiratory activitv with 
further increases m amount ol wild-t\pe mtDNA producing a 
gradual increase up to 1О0'# ol respiratory competence lor a 
wild-tvpe mtDNA level close to that of 14ЯВ TK cells [hese 
data were consistent with the results of Figure 6a in pointing to 
a ver\ low threshold in the protective capaulv ol wild type 
mtDNA against the phenotypic effect of the MbLAS mutation 
On the other hand the observation that a very small absolute 
amount ol wild-type mtDNA could support a substantial 
respiratory capacity (50% or more) strongly suggested that the 
mutant molecules contributed to the respiratory activity ol the 
iranslormants either as a result of intramitochondrial comple­
mentation by wild-type mtDNA as previously observed ( 18) or 
because ot residual functional capacity ot the mutant mtDNA 
This conclusion was supported by the observation that ten out ot 
eleven translormants ol patient lis when analyzed late alter 
fusion showed a normal mitochondrial protein synthesis pattern 
as concerns kith the electrophoretic mobility and labeling ol the 
mitochondrial translation products alter exposure to (^S) me 
thionine lor 2 h in the presence ot emetine an inhibitor of 
cytoplasmic protein synthesis Only transformant A7 showed an 
overall strong decrease in mitochondrial protein synthesis (results 
not shown) Surprisingly also Bl exhibited a normal mitochon­
drial protein synthesis pattern although it had a proportion ol 
only 2*7f wild type mtDNA and an От consumption rate of 2 
4 
2 
1 
1 
• A7 
¿B3 
4« [-.,, 
1 
I л 
ІА4 
AIO 
J A4 
AIO 
0 10 20 30 40 50 ВО 100 
% WT mtDNA 
τ 
fei 
9 ' 
/ 
Г 
Ά 7 
,-tB3 
1 
τ 
, 1 
•ΑΙ 
Î B 3 
- Β 1 2 
* 
" J L — - — — 
Івз 
τ AS 
. A I O , β ' 
Α10 
ÎA4 
0 0 0 1 0 2 0 3 0 4 0 9 1 0 
Absolute amount WT mtDNA 
l-i^urt* ή Relationship Ьи - ч п О; ілчімтіриип and Ί \\ I mil А Л іаі or 
absolute amount ol WT miDNA (b) гікаміачі earl· (-11 NO i l i w l I ) or Ι tu. 
Cí-I—1-114 davs) atter lusion ι # ι in u-uisformant.-. demed troni palimi I I , 
Tran·.! огтпапь чіп mtDNA ιορν nuinbtrs <Hft of ihe І-ИН I K - l i \ J are 
indicated h\ (V) The Lurvi lilting was donc manually in lu) and bv computer in 
ibi (logonüimii ϋ
ι Λ
| OWN) Emir hirs represent one SD ІЪе proportion ol 
MELAS mutation ^ імілетіігилІЬ ·ι Ι ιΜ radio*Ideivi,le К R W I wild-tvpv 
fmol/min/cell however this has also been observed previously in 
a few nearly homoplasmic mutant transformants (9) 
In order to obtain further ev idence on the contribution ol mutant 
mtDNA to the respiratory competence of the transformants from 
patient Us the influence of the mtDNA copv number on the 
phenotypic behaviourof these transformants was invesiigaied As 
shown in Figure 7 a plot of O: consumption rates versus the 
mtDNA copy numbers revealed a general tendency to a 
proportionality of the respiratory capacity of the individual cell 
lines to their mtDNA content, both in clones exhibiting a very 
small proportion ol wild type mtDNA (like Bl) and in clones 
containing homoplasmic wild-type mtDNA (like AIO) This 
observation supported the idea ol a functional role of the mutant 
mtDNA molecules The increase in respiratory capacity which 
100 Chapter Vili 
B12 36> 171-1 
0 5 1 0 1 5 2 0 
Relative mtDNA copy number 
Figure 7 K<J nion^hip r x i u n n О іппмітр іюп TJUN diid геІЛіч. imDS \ 
top^ luimtxr of Π loru к п п uillureil [ranslomuni«. I rum ρ ilii.nl 1Ц 
mi. iMin.il ι irK ι<Χ() LIJ\S ι иг 1 il«. OSO dj\s φ ) i lkr іимпп The 
л м ч п р invine ι tunee in p i n u u \
с
к ol inuudon i^ ai ν m in partnihLse·* tor 
е л h dont. Hit. urne l u m u w ι*, iltnu. b\ computer <pou.er R4J) О 74S) Ml 
\ j l iu·- ti iv*. ГЧ.І.П nomuli/LiJ in [hi. ruio ol miDNA lu n i k k j r I)N \ in 
1-ЛВТК I.L1IS w h k h h j s b L L n M i is eqiul to 1 
was observed in eight of nine clones when analyzed at dillerenl 
limes alter lusion in general paralleled more or less closely the 
mercase in iheir ini DNA top) number The mtDNA top) level 
ol two clones A l a n d A 7 was only investigated late aller lusion 
Four clones AIO B4 A5 and В12 initially exhibited a 
respiratory cap.icilv below 2 ^ Imol/minpercell which could nol 
be attributed lo a low proportion oí wild l)pe mtDNA (more than 
Ì9 rc oí ihelolal miDNA) However all fourelonesshoweda low 
mtDNA top) number below S87r of the l - П В Т К " level On 
continuous culture both their respiratory capacity and their 
miDNAtopv number increased in parallel to reach normal levels 
whereas iheir proportion ot wild type mtDNA remained consumi 
or decreased onl) lo an extent not expected to have an mtlueiiee 
on their СЬ consumption rale Both clones В1 and B6 exhibited 
a low proportion of wild type mtDNA (2-Wr) This accounts lor 
the respirator) deficiency in B l In clone B6 the normal 
respiratory rate ( - 1 6 fmol/min/cell) tan be presumably ex 
plained by the rather high mtDNA copy number which increased 
from M to 1 9 limes the 141B TK" level over a period of S1 to 
И 0 days alter lusion compensating for the low mutation level 
which decreased over the same period Irom 1 lo 2ck wild type 
mtDNA The increase in respiratory capacity of clones A4 and 
B l which cannot be attributed to an increase in their mtDNA 
copy number possibly poinis to some adaplalion phenomenon in 
which a selection of high respmng clones resulted from 
continuous growth in medium lacking undine as previously 
observed (9) 
DISCUSSION 
The present work has provided insights mio ihe muluple factors 
that play a role in determining ihe phenotype of transnutochon 
dnal cell lines constructed by mitochondria transfer mio mtDN A-
lesseelK In particular the relationship ol genotype to phenotype 
has been anal)zed in transformants obtained by using fibroblasts 
Irom members ol a lamily tarrying the MELAS A io G transition 
at position 1241 of mtDN A as mitochondria donors and the 14 IB 
ρ 2()6 cell line as recipient Three main conclusions have btLn 
derived Iron» these studies 
(ι) The transformants earning the MELAS mutation in 
heleroplasmic form with 157r to %Yk wild type miDNA 
exhibited a consistent genotype shift towards mutant mlDNA 
during prolonged culture by tonlrasi the transiomiants canning 
apparently pure wild-t)pe mtDNA or mutant mtDNA in nearly 
homoplasmic form exhibited a stable genotype over a period ol 
11 lo 18 weeks alter fusion ThemlDNA shift towards the mutant 
t)pe in ihe unstable heteroplasmic transformants was much 
slower (han prcviousK obsened in myoblasi derived mitochon 
dnal iranslormanls of ρ c 206 cells (16 17) 
(il) The re-establishment of the normal mtDNA/nuclear DNA 
ratio wuh fibroblast derived mtDNA in (hep cell transformants 
occurred at a variable rale bui in general more slow I) than 
previouslv observed in ρ 206 cell mitochondn il trinsfornunts 
derived trom established cell lines (6) and was accompanied b\ 
a paralkl increase in СЬ consumption 
(in) A vetv small absolute amount ot wild tvpe mtDNA (2-*)% 
ol (he contro] level) in p° cell iransfonnanls earrving sirunnlv 
predominant mutani mtDNA conlerred upon them a subsi niiial 
respirator) capatitv (50<7с or more) This observation as well as 
the evidence of a proportionality between mtDNA top) number 
and Ü2 consumption rate which occurred at widely dil It reni ratio 
ot mutant to wild type mlDNA strongly suggested thai the 
mutant mtDNA gives an essential contribution to the respiratory 
competence ol the transformants 
In the present work the near identity ol the average rxreen 
lages ot mutant mtDNA molecules in the iransloiniants derived 
from each member ol the pedigree and in ihe fibroblasts ol thai 
individual ma) point to a similar distribution ot genotypes in the 
transformants and in the parental fibroblasts 11 this interpretation 
is correct the correlation between seveniv ol the clinical 
phctiotvpt of the cell donors on one hand and increase in 
proportion ol heteroplasmic or nearlv homopl ismic mutant 
transi ormanl s derived Irom those donors on (he other stiegest s 
that the segregation towards the mutani genotvpe observed in the 
transformants ma) reflect a phenomenon occurring in ww> in the 
original fibroblasts In other studies among p°206lranslorniants 
constructed using fibroblasts from a family exhibiting a 
non insulin-dependent diabetes mellitus assoc latcd w nh the 
t R N A L L l l ( U L K l mutai ion (21) only one ol seven heleroplasmic 
clones showed a stable genotype while the oiheis segregated at 
a similar rate as that observed here towards mutant mtDNA (22) 
A mitochondn a I genotype shitl towards ihe mutant type has 
been previously observed m a number ol transformants ol ihe 
p^206 tel l line derived from myoblasts of individuals belonging 
to live different pedigrees canning the MLLAS 1241 mutation 
(16 17) In these studies the majontv ol the р л 206 cell 
translormants derived from the same MELAS patients main 
lamed a stable genoiype whereas no transformant exhibited a 
shill ol the milochondnal genome towards the wild tvpe 
Interestingly in one of the studies mentioned above (17) 
experiments utilizing myoblasts from ihe same MELAS patient 
as mitochondria donors revealed in a subset of heteroplasmic 
transformants a genotype shift towards either mutant mtDNA or 
wild type mtDNA depending on whether ihe ρ 206 cell line or 
respectively a dillerenl p* cell line ( p ° A M 9 ) was used as 
recipient These results clearly pointed to the role of the nuclear 
background in determining the direction ot genome segregation 
transmitochotidriai cell ¡mes with the 3243 mutation 101 
Retenti\ it was claimed that the segregation process for the 
MFl AS 1241 mutation in heleroplasmic myoblast derived p° 
tell transiormants grown under non selettive conditions is 
stochastic in nature (21) However differences in experimental 
procedures are likely to account fortheditterent outcomes ol this 
and our study 
The mechamsm(s) of the rapid segregation towards (he mutant 
or wild type genome is unknown and it is quite possible that two 
di Herent mechanisms, ι e replicative advantage and intercellular 
selection respectiveK operate in the shift towards the mutant and 
wild type miDNA In particular in previous work trom this 
laboratory a detailed analysis of myoblast-denved unstable 
p°206 cell transformants shilling towards the mutant genotype 
has provided evidence suggesting that a replicative advantage of 
(he mutant molecules was mainly responsible lor the genotype 
shilt (16) A plausible model lor this rephcalive advjniage 
involves ,i feedback phenomenon thai induces the selective 
replication of ml DNA in organelles lunctionally compromised by 
the presence in them ol mutated mtDNA in pure torni ι e under 
conditions excluding intrjmitochondnal complementation 
(16 2-1) Replicative advantage has been suggested belore to 
explain the prelerential accumulation ol deleted or otherwise 
grosslv altered miDNA m yeast and filamentous tungi (2^ 26) 
The observation that only a minority of the transformants 
obtained bv using cells from the same patient as mitochondria 
donors lor iransler to a given p" cell line exhibited an unstable 
genotvpe can be explained b\ posMble dillerences in nuclear 
backgiound among cells in these transformants Evidence tor 
such variation among cells of the same p° cell line has been 
previousK presented (15) Thus the more abundant stable 
translormants mav represent cells whose nuclear background 
does allow extensive inlramilochondnal complementation ol the 
ululation due for example to a slower rate ot mitochondrial 
division rel itive toorganellar growth which would lavor mutant 
and wild ivpe gene product mixing 
In the present work no direct evidence has been obtained 
concerning the mechanism underlying the mitochondrial ge 
nonne shilt towards the mutant type in the fibroblast derived 
p'206 transformants An analysis of the doubling times of these 
tianstormants failed to reveal any correlation with their propor 
lion ot mutant mtDNA or with their genotype stability or genomic 
sluli towards the mutant type (unpublished data) These results 
would argue against a significant role of intercellular selection of 
faster growing mutant mtDNA enriched cells suggesting that a 
replicative advantage of the mutant genomes due to the same 
mechanism occurring in the myoblast derived p°206 translorm 
ants may also operate here As to the slower rate of genomic shill 
towards the mutant ivpe in the fibroblast derived transformants 
analyzed here as compared to myoblast derived translormants 
an intriguing possibility is that it reflects the nature of the cell ty pe 
utilized as a mitochondria donor In particular, dillerences in the 
cytoplasts derived from distinct cell tvpes may affect ihe 
reintegralion ol the foreign mitochondria into the general 
organization of the recipient cell influencing the segregation 
behavior ol the mulanl mtDNA However on the basis of the 
available knowledge a more likelv possibility is that the 
particular mtDNA haplotype ol the MELAS pedigree investi 
gated in this work played an important role in the difference in 
behavior of the fibroblast-denved transformants 
There is ample evidence of the existence of a high degree of 
variation in human mtDNA (27 28) Although H has been 
generally assumed that mtDNA variants other than those 
carrying clearly pathogenic mutations are well tolerated an 
increasing amount of ev idence points to mtDNA poly morphism 
as a possible contributor to respiratory dysfunction (29) Thus, the 
synergistic etlect ot secondary mutations in miDNA genes 
encoding suhunits ot NADH dehydrogenase in the pathogenesis 
of the I eber s hereditary optic neuropathy (LHON) has been 
suggested (28 10) and the role ot the mtDNA haplotype as 
contributing lo the pathogenesis of certain neurodegenerative 
diseases has been proposed (28 11) although there is no direct 
evidence yet to support these suggestions (32) Recently an 
increased sequence variation in certain Complex I mtDNA-en-
coded suhunits has been reported in patients affected by a variety 
of mtDNA linked diseases, and it has been proposed that this 
variation may contribute to the Complex I defect in these patients 
(2°0 MtDNA polymorphism can also conceivably affect the 
segregation ol mutant and wild-type genomes Thus in human 
cell cybnds isolated by iransler ol fibroblast mtDNA mio HeLa 
cells prefciential loss of HeLa cell miDNA has been reported 
(11) In S ÍIMWWÍK evidence has been obtained indicating thai 
ihe expression of the mitochondrial genome is required lor 
maintenance of the mitochondrial genomes (14) It is, therelore 
possible that a difference in the rate ol synthesis or stability ol 
some mitochondrial translation products or in their functional 
elliciencv due lo the occurrence of miDNA polymorphism 
influences ihe segregation behavior of this genome Since as 
menlioned above ihe nuclear background can determine the 
direction ol segregation of the MELAS 1241 mutation it is 
conceivable thai the mtDNA haplotype by interfering with or 
facilitating the mechanism that underlies the shift towards the 
mutant or wild type genome can influence the rale of this shift 
Further work is needed to clanly the mechanism which deter-
mines the slower segregation of the mitochondrial genome 
towards the mutant type in the fibroblast derived (this study and 
rel 22) as compared to the myoblast derived transformants 
(16 17) cair>ing the MELAS 1241 mutation In particular it 
would be important to compare the segregation behavior ol 
miDNA in ρ cell translormants derived trom cloned myoblasts 
and fibroblasts ol ihe same MELAS patient 
I he slow rate of reesiablishment of the normal mtDNA copy 
number in ihe fibroblast derived translormants analyzed here as 
compared to the previously investigated transformants derived 
from established cell lines (6) may also be due to the donor cell 
mtDNA haplotype atlecting the p° cell repopulation process In 
another context the increase in Cb consumption observed during 
piolonged culture ot the fibroblasl-denved ι ran s form an ι s which 
paralleled in general the increase in iheir mtDNA copy number 
dearly illustrates the role ot the mtDNA level as a limiting factor 
in the mitochondrial respiratory phenotype This phenomenon 
has been seen previously in cultured cells trom patients with 
mtDNA depletion during restoration of the mtDNA level by 
nuclear complementation (15 16) On the other hand the 
observation ol an increase in Cb consumption rale which was 
seen upon prolonged culture in clones (A4 and Bl) already 
exhibiting ai early limes nearly wild-type respiratory aciiviiy and 
which was independent of an increase in mtDNA content 
suggests the intriguing possibility that a physiological adaptation 
may occur which increases the respiratory capacity ot the 
transformants by a mechanism not involving a change in mtDNA 
level As concerns the contribution of mutant mtDNA to the 
rcspiratorv competence ol the translormants which is strongly 
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suggested bv the evidence obtained in the present work it could 
be the result of a complementation of the MELAS mutation by. 
wild type genes and/or of a residual functional capacity of the 
mutant molecules 
MATERIALS AND METHODS 
Cell lines, media and mitochondria-mediated p°206 cell 
transformation 
Thebramodeoxyundine(BrdU) resistant 141B TK~cell line and 
p°206 cell line an mtDNA less derivative of the latter obtained 
by long term exposure of the cells to low concentrations of 
ethidium bromide were grown as described elsewhere (6) 
Human skin Fibroblast lines from members of a family with the 
MELAS tRNALeLJ<l- l-Rl 1241 mutation (19) were grown in 
Dulbecco s modified Eagle s medium (DMEM) containing 50 μg 
undine per ml and 20c/c fetal bovine serum (FBS) 
Cytoplast fusion was earned out as described previously (6) In 
particular enucleated fibroblasts (-2 χ IO4 cells) were fused to 
10^ p°206 cells and the cell mixture was subsequently plated into 
% wellfh II, Ih and lis) or 24 well (II Opiates at -0 26 or -5 2 
original fibroblasts per well respectively Transformants were 
isolated from wells containing single clones and maintained in 
DMEM with 5<7r dtalyzed FBS and 100 pg BrdU per ml 
Sixteen translormants of patient lis were analyzed lor the 
presence of mutant mtDNA between 27 and 51 days after fusion 
Of these eleven were maintained lurther in culture for analysis 
of their mtDNA copy number and their genotype to phenotype 
relationship One transformant (A7) grew only in medium 
supplemented with undine (SO pg/ml) while another one (Al) 
was only analyzed late after fusion 
All cell lines described in this repon tested negative for the 
presence of mycoplasma by Hoechst 11258 (bisben/imide 
Sigma) fluorescence 
Chromosome analysis 
Cells were arrested in meiaphase phase by treatment with uilcemid 
(0 1 pg/ml) Approximately twenty five air dried metaph.Lse spreads 
were examined according to standard procedures 
DNA analysis 
For quantitation of mtDNA total DNA samples were isolated 
from unlabeled cultured cells with an Applied Biosystems 140A 
DNA extractor and analyzed in triplicate by slot blot hybndi/a 
non as described ( 16) Possible quantitative variations among 
different DNA samples were corrected by normalizing the data 
for the amount of nuclear 28S rRNA genes using a 28S rRNA 
probe (18) Quantification of the hybridization reactions was 
earned out by analyzing the slot blots in a Phosphonmager 
(Molecular Dynamics) 
The presence and proportion of mutated mtDNA in total cell 
DNA samples prepared by proteinase К digestion of 0 Y/c Tween 
20 cell lysales (18) were determined by testing for the presence 
of the April site created by the MELAS mutation (17) at position 
1241(18)inaPCR amplified fragment The amplified fragments 
were digested with ApcA in the presence of pBluescnpt II KS(+) 
(Slralagene) DNA linearized with Xmn\ as an internal marker for 
completion of digestion and analyzed by agarose gel electro 
phoresis (10) Two pnmer pairs were used for the PCR reaction 
The first pair consisted of two oligodeoxynucleotidcs correspon 
ding to positions 1011-1050 and 1141-1160 in the Cambridge 
mtDNA sequence (18) yielding a PCR product ol 110 bp which 
was digested by AptA into two fragments ol 214 and 116 bp 
Digestion with Apui was performed lor 10 h at 25°C by adjusting 
the PCR reaction mixture to the pH and salt conditions 
recommended by the supplier The proportion ot digested and 
undigested molecules separated by electrophoresis at room 
temperature in a 1 47c agarose gel in Tris boratc-EDTA in the 
presence of clhidium bromide was determined by laser derisilo 
mctry (using an LKB Pharmacia instrument) and corrected lor 
the resistance to digestion ol heteroduplexes ol wild type and 
mutant mtDNA on the basis ot a mixed-template standard curve 
(16) Alternatively oligodeoxynueleotides corresponding to 
positions 3011-3050 and 1184-1402 were used lor PCR 
yielding a product ot 172 bp which is digested by АрсЛ into two 
fragments ol 214 and 158 bp Inthiscase heteroduplex lomiation 
was avoided by adding 5 μ Ο ot [a- , :P|dATP (1 000 Ct/mmol) 
only in the last (26th) cycle (1У) Alter digestion with Apo\ the 
radioactive products were clectrophorcsed at 4°C throujh an 8'/r 
nondenatunng Polyacrylamide gel and quantified with a Phos 
phorimagcr Completion of digestion ot the internal marker was 
checked by clectrophorcsing portions ot the samples at room 
temperature through a I 8r/r Metaphor agarose (FMC BioPro 
ducts Rockland) gel in the presence ol ethidium bromide 
Οι consumption analysis 
Rates ol O^ consumption were measured (in duplicate) wuh a 
Gilson 5/6 oxygraph on samples ol -5 χ It)'1 eells in I 85 ml ol 
DMEM lacking glucose supplemented wuh 5Vr dialyzed bovine 
serum (6) 
ACKNOWLEDGEMENTS 
Wc are grateful to Drs J Begeer and Ρ Smit (University Hospital 
Groningen the Netherlands) lor sending us [issues trom their 
patients Wc thank Η Janssen (Department ol Human Genetics 
Nijmegen The Netherlands) tor chromosome an.ilvsis and Λ 
Drew В Kcelcy S Τ Lai and L Teto lor technical assistance 
These investigations were supported by alellowship from the 1er 
Meulen Fund (Royal Dutch Academy ol Sciences) and a travel 
grant from the Netherlands Organization lor Scientific Research 
(NWO) (both to Η А С Μ В ) and by National Institutes ol 
Health Grant GM 11726 (to G A ) 
REFERENCES 
I Wallace D C < 19441 Mikxhondml USA mm moils in dist ises " I іпіг » 
metabolism J Bu eneri. fin inetti 2ή 2-D-2SO 
1
 Sehon E A Hirano M a n J D i M a u i o S I ІЧЧ4> Milothondri il ent iph ilo 
imopalhies «.Imitai and nkiktcilat anilssis J Ни entri, Hmititin 26 
241 "·99 
λ Boula L Кагрш G and Shouhndte t-A (ІС")2| Dislnhiilion and 
ihn.'•hold expression ol the (RNA1 ч nuil ilion in sktltl il must II ol palienb 
with msutlonit epiltpsj jnd r icLtd red fibers <\1t-RKt-| \tn J Hunt 
Genei SI 1187-ΡΙΙΟ 
•1 \1i>aba\ashi S Hj iu ini/υ H N i k n n u r i H hndo H j n d T j d j К (IÇW2I 
Deri t lsurni iuxhundn it icspit ilorv en/\nws in tloned tells Ironi Mi-LAS 
librublasls J Inliet Meuib Ho 15 7Ç)7-WI2 
S Bout tn in Τ d i t t i m i I) Rong A Munnith A andRusiin H l l W l l l ale 
and expression ol iht deleted milOehondnal DNA diller beltteen human 
hLltfoplasnnt skin libroni isls ind t-psiein Bin- sinjs iranslomved Itmphn 
t s l t t u l l u r t s J Hittl (lutti 2ЫІ 14IM-19176 
transmitochondrial cell lines with the 3243 mutation 103 
6 Κιπι. Μ Ρ and Attardi G [ 1989) Humancells locking mtDN \ repopulation 
with e*oeenous mitnchi ndria h\ complementolion Suai < 246 S0O-S01 
7 ( h o r m n A Mcol ι G Brcsolm N L J I S Τ Sur i im G und Aturdí G 
( 1991 ) In ν uro senelic transfer ol protein s> nthesis and respiration detects m 
miloehondnal DN Л less teils »uh mvopalh) pit itín miioehondna Mol 
irti Нші и 2"Чб-2244 
8 liavjshi J I OhtJ S kikuehi A Tokemilsu M Goto Y 1 andNonoka I 
(1991) Introduction ol disease related mitochondrial DNA deletions into 
Hcl ι tells latt in » miioehondn il USA results in mitochondrial dvslundion 
Рпн. Suif Atad Sa ІЬА H» I06I4-I06I8 
У King M P Koga Y Davidson M and Schon b \ U W ) Peleas in 
mitothondnal protein synthesis ind respiratory chain ictn ity se^rcj-ate with 
ilit I R N A I L U 1 1 H nun mon issociaicd w uh niil<>chondna) myopathy 
encephalopathy lactic acidosis and stroke like episodes Mol (til Biol 12 
4X0-490 
Id ( пшшп λ M irtmu//i A foiled ι M Data A Hurko Ο Johns D Lai 
ST Nonaka I Aneelim С and Attardi G ( I992i Ml I AS mutation in 
mtl)N A hindin° sue lor tr inscription termination г к lor e lusts defeits in 
protein s\nthesis and in nspir ition but no ι han L I in levels ut upstream and 
dc «nstream mature transtnpts PUH \atl At at! Sa Í SX 89 42"Ч —122^ 
II Hawshi J [ Ohta S I ík n I) Mivabryashi S S ikut ι R (»no Y I and 
Non ika I ( 1991) At ι mutilation ol miDNA with j mutation at position 3271 
in t R N A U w l l K ' (iene introduced from a MELAS patient to HeLa cells 
lacking mtDN A results in progressive inhibition ol iiiiiochoiidn il respiratory 
limaton Нин ¡win В«
 rli\% К, \ С nmm 197 1049 Ilí^S 
f M motu С Tiranti V Carrara F Dollapiecola В DiDonato S and 
7ечапі M 11 W4i Defeat ν e respirai ΊΓ\ с ipiutv anil nuioehnndn il protein 
svnthtsis in trinslorm nit cvhnds h irhonn the iRSA1 U l l H mutation 
issiv.1 ited with m i k m i lk inhaikd m\upalh\ and eardiomvopalhy J Clin 
M i o / 93 HO"· 1107 
Π I mi икс I Nul l S imi V. ill KL D C (1994) ( viopl ismic tr msler ol the 
iniDNA nl 8991 T ^ G ІЛТР6) point mutation assoa i k d with Leigh 
syndrome into mtDNA less tells demonstrates tose tree л ion with a decrease 
in state 111 respiration anil ADP/O ratio Рпк Nail \i cui Si LSA 91 
Щ Ц - 8 И 8 
14 Fnne|iit¿ JE Chom\n A and \ttardi G (199*4 MtDN \ mutation in 
MERRF svndronie causes deleaive aminoatvl ition ot [RNA144 and 
premiture iranslaluin urinili ilion nature Genti l ü 47-SS 
15 Chuinvn A Lai S T Shakele\ R Bresolm N Starlalo G and Attardi G 
(199-1) Platelet mediated transformation ol mtDNA Itss human tells 
inaksisol phenotypic ν in ihilitv nnon 'clones I rom norm il individuals and 
complement ilion beh м о г of the tRNA'> mutation causing myoclonic 
epilepsy and ragged red libers Am J Hum Gaul 54 966-97-1 
lo Yoneda M Chomyn Α Μ лііні/л A Hurku О md Alt irdi G [1942) 
Marked replicarne id\ nit iLe ot human mtDNA u m i n f a point mutation 
thattausestheMCLASentephalom\opath\ Рпн Natl Und Su Í. ÇA Я9 
11164 ΠΙηΚ 
17 Dunhar DR Moonit PA J itobs H T and Holt U 1199S) Différent 
ttllularbaek rounds eonler a marked ad\anuee to either mutant or udd tv pe 
milKhondnal eenonit PUH Nul \tatl Su US\ 92 fiW-ASofi 
IH Voritdi M Mivatake Τ md Attardi G ( 1994)Complement Uionol mut int 
md wild type human mitoehondnal DNAs coexisting sinee the mutation 
e\entandlackofeomplementationol DNAs introduted sep intely into a cell 
wnhin distinti organelles Mol Cell Ни,! 14 2699-2712 
19 IXVnes D D De Wijs I Ruitenbeek W Beseer J Smil Ρ Bentlage Η 
andVanOosl В 11994)Lstreme \anahilit\ of clinical symptoms among sibs 
in a MI-LAS laitnh correi i k d with haeroplasmv. lor (he mitoehondnjl 
A *241G mutation J \rtirot 5ч 124 77 82 
20 Vaili int F and Naglev Ρ (I99S) Human cell mutants uith very low 
mitochondrial DN \ copy number (pd) Hum Mol (miri 4 901-914 
21 Van den Ouweland J M V* Lemkes H H PJ RuitenbtLk W S indkuijl 
L A De Vijlder M F Stmv\enberg PA A Van de К и п р J J Ρ and 
Maassen J A ( 1992) Mut ition in mitochondrial t R N A U u l L l R Lene m a 
large pedigree with nutemall) trinsmmed type II diahacs nulluus and 
dealness \цшгс Gruft 1 lHf>- Π ) 
2"* Van den Üuweland J M W 11994) A new type ol non insulin dependent 
diabetes mellitus is assotuk-d with a miiœhondnal gate mut mon Thesis 
State I m\ersit\ Leiden The Netherlands 
21 Shoubndee EA (MWS) ^ге^ mon of miiochondnil DNAs t a m m a 
pathogeniL point mutation ( t R N A l l u , - 4 l l in c\bnd cells Bu ι hem Hi >ph\i 
Rr\ Commun 213 IH9-19S 
24 Attardi G Yonedl M anilChomyn A ( 199^) Complementation and 
segreg ition behavior ol disc isc с lusing nuicKhondn il DNA mut »ions in 
cellul ir model systems Нин him Ни ph\i Aito 1271 "*41-24K 
25 Hennnd H Gnllilhs A J F Coun D A and Che n t C K (1986) An 
e^trachromosomal plasiuul is the aioloLical precursor ol k ilDNA insertion 
stciucnces m the mitoth indnal chromosome ol sencsceni Vurospora Cell 
47 K"*9 817 
2fi Shoubndjc EA К а ф і І і С і md Hastings К E M ( ]99di IX Ιαιοη mutants 
arc tunctionalK dominant пег wild l\pe mitochundn i! ^uinmcs in skekt il 
muscle fiber segments in mitochi ndn il disease Cdl 62 4^—19 
27 Brown W M George M md Wilson A C ( 1979) R ipid evolution of 
шип il mitochondrial DNA Рпн Natl Attui Su USA 77 1969-1971 
2К W ili ice D C (1994) Milmliondnal DNA sequence \ ination in human 
evolution and disease PUH Nuli Attui Sa CSA 91 87Я9 87-16 
29 Unric Ρ Kapsd R M I Je m P-гни,ois M J В Th\ ι ir M m D Noir A S 
Mir/uki S and B\me F 1199-1 ) Mikxhondnal DN A роічпк фЬічпі m 
dise isc a possible contributor tu η spiratoti d^slimctu η Hum V/ / Gi' itf 
ΐ 1971-1981 
M) Johns D R and Henn η J (1991) Alternatie simuli ineoiis Complex I 
mitochondrial DNA mut nions in Lebers hendiljrs optie Псіігораігн 
HuHhem Buuthw He\ (omni 174 Ц24-ПЗО 
11 Ikche S I Тапакі M md ü / і л а Τ (I99"í| Point mutations ol 
iiiilochoiidnal genome in Pirkmsttn sdisease Mol Bi ooi Κι \ 28 281 29s 
12 Howell N [1994) Mm*.hi ndn I L.ene mutinons and human diseases a 
prole onicnon [editori i l| Am J Hum Genet 55 Ί 19 2*M 
H Hiwshi } I Werbin H md Shj> JW ( 1986) Effects of minml human 
tihrohl ist mitochondn il DNA un si^re^ition of HeLa TG mitothondnal 
DNAandoniumon_enicii\ ol HclaTGcells CoinirR^ 46 4001-1006 
U M\crs A M Pape L K and T/a^ololT A ( I98S) Miloehondnal protein 
sMithesis is required lor maintenance of intact mitothondnal Lenomes in 
Stitthomm\tntere4Moe EM BO J 4 2087 2092 
15 BiHÍntr A G Cooper J M Holt I J Uonard J V and Sth ipira A H V 
(1991) Nuclear complement »ion rtstores mtDNA levels in cultured cells 
I rom a patient with mtDNA depletion Am J Hum Gaitt * 1 661-669 
16 Poulum J Morten К Facm in Emincrson С Scwr\ С Dubowiu V 
Kidd H Stephenson J Whikhoust W Hansen i~J Pansi Vt and Broun 
G (19941 IVhciencv ol the hum in nntcxhondnal innstnption f IL (or 
h m i l FA m iniantik mik^hondnal m\opjth\ is associated with nilDNA 
dtpletion //i«» Mol Gemi 3 1761 1769 
17 Goto Y Nunakj I ind Hor u S ( I990l A mut ition in the (RN A U u ( l l H 
gene is4iciated with the MELAS subcroupül miuxhondnal aietphalumyo 
pilhies Nature 348 6SI-6S1 
18 Anderson S Bankier A T Barrcll В G de Bru ij η M U L Coulson A R 
Droiiin J Eperon 1С Nicrlich D Ρ Roe В A San t r F Schreier PH 
Smith A J H Staden R and Youn^. I G ( 1981 iScqutnec and organisation 
ol thi human miloehondnal genome Nomre 290 4S7—16S 
19 Morics C T Rica E Bonill ι E DiMauro S andSthon E A (l992)The 
miloehondnal tRNA1 eu,i l H l mulation in miloehondnal encephaloimo 
ρ ilhc Ι к tic acidosis and stroki. Д;Ііке episodes (MELAS) ілпеік bio 
chemical and morphologic il correlations in skeletal muscle Am J Hum 
Cruet 50 914-949 

Chapter IX 
Summary and suggestions for future studies 

summary and suggestions for future studies 107 
The major goal of the study presented in this thesis was to improve the diagnostics of 
mitochondrial encephalomyopathies, a heterogeneous group of disorders affecting predominantly 
skeletal muscle and the central nervous system The mitochondrial energy metabolism, in which the 
five enzyme complexes of the oxidative phosphorylation (OXPHOS) system participate, is often 
defective in tissues of these patients 
The general introduction (chapter I) describes several features of mitochondrial 
encephalomyopathies, and the structure and functioning of the five multimene enzymcomplexes of 
the mitochondrial respiratory chain and OXPHOS Complexes I, III, IV, and V, have their genes 
located in both the mitochondrial DNA (mtDNA) and the nuclear DNA (nDNA) Complex II 
contains only nDNA encoded subunits The mode of inheritance can be either autosomal (nDNA), or 
maternal (mtDNA) All nDNA encoded subunits are synthesized in the cytosol, and imported into the 
mitochondria where they are assembled together with the mtDNA encoded subunits, which are 
synthesized inside the mitochondria The function of many subunits of the OXPHOS system still 
remains elusive A growing number of mitochondrial encephalomyopathies or other neurological 
disorders have been associated with deletions, depletions and more than 40 point mutations in the 
mtDNA The co-existence of mutant with wild-type molecules (heteroplasmy) further complicates 
the understanding of the mechanism(s) by which these mutations exert their pathophysiological 
effects Despite the fact that the cDNAs of most nuclear genes of the bovine OXPHOS are 
characterized and thought to be very homologous to the human counterparts, only one nDNA 
mutation, in a gene coding for a complex II subunit, has been found to date 
Chapter II describes the use of peptide-specific antibodies in immunoprecipitation experiments 
involving mtDNA-encoded polypeptides Antibodies against peptides of computer predicted internal 
epitopes of human complex I subunits, ND4, ND5 and ND6, were succesfully made in our 
laboratory 
Chapter III describes the selection of peptides, immunization protocols, and characterization of 
peptide-specific antibodies against ND4, ND5, and ND6, three mtDNA encoded subunits of human 
complex I These antibodies and other complex I antibodies revealed in an immunoblot assay that the 
reduction of complex I activity in seven mitochondrial myopathy patients correlated with a decrease 
of both the mtDNA and nDNA encoded subunits of complex I 
Chapter IV describes the quantitation of assembled OXPHOS complexes in 20 mg muscle tissue of 
mitochondrial encephalomyopathy patients using a two-dimensional electrophoretic procedure (blue 
native electrophoresis/Tricine-SDS-PAGE) Two patients with a large mtDNA deletion had normal 
amounts and activities of the complexes Two MELAS patients with the tRNAUu<uul,) A3243G 
mutation had decreased amounts of multiple OXPHOS enzymes In three cases of fatal infantile 
encephalomyopathy either an isolated complex I or complex IV deficiency was seen, both by 
electrophoretic and enzymatic measurements Partially assembled complexes were not seen in any of 
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the patients Concordantly, Western blotting showed decreased levels of all subunits of the affected 
complex, indicating that the unassembled subunits were proteolytically degraded 
In chapter V the same two-dimensional electrophoretic technique was extended to the analysis 
of platelets and cultured cells Due to the low mitochondrial content of these cells, mitochondria had 
to be isolated and the gels were stained with silver instead of Coomassie In platelets also the platelet 
glycoprotein complex could be readily identified in the two-dimensional gels The technique showed 
that complex IV was nearly absent in fibroblasts of a mitochondrial encephalomyopathy patient, in 
agreement with the enzymatic measurements, but also a considerable amount of free F, subcomplex, 
the catalytic portion of complex V, was seen The presence of the latter may be indicative for a 
mtDNA mutation, possibly in one of the tRNAs 
Chapter VI describes a unique patient who died of a lethal infantile mitochondrial disease with 
severe lactic acidosis Histochemical analysis of skeletal muscle showed that cytochrome с oxidase 
staining was completely lacking in all muscle fibers, but was present in arterioles Biochemical and 
two-dimensional electrophoretic analysis revealed a combined complex I and IV déficience in 
skeletal muscle, but only a complex I deficiency in fibroblasts A hypothesis explaining this curious 
phenomenom was postulated 
Chapter VII describes a patient with neonatal De Toni-Debre-Fanconi syndrome, a renal 
tubulopathy Complex III of the mitochondrial respiratory chain was measured directly by a 
spectrophotometric assay, using decylubiquinol as a substrate This enzyme activity was severely 
reduced in skeletal muscle and liver of this patient, and also in a second patient with renal 
tubulopathy Therefore, complex III deficiency should be included in the differential diagnosis of 
neonatal De Toni-Debre-Fanconi syndrome 
Finally, in chapter VIII the relationship of genotype to phenotype was studied in a cellular 
model system of mtDNA-linked diseases Transmitochondnal cell lines were isolated by fusing 
mtDNA-less p°206 cells with enucleated fibroblasts derived from members of a pedigree carrying a 
mutation at position 3243 in the tRNALcu(UUR) gene which is associated with the MELAS syndrome 
The proportion of wild-type transformants appeared to decrease in correspondence with an increase 
in severity of the clinical symptoms of the cell donor Furthermore, the average proportion of wild-
type mtDNA in the transformants derived from each member of the pedigree was very similar to that 
found in mtDNA from the fibroblasts ofthat individual, suggesting that the distribution of genotypes 
in the transformants reflected fairly closely that in the fibroblasts All heteroplasmic clones showed a 
shift of the mitochondrial genotype towards higher levels of the tRNALeι,<UUR, (3243) mutation upon 
continuous culture, whereas the mitochondrial genotype remained constant in apparently 
homoplasmic clones The re-establishment of the parental mtDNA copy number was in general slow 
in the p° cell transformants and accompanied by an increase of rate of 0 2 consumption The 
observation that a very small amount of wild-type mtDNA (2 to 5% of the control level), coexisting 
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with strongly predominant mutant mtDNA, conferred upon the transformants a substantial 
respiratory capacity and the evidence of proportionality between 0 2 consumption rate and mtDNA 
copy number, which occurred at widely different mutant to wild-type mtDNA ratios, strongly 
suggested a contribution of the mutant mtDNA to the cell respiratory competence 
Suggestions for future studies 
The research presented in this thesis has yielded several new methods to study OXPHOS 
dysfunction in mitochondrial encephalomyopathy patients 1. An immunoblot assay using self-made 
antibodies against peptides of mtDNA encoded subunits or against purified complexes or their 
subunits (chapters II to IV) Only 2 μg of skeletal muscle mitochondrial protein was sufficient for the 
enhanced chemiluminiscence (ECL) detection system 2. Two-dimensional blue native/Tncine-SDS 
electrophoresis could be used to detect in one gel all OXPHOS complexes 10 mg homogenized 
tissue or sedimented cells (e g platelets or fibroblasts) are sufficient for staining with Coomassie or 
with silver (complex I not visible in fibroblasts), respectively (chapters IV to VI) 3. An assay for 
measurement of complex III in several tissues, using decylubiqumol and horse heart cytochrome с as 
substrates Tween 20 was added to inhibit the spontaneous, nonenzymic reaction between the 
substrates and to break the mitochondrial membrane (chapter VII) 4. Preparation of a mitochondria-
enriched fraction, by hypotonic pottering of only 107 fibroblast cells and subsequent differential 
centrifugation, was sufficient for measurement of most OXPHOS enzymes, including complex I, in 
these cells (chapter VI) 5. A cellular model system for mtDNA mutations was applied for the study 
of the genotype to phenotype relationship of the MELAS 3243 mutation Many deficiencies have 
been established in tissue specimens or cell lines of patients MtDNA point mutations or 
rearrangements, that occur frequently in mitochondrial encephalomyopathy patients, are not found 
often in our patients Thus the question of the genetic origin of the enzymatic OXPHOS defect in 
many of these patients remains elusive 
Immunoblotting and two-dimensional electrophoresis revealed that only assembled OXPHOS 
complexes are present in tissues of patients (chapter III and IV) Unassembled subunits are probably 
proteolytically degraded F, subcomplex, the catalytic portion of complex V, is an assembly 
intermediate that we observed in two groups of patients 1) four unrelated patients with NARP or 
Leigh's disease and a point mutation at position 8993 in the mitochondrial ATPase 6 gene 
(unpublished results), 2) more than 10 patients without this mutation, but having multiple OXPHOS 
enzyme deficiencies (chapter V, unpublished results) Because the latter patients also have frequently 
ragged red fibers in their muscle tissue, we suspect the presence of a mutation in one of the 
mitochondrial tRNAs in these patients 
Routine screening of mitochondrial enriched fractions of patients fibroblasts has yielded a large 
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number of cell lines deficient in one or more respiratory chain enzymes (chapter VI, unpublished 
results), e g , up to 15 cell lines with an isolated complex I deficiency have been found These cell 
lines are extremely useful to find the genetic cause of the complex I defect The preponderance of the 
male gender suggests that a mutation on the X chromosome might be involved in a number of cases 
Complex I genes that are encoded on the X chromosome should be checked for mutations in these 
cell lines Future research might encompass also 1) complementation analysis to see whether the 
deficiency in these cell lines is caused by a mutation in the same gene, 2) the study of 
transmitochondrial cell lines isolated by fusion of mtDNA-less cells to enucleated fibroblasts or the 
reverse experiment to prove whether the mutation is of nuclear or mitochondrial origin, 3) metabolic 
labeling in the presence of either cytosolic or mitochondrial protein synthesis inhibitors, followed by 
immunoprecipitation with subunit-specific antibodies of which many are already available, 4) 
neutrilizing the deficiency by transfection with a cDNA extression library The latter two procedures 
will prove which genes causes the complex I deficiency 
A number of patients have been diagnosed with a complex III deficiency in their tissue 
(chapter VII, unpublished results) Immunoblotting and/or two-dimensional electrophoresis should 
be performed to check whether the correctly assembled, but inactive, enzyme is present as has been 
described for yeast mutants This could be indicative for (point) mutations in the mitochondrial 
cytochrome b gene Complex III deficient fibroblasts have not been found to date 
The transmitochondrial cell lines of patient II3 described in chapter VIII have not yet been 
studied thoroughly Measurement of all OXPHOS enzyme activities and quantitation of assembled 
enzymes by two-dimensional electrophoresis in cell lines with variable proportions of mutant mtDNA 
will give an insight on the correlation between proportion of mutation and individual enzyme 
deficiencies Transmitochondrial cell lines of three patients with isolated complex I deficiency are 
already isolated These have to be further analyzed to see whether the complex I deficiency present 
in the fibroblasts is transmitted with the transfer of their mitochondria into p° cells The cellular 
model described in chapter VIII can also be used to study the genotype/phenotype relationship of 
newly found mtDNA mutations 
To assess whether nuclear mutations in structural genes of OXPHOS enzymes can cause 
encephalomyopathy, it is desirable to make an animal model, like a knockout mouse It is also 
possible to knock out or mutate homologues of genes which in yeast control OXPHOS biogenesis 
(pel mutants), e g Oxa\ and COXÌ4 are two genes which are essential for cytochrome с oxidase 
assembly, but are not present in the enzyme However, complex I has not been found in yeast Thus, 
genes controlling specifically this enzyme will probably be missed 
Myoblast cultures can be used to study the expression of the defect, when the deficiency is 
limited to muscle tissue Similarly, 2D-electrophoretic analysis of 2-5 mg heart muscle is possible 
when the defect is suspected to be limited to the heart muscle, as is the case in cardiomyopathies 
Ill 
Samenvatting 
Het in dit proefschrift beschreven onderzoek had als doelstelling de diagnostiek van 
mitochondrièle encephalomyopathieen te verbeteren. Dit is een heterogeen ziektebeeld dat 
gekenmerkt wordt door een falende energieproductie in de mitochondrien van voornamelijk hersenen 
en spieren De vijf enzymcomplexen (complex I t/m V) van de oxydatieve fosforylering (OXPHOS) 
spelen hierbij vaak een belangrijke rol Klinische symptomen kunnen variëren van spierzwakte, 
stuipen of vertraagde ontwikkeling bij jonge kinderen tot inspanningsmoeilijkheden of diverse 
neurologische aandoeningen bij volwassenen Een veelvoorkomende bevinding is de aanwezigheid 
van grote hoeveelheden melkzuur in bloed, urine of hersenvocht 
In de algemene inleiding (hoofdstuk I) worden enkele kenmerken van mitochondrièle 
encephalomyopathieen en de vijf OXPHOS enzymcomplexen beschreven Mitochondrien hebben hun 
eigen DNA (het mitochondrièle DNA=mtDNA) en eiwitsynthese-machinerie De OXPHOS 
enzymcomplexen bestaan uit vele subeenheden, die samen in het mitochondrion tot enzym 
geassembleerd worden Vier van de vijf enzymcomplexen (I, III, IV en V) bevatten ook subeenheden 
die door het mtDNA gecodeerd worden Complex II beval alleen maar subeenheden gecodeerd door 
het nucleaire DNA Het mtDNA wordt exclusief door moeders aan hun nageslacht doorgegeven, in 
tegenstelling tot het nucleaire DNA dat zowel van vader als moeder afkomstig is Een toenemend 
aantal mitochondrièle en neurologische ziektebeelden worden geassocieerd met afwijkingen in het 
mtDNA Het feit dat naast afwijkend mtDNA tegelijkertijd normaal mtDNA wordt gevonden 
(=heteroplasmie) maakt het begrip van de effecten van een afwijking in hel mlDNA erg moeilijk 
Slechts één afwijking in het nucleaire DNA van een OXPHOS eenheid is tot nu toe gevonden bij 
twee patiënten met een mitochondrièle encephalomyopathie 
Hoofdstuk II beschrijft hoe antilichamen tegen peptides van mtDNA gecodeerde OXPHOS 
subeenheden gemaakt en uitgetest kunnen worden Tegen drie subeenheden, ND4, ND5 en ND6, 
van complex I werden op deze manier antilichamen gemaakt 
Met behulp van deze en andere antilichamen wordt in hoofdstuk III aangetoond dat bij alle 
zeven geteste mitochondrièle myopathie patiënten de afname van de enzymactiviteit van complex I 
correlleert met de resthoeveelheid subeenheden van dit complex, zowel subeenheden gecodeerd door 
het mtDNA als door het nucleaire DNA 
Hoofdstuk IV beschrijft de kwantificering van alle vijf OXPHOS complexen in slechts 20 mg 
skelet spierweefsel van mitochondrièle encephalomyopathie patiënten met behulp van een twee-
dimensionale electroforesetechniek Bij een aantal patiënten met mtDNA afwijkingen en/of verlaagde 
OXPHOS enzymactiviteiten bleken één of meerdere OXPHOS enzymen sterk verminderd aanwezig, 
of zelfs niet aantoonbaar 
Hoofdstuk V beschrijft de aanpassingen van deze techniek voor de bestudering van 
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bloedplaatjes of gekweekte cellen In gekweekte huidcellen van een patient met een verlaagde 
complex IV activiteit kon worden aangetoond dat dit enzym inderdaad afwezig was, maar ook dat 
F,, een deel van complex V, aanwezig was Mogelijk is dit een indicatie voor de aanwezigheid van 
een mtDNA afwijking 
Hoofdstuk VI beschrijft een patientje dat overleed ten gevolge van een mitochondriele ziekte 
met een enorme melkzuur acidóse In coupes van skeletspier was de complex IV activiteit afwezig in 
de vezels, maar aanwezig in de arteries In dit spierweefsel bleek naast complex IV ook complex I 
sterk verlaagd, terwijl in gekweekte huidcellen alleen complex I afwezig was Een hypothese voor dit 
curieuze fenomeen wordt gepresenteerd 
Hoofdstuk VII beschrijft een patientje met het De Toni-Debré-Fanconi syndroom, een 
nierfunctiestoornis Bij deze patient kon een defect in complex III in zowel skeletspier als lever 
worden aangetoond Ook bij een andere patient met dezelfde symptomen werd in ingevroren weefsel 
een complex III defect vastgesteld 
Hoofdstuk VIII, tenslotte, beschrijft een cellulair modelsysteem om de gevolgen van mtDNA 
afwijkingen te bestuderen Hierbij werden gekweekte huidcellen van patiënten met een nucleotide 
verandering op positie 3243 in het mitochondriele tRNALcu(L'UR) gen eerst ontdaan van hun kernen (= 
nucleaire DNA) en daarna gefuseerd met cellen zonder mtDNA Aldus ontstaan transmitochondriele 
cellijnen met variabele hoeveelheden normaal en afwijkend mtDNA Naarmate het ziektebeeld van de 
patiënten ernstiger was, werden er minder transmitochondriele cellijnen met 100% normaal mtDNA 
gevonden Tevens nam het percentage afwijkend mtDNA toe tijdens langdurig kweken van de 
heteroplasmische cellijnen De cellijnen bereikten langzaam de oorspronkelijke, absolute hoeveelheid 
mtDNA hetgeen gepaard ging met een toename van de celrespiratie Het feit dat cellijnen met een 
zeer gering percentage normaal mtDNA toch een behoorlijke celrespiratie kunnen hebben, suggereert 
dat ook het afwijkende mtDNA hier een bijdrage aan levert 
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